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ABSTRACT 
SMS is an enzyme belonging to the sphingolipid metabolic pathway. 
Since the discovery and initial characterizations of sphingolipids (SLs) in 
1884, extensive research has established that these molecules not only are 
structural components of eukaryotic membranes but they are also critical 
bioactive lipids involved in fundamental cellular processes such as 
proliferation, differentiation, apoptosis, inflammation, migration, and 
autophagy. In particular, SMS produces sphingomyelin (SM) in mammalian 
cells by transfering the phosphorylcholine moiety from phosphatidylcholine 
(PC) onto ceramide forming SM and diacylglycerol (DAG). Both ceramide 
and DAG are bioactive lipids with opposing functions, and SMS produces 
sphingomyelin (SM) while consuming ceramide (negative regulator of cell 
proliferation) and forming diacylglycerol (DAG) (a mitogenic factor). 
Therefore enhanced SMS activity could favor cell proliferation. 
To examine if disregulated SMS contributes to leukemogenesis, we 
measured SMS activity in several leukemic cell lines and found that it is 
highly elevated in K562 chronic myelogenous leukemia (CML) cells. The 
increased SMS in K562 cells was caused by the presence of the BCR-ABL 
oncogene, a hallmark of CML, as stable expression of BCR-ABL elevated 
SMS activity in the BCR-ABL negative HL-60 cells while inhibition of the 
tyrosine kinase activity of Bcr-abl with Imatinib mesylate, decreased SMS 
activity in K562 cells. The increased SMS activity was the result of up-
regulation of the SMS1 isoform. Inhibition of SMS activity with D609 (a 
pharmacological SMS inhibitor) or down-regulation of SMSl expression by 
siRNA, selectively inhibited the proliferation of Bcr-abl positive cells. The 
VIll 
inhibition was associated with an increased production of ceramide and a 
decreased production of DAG, conditions that antagonize cell proliferation. 
A similar change in lipid profile was also observed upon pharmacological 
inhibition of Bcr-abl (K526 cells) and siRNA-mediated down-regulation of 
BCR-ABL (HL-60/Bcr-abl cells). These findings indicate that SMS1 is a 
downstream target of Bcr-abl, involved in sustaining cell proliferation of 
Bcr-abl positive cells. 
The increased SMS 1 activity in bcr-abl positive cells was associated 
with higher levels of the SMS 1 protein due to enhanced transcription, as 
measured by quantitative real time PCR (QRT-PCR) of heteronuclear RNA 
(hnRNA). In particular, the highest increase of SMSl transcript and mRNA 
was observed when probing down-stream of exon 6, suggesting the 
preferential utilization of an alternative transcription start site (TSS) in Bcr-
abl positive cells. Thus this study investigated the effect of Bcr-abl on SMSl 
transcription. Indeed, RLM-RACE based analysis of Bcr-abl positive cells 
identified multiple SMSl TSSs, including a TSS located within intron 6 in 
close proximity and upstream to exon 7 (TSS C). Notably, in silica analysis 
of the entire SMSl locus, including large areas of its 5' and 3' UTR, revealed 
multiple putative promoter regions, including Promoter C located upstream 
to TSS C. Further promoter-based studies corroborated the possibility of 
Bcr-abl to mediate transcription of SMSl through the putative Promoter C 
and the dependence of SMSI transcription on Bcr-abl was further confirmed 
by demonstrating the inhibition of Promoter C activity upon inhibition of 
bcr-abl activity with Imatinib. A series of deletions from the 5' end of 
promoter C revealed a core promoter region from -110 to -113 from TSS C 
suggesting that the cis-element(s) needed for Bcr-abl mediated SMSl 
regulation was located within this area. Overall, these results provide strong 
IX 
evidence of Bcr-abl's regulation of SMSl expreSSIon through enhanced 
transcription via a promoter switch. 
x 
Introduction 
Sphingomyelin synthase (SMS) is the class of enzymes responsible 
for production of sphingomyelin (SM) in mammalian cells. In particular, 
SMS transfers the phosphorylcholine moiety from phosphatidylcoline (PC) 
onto ceramide forming SM and diacylglycerol (DAG) (1-7). Since SMS can 
up- and down-regulate levels of ceramide, a negative regulator of cell 
growth and promoter of differentiation, and DAG, a well-established 
mitogenic factor (8) (Figure 1), SMS activity may play an important role in 
the regulation of pathologies associated with aberrant cell proliferation and 
differentiation, such as leukemia. In mammalian cells SMS activity is 
encoded by two recently identified genes, SMSl and SMS2 (9). 
Figure 1. Enzymatic Reaction of SMSI 
Other bioactive { .] SMS ( DAG )-----t> Other.bi.oactive 
lipids <J •.••• -- Ceramlde + Phos~hatidy~ (J [> SM + lipids 
choline 
Figure 1. SMS is a bi-directional transferase that uses ceramide and phosphatidlycholine 
to produce SM and DAG. Ceramide and DAG can be further processed by other 
members of the sphingolipid metabolic pathways to become or act upon other bioactive 
lipids. 
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Previous studies have shown increased SMS activity and decreased 
ceramide levels in a pool of chemoresistant versus chemosensitive patients 
with different leukemias (10). This study led to an in vitro screening of 
SMS activity in various leukemia cell lines revealing an upregulation of 
SMS activity in K562 cells compared to all other screened leukemia cell 
lines. K562 cells are known to express the Bcr-abl oncogene, a hallmark of 
95% of chronic myelogenous leukemia (CML) cases. CML is a 
myeloproliferative disorder of the hematopoietic stem cells and is clinically 
characterized by three phases: chronic, accelerated and blast phase. The 
most aggressive and refractive phase is the blast phase which is clinically 
defined as an up to 30% increase of highly undifferentiated blast cells in the 
bone marrow and peripheral blood. K562 cells were originally isolated from 
a patient with CML in blast crisis; consequently these cells have an 
undifferentiated blast-like phenotype. 
In our preliminary results, we demonstrated that increased SMS 
activity observed in K562 cells (compared to other leukemia and lymphoma 
cells lines) could be recapitulated by stable expression of the Bcr-abl 
oncogene In otherwise Bcr-abl negative cells. Furthermore, expression 
analysis by quantitative reverse real time RT-PCR (QRT-PCR) and 
modulation of gene expression by siRNA treatment suggested that enhanced 
expression of SMS1, and not SMS2 was responsible for increased SMS 
activity in Bcr-abl-positive versus negative cells. Additional studies 
suggested that elevated SMS 1 expression, in Bcr-abl positive versus 
negative cells, resulted from increased transcription and was most likely 
regulated by an alternative transcriptional start site. 
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Therefore based on these observations and given the opposing roles of 
ceramide and DAG on proliferation and/or differentiation, we 
HYPOTHESIZED that enhanced transcription of SMSI contributes to 
the undifferentiated, pro-proliferative phenotype of Bcr-abl positive 
cells. To test this hypothesis the following specific aims were proposed: 
Specific Aim 1: Determine the function o(SMSl in maintaining 
the cancerous phenotype exhibited by Bcr-abl positive blast cells. 
The over-all goal for Specific Aim 1 was to elucidate the role and 
function of SMS in the regulation of cellular functions such as proliferation, 
differentiation, and stress response in Ber-abl positive cells. 
Rationale for Specific Aim 1: 
Preliminary results demonstrated that Bcr-abl drives SMSl expression 
and activity and that inhibition of SMS 1 resulted in a significant reduction of 
proliferation that coincided with an induction of differentiation of Ber-abl 
positive cells. Bcr-abl's role in regulating SMS activity was further 
substantiated by experiments using Imatinib, a catalytic inhibitor of Bcr-abI. 
These experiments revealed both a time and dose dependent decrease of 
SMS activity following Bcr-abl inhibition. Furthennore, SMS's role in 
modulating bioactive lipids was confirmed by mass spectrometry 
measurements subsequent to SMS inhibition. These results showed that 
pharmacological inhibition of SMS activity in K562 cells resulted in 
increased ceramide and decreased DAG levels. SMS inhibition, in both 
K562 and HL-60/Bcr-abl cells did not provide evidence for increased cell 
death as measured by trypan blue exclusion. Based upon these observations, 
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we proposed that inhibition of SMS/SMS 1 expression would result in 
decreased cellular proliferation and increased cellular differentiation and that 
this modulation does not affect cellular toxicity_ Furthermore, we proposed 
that inhibition of SMS/SMS 1 would produce an alteration of the levels of 
the bioactive lipids, cerami de and DAG, resulting in a lipid profile consistent 
with cell growth arrest (high ceramide and/or low DAG). 
Therefore, in order to further consolidate the specific hypothesis, the 
following sub-aims were proposed: 1) confirm SMSI 's role in maintaining 
the undifferentiated phenotype in Bcr-abl cells, 2) verify absence of cellular 
cytotoxicity upon inhibition of SMS activity and 3) validate modulation of 
ceramide and DAG levels upon SMS 1 inhibition. 
Specific Aim 1 resulted in an accepted publication with 1ll1nor 
revisions in the Journal of Lipid Research, titled "Sphingomyelin synthase 1 
activity is regulated by the Bcr-abl oncogene." Full details in manuscript 
format can be found in Chapter 1, with the exception of ex vivo experiments 
from CML patients which are included in Appendix A (Chapter 1). 
Specific Aim 2: Determine if there is transcriptional activation of 
SMSl upon Bcr-abl expression 
The over-all goal for Specific Aim 2 was to provide an in depth 
investigation of Bcr-abl-mediated regulation of SMSI transcription. 
Rationale for Specific Aim 2: 
Preliminary data strongly suggested that Bcr-abl promotes a 33-38-
fold increase of SMSl expression above levels seen in Bcr-abl negative 
leukemia cell lines. In fact, experiments studying SMSl expression indicated 
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that Bcr-abl regulates SMSl via transcription. Notably, these investigations 
also revealed the presence of an additional putative transcription start site 
preferentially utilized upon BCR-ABL expression. Therefore the following 
sub aims were proposed in order to examine the mechanism by which Bcr-
abl regulates SMSl transcription: 1) verify increased SMSl expression and 
transcription upon Bcr-abi expression 2) identify the transcriptional start site 
located within SMSl that is activated upon Bcr-abi expression, and 3) 
characterize SMSl 's promoter utilized upon Bcr-abl expression. 
Results obtained while addressing Specific Aim 2 are being organized 
In a manuscript in preparation with a tentative title, "Transcriptional 
regulation of SMSl by the Bcr-abl oncogene." This aim is covered in its 
entirety in Chapter 2. Moreover, additional preliminary results indicating the 
potential transcription factor responsible for Bcr-abl-dependent SMSI 
enhanced transcription are presented in Appendix B (Chapter 2). 
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Review of Literature 
Overview of sphingolipid metabolism and signaling. 
Introducing sphingolipids. 
Sphingolipids (SL) are a diverse class of lipids originally identified as 
integral structural components of eukaryotic membranes (11). The first SL 
was isolated from the human brain and described in 1884 by the German 
physician and biochemist, J.L. Thudichum (12). Due to its enigmatic 
characteristics, this newly found lipid was termed sphingomyelin (SM) in 
reference to the Greek mythological Sphinx who asked riddles for mortals to 
answer to gain entrance into Thebes. Since the discovery and initial 
characterization of SLs, extensive research has established that these 
molecules not only act as structural components of eukaryotic membranes 
but also they are bioactive lipids, regulators of essential biological processes 
such as cellular proliferation, differentiation, apoptosis, inflammation, 
migration and autophagy, (for excellent reviews, see (11,13-18). 
Simple mammalian SLs are characterized by the presence of an 
amine-containing lipid backbone either saturated or unsaturated 
(dihydrosphingosine or sphingosine) (Figure 2). 
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Figure 2. Ceramide Structure 
Primary hydroxyl for linkage 




Double bond in position 4-5, absent in 
dihydroceramide 
Figure 2. Ceramide Structure. Ceramide as an example of a sphingolipid. Contains a 
fatty acid linked via an amine-containing lipid backbone, and a primary hydroxyl for 
possible linkages of head groups in complex sphingolipids. 
A fatty acid can be linked via an amide-bond to this "sphingoid" 
backbone, generating dihydroceramide or ceramide (saturated or unsaturated 
backbone, respectively), considered to be the central block of the SL 
pathway (Figure 2). The presence of a variable polar head group (from a 
simple phosphate to very complex sugars, for example) connected to the 
primary hydroxyl of ceramide characterizes complex SLs (17). Overall, SL 
nomenclature is derived from the nature of the different groups attached to 
the sphingoid backbone, and, so far, hundreds of SL species have been 
identified. 
SL metabolism and its regulation. 
Since the discovery of SLs and their metabolism, the highly regulated 
nature of this pathway has become apparent. SL metabolism presents several 
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levels of complexity: 1) the pathway proceeds through a number of 
interconnected reactions, some of which are reversible, potentially 
redirecting certain steps of the pathway (Figure 3); 2) the pathway is a 
reservoir of bioactive (signaling) lipids, often with opposing roles (i.e. 
ceramide, sphingosine, and sphingosine-I-phosphate); 3) ceramide (and the 
derived complex SLs) represents an array of molecular subspecies, each 
characterized by the presence of a different fatty acid (Figure 2), often with 
opposing biological functions; 4) different segments of the pathway reside in 
different cellular compartments, thus the regulation of the modes by which 
one SL produced in one organelle reaches another organelle (where it 
functions as substrate for the next reaction) significantly affects the pathway 
itself; 5) several SL-metabolizing enzymes are represented by different 
isoforms, sometimes distributed in different cellular compartments, splitting 
the pathway into multiple mini-modules; and 6) in one of the SL pathway 
reactions, diacylglycerol (DAG) is produced, establishing the potential for 
cross-talk between the sphingo- and glycero-lipid pathways (Figure 3). 
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Figure 3. Schematic of SL metabolism 
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Figure 3. Schematic of SL metabolism. SL metabolism is characterized by a complex 
network of interconnected reactions, each regulated by one or more enzymes. Some of 
the enzymes have birectional activity (SMSs, nCDases and Acers), and many of the 
enzymes that catalyze the reaction reside in distinct intracellular compartments (Refer to 
introduction for details). Different bioactive lipids are formed through the SL pathway, 
such as ceramide, sphingosine, SIP, Ceramide-l-P, DAG. SPT:serine palmitoyl 
transferase; CerS:ceramide synthase; DES:dihydroceramide desaturase; 
SMS:Sphingomyelin synthase; aSMase:acid sphingomyelinase; nSMase:neutral 
sphingomyelinase; Cer 1 P-P:ceramide-l-phosphate phosphatase; Cerk:ceramide kinase; 
GCS :glucosylceramide synthase; Glyases: glycosidases; GalCS :galactosylceraide 
synthase; aCDase:acid ceramidase; SK:sphingosine kinase; SPP:sphingosine-l-phosphate 
phosphatase; FA: fatty acid; SM:sphingomyelin; DAG:diacylglycerol; 
PC:phosphatidylcholine; ceramide-l-phosphate. * in vitro, SMS 1 and SMS2 catalyze 
bidirectional reactions. (9 ,19) 
In the sections that follow, these aspects will be discussed in addition 
to the fundamental concepts important for appreciating the specific role of 
SLs in leukemia. 
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The SLpathway: a complex network o/interconnected reactions. 
The biosynthetic branch of the SL pathway generally begins with the 
condensation of a serine and a palmitoyl-CoA to generate 3-keto-
dihydrosphingosine, catalyzed by the serine palmitoyl transferase (SPT) 
(Figure 3). The 3-keto-dihydrosphingosine IS then reduced to 
dihydrosphingosine (also called sphinganine) by 3-keto-dihydrosphingosine 
reductase. Subsequently, dihydrosphingosine IS N-acylated to 
dihydroceramide by ceramide synthase (CerS, also known as Lass) and 
dihydroceramide IS desaturated to form ceramide by dihydroceramide 
desaturase (DES). These initial steps of de novo SL synthesis occur in the 
ER. Once ceramide is formed, it is transferred to the Golgi apparatus where 
it can be used as a substrate for formation of complex SLs, namely 
sphingomyelin (SM) through the action of SM synthase (SMS), glucosyl- or 
galactosylceramide through the action of glucosylceramide synthase (OCS) 
or galactosylceramide synthase respectively, and ceramide-l-phosphate 
through the action of ceramide kinase (CERK). Complex SLs then reach the 
plasma membrane, where they accumulate, via vesicular trafficking. 
Breakdown of SLs occurs at the expense of complex SLs and 
ceramide. The bulk of SL breakdown occurs in the lysosomes (via enzymes 
with an acidic optimal pH) whereas a number of isoforms for the same 
reactions (with neutral or alkaline optimal pHs) intervene to modulate SL 
levels in response to specific stimuli in other organelles (Figure 3). A group 
of enzymes named sphingomyelinases (SMases, characterized by acidic, 
neutral or alkaline pHs), hydrolyse SM into ceramide (20). In addition, 
glucosyl- and galactosyl-ceramide are catabolized by their own glycosidases, 
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and ceramide-l-phosphate is dephosphorylated by the ceramide phosphate 
phosphatase. Once produced, ceramide can, in tum, b~ converted to 
sphingosine through fatty acid cleavage via several ceramidases (CDases, 
characterized by acidic, neutral or alkaline optimal pHs). Sphingosine can 
then be converted into spingosine-I-phosphate (SIP) by the addition of a 
phosphate group via sphingosine kinase (SK) (21). SIP is then broken down 
by a lyase into hexadecenal and ethanolamine phosphate (22). Also, 
sphingosine can be converted back to ceramide by CerS or by the neutral or 
alkaline CDases since they operate bidirectionally (23-25). In spite of the 
number of interconnected reactions within the SL pathway, it is important to 
point out that there is only one way in (through the SPT) and one way out 
(through the SIP lyase). 
The SL pathway as a reservoir of bioactive lipids. 
Considering SL metabolism and its effect on cell function 
regulation, a complication arises in that SL metabolism produces several 
bioactive lipids, such as ceramide and dihydroceramide, sphingosine, SIP, 
ceramide-lP, GD3 ganglioside, and DAG. Depending on their specific 
biochemical and biophysical properties, each of these lipids likely has its 
own set of cellular targets (please refer also to the discussion on the 
compartmentalization of the SL metabolism). Different downstream targets 
may elicit specific cellular responses, which may eventually elicit totally 
different effects on the fate of the cell. In this regard, ceramide and 
sphingosine, for instance, have been shown to transduce signals generally 
associated with growth arrest, and/or differentiation, and/or apoptosis, 
whereas SIP and ceramide-lP mostly transduce pro-proliferative and 
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prosurvival signals (11,26-28). Thus, it is important to keep in mind that the 
ultimate balance among all these bioactive lipids is the true final determinant 
of the observed phenotype (29). To this end, the "lipidomic" analysis 
(measurements of a large number of SLs from the same sample) is currently 
the most effective approach to precisely model how a specific stimulus 
interferes with SL metabolism and which of the SLs is most likely to be 
involved in downstream signaling. 
In leukemia, most of the evidence linking SL metabolism with 
regulation of this cancer has focused on ceramide and SIP. Thus, we present 
a brief overview of the biological effects, regulatory pathways, and 
downstream targets for these two bioactive lipids. 
Ce ram ide 
The "signaling" function of ceramide was first proposed more than 
twenty years ago. This discovery arose from studies showing that SL 
metabolism can be regulated in response to extracellular agents in HL-60 
leukemic cells. Specifically, after exposure to lu,25-dihydroxyvitamin D3 
(Vitamin D3), SM was hydrolyzed into ceramide, the proposed mediator of 
vitamin D3-induced differentiation (30,31). Regulated SM hydrolysis was 
subsequently observed in response to a variety of different cytokines, such 
as tumor necrosis factor (TNF) u, interferon y, and interleukin-l (IL-I). 
Other cellular functions in addition to differentiation appeared to also be 
affected by ceramide. Indeed, ceramide was found to induce a cytotoxic 
effect consistent with the apoptotic phenotype (32). Currently, cerami de is 
thought to be involved in a variety of cellular processes such as apoptosis, 
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differentiation, terminal differentiation, cell proliferation, and autophagy 
(5,11,13-18,26,28,33-37). Of note, the bioactive functions of ceramide are 
not only observed in connection with stress agents but are also observed 
during physiological processes. For instance, ceramide's contribution to 
apoptosis was also investigated in an ex-vivo setting using neutrophils 
isolated from human blood. Neutrophils spontaneously undergo apoptosis 6-
8 hours after entering the bloodstream, so ceramide's relationship to 
apoptosis can be analyzed during this process. In this model, a substantial 
increase in intracellular ceramide derived from de novo generation prior to 
apoptosis was observed. Inhibition of the de novo pathway significantly 
reduced caspase activation and spontaneous apoptosis, whereas ceramide 
accumulation (either by exogenous addition or by inhibiting the synthesis of 
complex SLs) resulted in increased apoptosis and caspase activation (38). 
Ceramide accumulation in response to stress signals or during 
physiological processes occurs due to one or more of these events: induction 
of de novo synthesis (as in spontaneous apoptosis of neutrophils), 
stimulation of SMases, and inhibition of complex SL synthesis (Figure 3). 
Accumulation of ceramide through the de novo pathway via induction 
of SPT (initial enzyme of SL metabolism) or CerSs has been shown to occur 
in response to various stimuli such as UV radiation, palmitate overload 
(implicating the involvement of SLs in diabetes or metabolic syndrome), 
chemotherapeutic agents (etoposide, doxorubicine, daunorubicine and 
gemcitabine), cytokines (TNF and IL-I), heat stress, hypoxia/reoxygenation, 
and N-hydroxyphenyl retinamide (39-48). Moreover, de novo ceramide 
synthesis has been linked to the onset of several diseases (49) such as cystic 
fibrosis, diabetes, and chronic obstructive pulmonary disease (50-54). 
Historically, two inhibitors, Myriocin and Fumonisin Bl have been 
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instrumental in establishing a critical role for ceramide generated by this arm 
of the pathway and to discriminate between SPT (inhibited by Myriocin) and 
CerS (inhibited by Fumonisin B 1), when the enzymes had not been yet 
identified (41,55,56). Now that the CerS family has been identified, progress 
can be made on dissecting the specific molecular mechanisms through which 
ceramide is generated by these enzymes. 
Extensive literature documents the generation of ceramide VIa 
activation of SMases, which are a family of enzymes consisting of several 
isoforms characterized by different pH optima and subcellular localization. 
This group includes one acidic SMase (acid pH), localized in the lysosomes; 
four different neutral SMases (neutral pH), localized in different cellular 
compartments (neutral SMase 1 in the ER, neutral SMase 2 in the Golgi and 
plasma membrane, neutral SMase 3 in ER and Golgi and neutral SMase 4 in 
the ER and mitochondria); and one alkaline SMase exclusively expressed 
and secreted in the gut (57-64). The majority of the studies addressing the 
regulation of ceramide production via this pathway and its implications refer 
to acid SMase and neutral SMase 2. In fact, neutral SMase 1, although 
possessing SMase activity in vitro, does not seem to be a major nSMase in 
human cells and in mice. Neutral SMase 3 and 4 were only recently 
identified (60,61,63,65). 
The study of acid SMase (aSMase) as a modulator of ceramide has 
exploited the existence of both a human disease, Niemann Pick type A and B 
(characterized by aSMase gene deficiency) and a knock out mouse model 
(66,67). With these tools, it has been convincingly shown that activation of 
aSMase occurs in response to a variety of stimuli such as bacterial and viral 
infections, ionizing and UV radiations, CD95 treatment, chemotherapeutic 
agents and nitrosative stress in a variety of cell types including leukemia 
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cells (5,68-80). Interestingly, the same aSMase gene gives fise to two 
distinct isoforms, one targeted to the lysosomes and one zinc-dependent, 
secreted in the extracellular space. Most studies investigating the signaling 
role for aSMase have referred to the lysosomal enzyme. A current model for 
regulation of aSMase in response to both receptor stimulation (CD95, CD40 
or EGFR) (81,82) and cytotoxic agents (such as cisplatin) (83) involves 
translocation to the plasma membrane and formation of ceramide enriched 
microdomains which coalesce to form large platforms and amplification of 
the signaling cascade. 
ASMase was also found to signal through the lysosomes via activation 
of cathepsin D (84). In fact, cathepsin D was found to bind ceramide and, as 
a consequence, to mature into the active 32kDa form. Upon TNF treatment, 
it was observed that mature cathepsin D (after aSMase activation) cleaved 
and activated the proapoptotic factor, bid, suggesting a role for aSMase in 
TNF-dependent cell death (85). Several mechanisms have been reported for 
aSMase activation. In particular, aSMase was found to be activated by 
reactive oxygen species, potentially through disruption of protein disulfide 
bridges (86-89), by phosphorylation of serine 508 through protein kinase C 
delta (an event critical for the translocation of the enzyme to the plasma 
membrane), (73,90) and by direct proteolytic cleavage through caspase 7 
(91). 
Neutral SMase (nSMase) activation has also been reported in response 
to a variety of treatments such as cytokines (TNF and IL-l (3), 
chemotherapeutic agents, serum deprivation, amyloid J3 petide, hydrogen 
peroxide, and upon ageing and cell confluence (92-94). The study of the role 
of nSMase in ceramide-mediated signaling has suffered from a lack of 
specific inhibitors and late identification of the genes. Thus for years, 
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nSMase was just a biochemical activity that changed upon varIOUS 
treatments. The recent identification of several isoforms represents a 
milestone for SL investigations and current efforts are placed on revisiting 
the involvement of specific nSMases under various experimental conditions. 
Currently nSMase2 is the best characterized isoform. Regulation of 
nSMase2 may occur through different mechanisms, and like aSMase, 
nSMase2 has been localized to various intracellular compartments such as 
the Golgi, nucleus, and plasma membrane, and cellular localization has been 
shown to change upon treatment. For example, in subconfluent MCF-7 cells, 
nSMase2 is found predominantly intracellularly and at cell-to-cell contact 
sites, but as cells reach confluency, the enzyme is found almost exclusively 
at the plasma membrane (95). Moreover, under oxidative stress, nSMase2 
was found at the plasma membrane, whereas the addition of reduced 
glutathione promoted its translocation to the perinuclear region (96). 
Importantly, the plasma membrane localization of nSMase2 may be 
regulated by the presence of two palmitoylation cystein clusters present in 
proximity of the protein N-terminus and nSMase2 action in- this 
compartment may also depend on the presence of phosphatidylserine, an 
activator of the enzyme naturally enriched in the inner leaflet of the plasma 
membrane (97,98). Translocation to the plasma membrane after TNF 
stimulation of lung epithelial cells was also shown to be dependent on p38 
mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) 8 
(99,100). Increased transcription of nSMase2 was observed in response to 
the chemotherapeutic agent, daunorubicine and this event was characterized 
as a critical step for the cytotoxic action of the drug (101). 
A strong link exists between nSMase2 and regulation of 
inflammation. In fact, nSMase2 activation after TNF treatment has been 
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reported in a variety of cell lines, such as A549, HUVEC, smooth muscle 
cells (100,102,103), and a model has been proposed in which, at the plasma 
membrane, a complex forms containing the TNF receptor, FAN (the factor 
associated with N-SMase activation), the FAN interacting protein RACKI 
and the polycomb group protein EED, and this leads to nSMase2 activation 
(104,105). Compelling evidence for nSMase2 regulation by IL-l~ also 
exists. In fact, hepatocytes from aged rats have been reported to have 
increased nSMase activity and hypersensitivity to IL-l f3 stimulation; 
nSMase2 inhibition in these cells significantly reduced the IL-l b response 
(93). In line with these observations, over-expression of nSMase2 in primary 
hepatocytes from young rats exacerbated the IL-l f3 response, mimicking the 
phenotype observed in aged rats. 
Ceramide accumulation can also be prompted by inhibition of the 
synthesis of complex SLs. Indeed a decrease in SMS activity before the 
onset of apoptosis has been observed in Kym-l cells after treatment with 
TNF (which also inhibited glucosylceramide synthase), and in Jurkat cells 
after CD95 stimulation or photodynamic therapy (106-109). 
Several ceramide downstream targets have been identified, and in 
addition to cathepsin D, ceramide has been reported to activate protein 
phosphatases PPI and PP2A. The first has been proposed to be a mediator of 
ceramide-induced cell cycle arrest via dephosphorylation of the 
retinoblastoma (Rb) protein (105,110,111), and the second has been linked 
to c-jun N-teminal kinase (JNK) dephosphorylation and ubiquitination of the 
IL-l f3-receptor-associated kinase (IRAK) (both involved in IL-1 ~ signaling), 
and Akt dephosphorylation (112,113). Interestingly, ceramide seems to 
activate PP2A in two ways, by directly activating the protein as shown by in 
vitro assays (114) and by binding to the inhibitor of PP2A (IPP2A), inducing 
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its dissociation from PP2A and consequent loss of inhibitory activity (115). 
Other targets of ceramide include PKCa, PKC~ and the kinase suppressor of 
Ras (116-119). 
Sphingosine-l-P (Sl P) 
SIP is the best characterized bioactive SL and it is thought to 
counteract the actions of ceramide. SIP is produced by phosphorylation of 
sphingosine which, in tum~ is formed from ceramide hydrolysis by one of 
several CDases (Figure 3). On the other hand, given the large difference in 
cellular content between sphingosine and SIP (approximately 100:1), 
activation of CDases is not theoretically necessary for acute intracellular 
increases in SIP. Nevertheless, activation of CDases has been observed in 
response to a variety of stimuli, such as cytokines, dexamethasone, 
doxorubicin, gamma radiation, serum deprivation, interestingly many of the 
same stimuli also found to activate SMases (for a comprehensive review on 
CDases see (27)). 
Similar to ceramide, sphingosine has been associated with a negative 
effect on cell proliferation and induction of apoptosis, thus the balance of the 
"ceramide-CDases-sphingosine-SK-S IP" branch of the SL pathway is often 
critical for treatment outcomes. 
Sphingosine can be converted to SIP by either one of two sphingosine 
kinases, SKI or SK2, and once formed, SIP may act intracellularly or 
extracellularly. SIP has been found to be a ligand for the SIP (1 to 5) 
receptor family (previously named EDG receptor family), and its 
extracellular functions proceed through the activation of one or more of 
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these receptors (120). Specific cellular effects of extracellular SIP are likely 
due to the tissue-specific expression patterns of the receptors and their 
coupling to specific G proteins (121). 
Addition of extracellular SIP generally has pro-proliferative and pro-
survival effects, which can be recapitulated by over-expression of SKI. 
Moreover, activation of SKI and production of SIP has been shown to occur 
in response to cytokines, chemokines, growth factors, and hormones, to 
name a few [reviewed in (28)]. Because SIP is charged, once formed, it is 
actively transported from inside the cells to the extracellular milieu, possibly 
through the ABCCI and ABCAI transporters (122,123). When outside the 
cell, SIP may act in an autocrine or paracrine fashion via the SIP receptors. 
Most SIP induced effects (either after extracellular addition of SIP or in 
response to agonist stimulation) have been found to depend upon SIP 
receptors. After an early acute activation of SKI, many agonists later induce 
a sustained increase of SKI expression as a result of increased transcription 
(124-128). 
SKI and SK2 are primarily cytosolic enzymes but their localization 
changes in response to certain stimulations. For example, after treatment 
with TNF, SKI translocates to the plasma membrane [via extracellular 
signal-regulated kinases 1/2 (ERKI/2)-mediated phosphorylation of serine 
225 and interaction with the calcium- and integrin-binding protein 1] to 
produce SIP locally (129,130). Recently, it was reported that SIP generated 
by SKI in response to TNF binds to the TNF receptor associated factor 2 
(TRAF2), stimulating its E3 ligase activity and the ubiquitination of the 
receptor interacting protein 1 (RIPl), a critical step in the activation of the 
pro survival transcription factor Nuclear Factor kappa B (NF-kB) (131). 
These events were shown to occur independently from SIP receptors, thus 
19 
demonstrating an intracellular role for SIP. Another potential intracellular 
target for SIP is represented by thapsigargin-sensitive calcium channels in 
the ER. Specifically, SIP elicited inositol triphosphate receptor-independent 
calcium release from subcellular fractions enriched in rough ER (132). In 
addition to the plasma membrane, SKI has been found to translocate into the 
nuclear envelope, in the phagosome or extracellularly, whereas SK2 has 
been also localized in the ER and inside the nucleus (21,133-135). It has 
been shown that nuclear SK2 and SIP associate with the histone 
deacetylases 1 and 2 (136), preventing deacetylation of lysines within 
histone tails, and thus affecting their DNA binding and gene expression. 
Activation of SK2 is induced by fewer agonists than SKI, and 
overexpression of SK2, in contrast to SKI, generally induces cell growth 
arrest and apoptosis, and it sensitizes cells to chemotherapeutic agents (with 
few exceptions) (137,138). Although it appears that SKI and SK2 functions 
are significantly different, SK2 can, in part, compensate for SKI and vice 
versa because the single knock out mouse for SKs are viable, whereas the 
double knock out mouse model is not (139). 
Overwhelming evidence supports a role for SKI and SIP in 
carcinogenesis. In fact, SKI overexpression has been shown to be sufficient 
for inducing transformation of 3T3 cells as it promotes focus formation and 
colony formation in soft agar, and tumors in immunodeficient mice, 
suggesting that SKI may act as an oncogene. Moreover, SKI was found to 
be involved upstream of H-Ras-dependent transformation (140). SKI is also 
a positive regulator of cell growth and survival of human glioblastoma cells 
because its inhibition hinders growth in a xenograft model (141). 
Additionally, SKI was found to be involved in colon carcinogenesis by 
regulating cyclooxygenase 2 expreSSIon and prostaglandin E2 formation 
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(142,143), and in head and neck squamous cell carcinoma, for which its 
expression was up-regulated and found to be necessary for disease 
development (144,145). Interestingly, not only SKI is up-regulated in 
various cancers (acute leukemia, breast, colon, lung, ovary, stomach, uterus, 
kidney, and rectum) compared with normal tissue from the same patient but 
SKI expression often correlates with more malignant phenotypes and/or 
chemotherapy resistance (28,142,146-149). Involvement of SKI in cancer is 
not only due to SKI-mediated regulation of cell growth and survival but also 
due to migration, invasion, andangiogenesis (21,139,150-156). Importantly, 
a monoclonal antibody for SIP that sequesters and neutralizes extracellular 
SIP unequivocally demonstrated the requirement of SIP for endothelial cell 
migration and capillary and blood vessel formation in various human 
xenograft tumors (157). 
Location, location, location: the importance of 
compartmentalization of the SL pathway 
Understanding the effects of SL metabolism is further complicated by 
the fact that both SLs and their associated enzymes have distinct sub-cellular 
localizations. The subcellular localization of SLs depends upon their 
inherent biochemical characteristics. For example, the simple SLs, 
sphingosine and dihydrosphingosine are sufficiently amphipatic, that they 
are able to freely diffuse from the membrane where they were produced, and 
to travel through the cytosol to other cellular compartments or the 
extracellular space (158). In contrast, the respective phosphorylated lipids, 
sphingosine-l-P and dihydrosphingosine-l-P cannot diffuse through the 
membranes thus, unless actively pumped, they remain in the hydrophilic 
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compartment in which they are formed (122,123). Different from simple 
SLs, ceramide does not freely diffuse through the membranes and it only 
moves between cell compartments via vesicular trafficking or via protein 
transport with the ceramide transfer protein (CERT) (159). However, 
ceramide can still flip from one leaflet of the membrane to the other, thus it 
can access the catalytic sites of enzymes localized on either leaflet (160-
162). This action contrasts to more complex SLs such as SM and 
glucosylceramide, which cannot readily flip because of the steric 
impediment of their head-groups. So, they remain in the leaflet in which 
they were produced. For glucosylceramide though, it is possible that a 
flippase may help the lipid to reach the opposite leaflet for further 
modifications. 
Localization of SLs that do not readily diffuse through membranes 
mostly depends upon the localization of the enzymes that produce them. De 
novo synthesis of SLs, up to the formation of ceramide, takes place in the 
ER and from there ceramide is transported to the Goigi apparatus via 
vesicular trafficking for glucosylceramide synthesis and mostly through 
protein transport (CERT) for SM synthesis. Therefore, SL levels are not only 
determined by regulation of the enzymes through which they are 
metabolized but also by regulation of the processes that connect different 
branches of the pathway residing in different organelles. 
Several reactions may be catalyzed by different isoforms of the same 
enzyme. For instance, CerS is represented by six isoforms (CerS 1-6) that 
have been localized in the ER (for a review please see (163)), as are the two 
dihydroceramide desaturase isoforms, DESI and DES2 (164). The situation 
is further complicated by the fact that for some enzymes, different isoforms 
are localized in different organelles, as is the case for SMS 1 which is present 
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in the Golgi, and SMS2, which is present in the Golgi and plasma membrane 
(9,165). Likewise, acid CDase is found in lysosomes, neutral CDase is found 
in the mitochondria and plasma membrane, and alkaline COase (Acerl) is 
localized to the ER, Acer2 is found in the Golgi, and Acer 3 in the ER and 
Goigi (for a comprehensive discussion on CDases please refer to (27)). 
Thus, it follows that distinct enzymes that regulate the same reaction 
may coexist in the same organelle and that same reactions are carried out in 
different organelles. Modes by which each enzyme accesses its substrate (in 
particular for different isoforms within the same organelle) and the way each 
substrate accesses its enzyme (in particular for different isoforms in different 
organelles) become determining factors in the regulation of specific 
functions of the different enzymatic isofonns. 
Not all ceramides are created equal. 
With the advancement of techniques that permit characterization and 
quantification of SLs, a significant finding of the last 15 years is that 
ceramides consist of a diverse class of molecules. In fact, via mass 
spectrometry, it has been shown that different fatty acid moieties may be 
naturally linked to the sphingoid backbone, mainly long fatty acids (with 14 
to 18 carbons) and very long fatty acids (with 20 carbons and above) 
(Figure 2). 
The significance of such ceramide variety may lie within specific 
functions of each species. In support of this hypothesis, in head and neck 
squamous cell carcinoma (HNSCC), C I6 and C I8 ceramides have been 
shown to exert opposing effects: accumulation of C I8 ceramide by 
overexpression of CerS 1 induced apoptosis and potentiated the cytotoxic 
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effect of chemotherapeutic agents (42), whereas accumulation of C 16 
ceramide via CerS6 was essential for HNSCC survival (166). Of note, the 
same ceramide species may exert different effects in different cell types. In 
fact, in Ramos B cells, the specific increase of C I6 ceramide contributed to 
apoptosis induced by IgM cross-linking (167), and, in colon cancer cells, C 16 
ceramide produced by CerS6 restored sensitivity to tumor necrosis factor-
related apoptosis-inducing ligand, TRAIL(168), thus exerting a pro-
apoptotic function in both cell types. In HEK 293 T cells, unlike HNSCC, 
CIS ceramide generated by CerSI overexpression did not cause apoptosis 
(169). In addition to specific functions for C 16 and C I8 , it was also observed 
that an increase of C 24:0 and C24:1 ceramides via activation of nSMase2 
induced cell growth arrest in the breast cancer cell line, MCF-7 (95). 
The possibility that different ceramide species may exert different 
functions perhaps justifies the presence of many different enzyme isoforms. 
The most eloquent example is represented by the CerS family. Strikingly, 
each family member has a clear substrate preference for specific fatty acyl-
CoAs, which determines the specific molecular ceramide species produced. 
For example CerSl utilizes mostly C 1S- and C 18:I-CoA; CerS2 utilizes CoAs 
carrying very long chain fatty acids; and CerS5 and CerS6 utilizes mostly 
C I6-CoA (163). Therefore, this substrate preference ensures that CerS are not 
redundant when more isoforms are expressed at the same time. It is tempting 
to speculate that different substrate specificity may be shared also by other 
enzymes of SL metabolism for which different isoforms are present in the 
same cellular compartment, such as neutral SMases or SMSs. However, 
experimental evidence to support this is presently lacking. 
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Crosstalk between the SL and glycerolipid pathways .. Role of 
Sphingomyelin Synthase. 
The enzyme that synthesize SM, SMS, do so by transferring a 
phosphocholine moiety from PC onto the primary hydroxyl of ceramide (6). 
Therefore in the course of the reaction, a DAG molecule is also produced 
(Figure 3). DAG is a well-established bioactive glycerolipid associated with 
pro-proliferative and prosurvival phenotypes and with several important 
cellular targets such as PKCs, protein kinase D, RasGRP, and chimaerins 
[for reviews, see (170-173)]. Thus, it is apparent that SMS can regulate in 
opposing directions levels of two bioactive lipids with opposing cellular 
effects, cerami de and DAG. 
The SMS family has have only been recently molecularly identified 
(174,175). In mammals, two genes SMSl and SMS2 are responsible for 
encoding two SMS isoforms, SMS 1 and SMS2. At the protein level, human 
SMS1 and SMS2 consists of 413 and 365 amino acids, respectively, with an 
apparent molecular weight slightly above 37kD. SMS 1 and SMS2 share 
50% identity and 64% similarity. Significant divergence is found in the 
amino termini of the proteins where SMS 1 carries a sterile alpha motif 
(SAM) missing in SMS2. SMSI and SMS2 are both integral membrane 
proteins with 6 predicted transmembrane domains (174). Importantly, SMS1 
and SMS2 differ for their sub-cellular localization. SMS 1 is localized in the 
Goigi and SMS2 in Goigi and plasma membrane. Importantly, this 
localization pattern is in agreement with early biochemical studies that found 
the bulk of SMS activity in the Goigi and residual activity in other cellular 
compartments including plasma membrane (176-181). Recent studies have 
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established that the SAM domain is not important for SMS 1 localization 
since it neither changes localization of SMS2 when a SAM-SMS2 chimaera 
was studied (182). On the other hand, 4 palmitoylation sites present on the 
C-terminus of SMS2, and absent on SMS 1, seem to be instrumental for 
SMS2localization to the plasma membrane (183). 
In vitro biochemical characterization of the two proteins, using a yeast 
expression system, showed that both enzymes work as bidirectional 
transferases potentially able to synthesize either SM or PC (174). In addition 
to PC, SMS2 can also convert Phosphatidylethanolamine (PE) into 
phosphorylethanolamine-ceramide (EPe) (5). In Hela and macrophage cell 
lines, studies conducted by Luberto, et al. (165) and others (184,185) have 
shown that down-regulation of either SMS 1 or SMS2 causes a decrease in 
SM and a concomitant increase of ceramide, lipid changes that suggest a 
basal SM synthetic activity. Moreover, it was shown that both SMSI and 
SMS2 are active in the Goigi and contribute to de novo SM synthesis. The 
effect of modulation of SMSs on DAG are less apparent. Down-regulation 
of both SMSs slightly reduces DAG levels in macrophages (185), but it does 
not exert a net effect in Hela cells (165,184). On the other hand, subcellular 
localization studies conducted by our laboratory in Hela cells (165), have 
revealed as modulation of both SMSs induces a relocalization of DAG 
subcellular pools. These studies suggest as both SMSs have the ability to 
modulate also DAG cellular levels. Modulation of SMS 1 or SMS2 in 
macrophages, HEK 293, and lymphoma have demonstrated the importance 
of either SMS in the maintenance of proper homeostasis of lipid rafts and 
consequently proper lipid-raft-mediated receptor signaling, as for CD95, 
TNFR and TCR (186-188). 
26 
Furthermore, in addition to direct regulation of DAG levels, SMSs 
may also affect levels of other bioactive glycerolipids derived from DAG, 
such as phosphatidic acid or glycerolipids with metabolic functions such as 
monoacylglycerol or triacylglycerol. Importantly, SMS1 knock out mice 
have been recently characterized as having significant neonatal lethality, 
smaller size, reduced body weight, loss of fat tissue mass, and impaired 
insulin secretion (189), thus, whether these phenotypes are related to 
alteration of glycerolipid metabolism will be of interest. 
Evidence for the regulation ofSMS 
The following are key studies that helped to elucidate SMS' role 
within regulated cellular processes. These studies are limited since there 
was a great deal of difficulties in the past identifying the proteins or genes 
that are responsible for SMS activity and its regulation. Nevertheless, SMSs 
role in addition to SM biosynthesis has been validated by a number of nicely 
crafted studies. These studies were performed, for the most part, in 
experimental conditions characterized by altered proliferation and/or 
transformation. Miro-Obradors and colleagues showed that SMS activity is 
increased during rat liver regeneration compared to non-proliferating cells 
(190). In a different study, SMS activity was increased in quiescent primary 
astrocytes after stimulating the cells with J3-fibroblast growth factor, a 
cellular proliferation stimulus (191). Other studies demonstrated elevated 
SMS activity in transformed phenotypes (such as hepatocellular carcinoma 
versus normal liver and SV -40 transformed fibroblasts versus their normal 
counterpart)(192,193). Alternatively, a decrease of SMS activity preceded 
the onset of apoptosis induced by either TNF or FAS ligand (108,194). The 
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decrease of SMS was an early event concurrent with early accumulation of 
ceramide. Importantly, the loss of SMS activity was found to be a caspase-
dependent event thus suggesting that inhibition of SMS could be a regulated 
process required for the full development of the apoptotic program. 
In spite of the great biological potential of SMS, its role and function 
In important cellular processes, such as proliferation, apoptosis and 
differentiation is still poorly understood. The recent identification of 
candidate SMSs genes provides us with a unique and long awaited 
opportunity to start shedding some light on these important enzymes. 
General concepts of leukemia. 
Classification and incidence of leukemia. 
Leukemia can be broadly classified as a malignant neoplasm arising 
from the transformation of a hematopoietically derived blood cell. Like other 
cancers, leukemia is characterized by abnormal and uncontrollable cell 
division. Most leukemias fall into four different classes: acute myelogenous 
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic 
myelogenous leukemia (CML), and chronic lymphocytic leukemia (eLL) 
(195). Each of these leukemias include numerous sub-types, so a uniform 
classification system does not exist at this time. Currently, designations of 
different leukemia subtypes are made according to either the French-
American-British (FAB) system or the World Health Organization (WHO) 
classification. The F AB system represents a more classical approach that 
uses morphological, cytochemical, and to a lesser degree, 
immunophenotyping analysis for classification (196-200). The WHO 
classifications are gradually replacing the more traditional FAB groups. Like 
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the F AB designations, WHO classifies different leukemia types according to 
morphology, but also relies heavily on cytogenetic and genetic features. 
According to the WHO classification system, leukemia can be initially 
classified based on lineage, namely: myeloid neoplasms, lymphoid 
neoplasms, mast cell disorders, and histiocytic neoplasms. In addition, each 
category is further narrowed according to a combination of diagnostic 
features including morphology, genetic abnormality, clinical symptoms, and 
immunophenotype (195,201). 
ALL and AML are clinically characterized by sudden onset and, if not 
treated, the progression of these diseases is rapid. Patient signs and 
symptoms are related to depressed bone marrow function. ALL is the most 
common leukemia, representing about 80% of all acute leukemias and is far 
more common in children than in adults. In fact, ALL is the cause of 75% of 
childhood cancers, with AML accounting for most of the remaining cases 
(202). AML is mostly a disease that occurs in adults although, occasionally, 
AML arises in children and young adults (203). 
In general, the chronic leukemias, eLL and CML, are initially 
characterized by increased proliferation of more differentiated myeloid and 
lymphoid cells. Both CML and eLL are mainly adult-onset diseases and 
thus are rarely seen in children. CLL is responsible for 30% of all leukemias 
and occurs mostly in older adults with an average age at diagnosis around 72 
years-of-age. Finally, CML accounts for 10-15% of all leukemias, with the 
average age of onset at 67 years-of-age at the time of diagnosis. (203). 
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Leukemia as a stem cell disorder. 
Leukemia is thought to be the result of a neoplastic transformation of 
the hematopoietic stem cell (HSC). Normal HSCs, and their partially 
differentiated progenitor cells (collectively called blast cells) are an 
important reservoir for short-lived, mature blood cells. HSCs are classified 
into compartments according to their distinct, laboratory-based 
characteristics. The three compartments are the stem, progenitor, and 
precursor compartments, and although each of these compartments includes 
a number of different cell types, each compartment is distinctive. All cells in 
the different compartments have self-renewal capabilities for maintaining a 
stable HSC population. Determination of the differentiation status is based 
upon the detection of a variety of unique surface antigens (204-207). The 
stem cell compartment contains the least number of cells. These cells are 
molecularly defined by antigens expressed on the surface, such as Thl-l, the 
Flk-l/KDR receptor as well as the expression of CD34 (205,208,209). The 
next compartment is the progenitor cell compartment; these cells are not 
morphologically distinguishable. Progenitor cells have become partially 
differentiated to initiate a lineage specific pathway and are more copious 
than those within the stem cell compartment. The molecular pathway 
committing these cells to lineage dependence is not completely understood. 
Within the progenitor compartment, cells are at different differentiation 
stages, which are defined based upon a variety of different criteria including 
proliferative potential, maturation time, response to a variety of cytokines, 
and the ability to produce partially differentiated progeny. The final 
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compartment is the precursor cell compartment in which cells can be 
distinguished based on their morphological characteristics (207). 
The most compelling evidence establishing leukemia as a stem cell 
disease comes from experiments using AML cells isolated from human 
patients. These cells, after transplantation into an immuno-compromised 
mouse, gave rise to AML, establishing a novel mouse model for the disease 
(210). These studies reveal similarities between hematopoietic stem cells 
and leukemic stem cells, including properties of multi-potency and self-
renewal that were maintained even upon serial transplantation of AML cells 
into mice. Interestingly, upon transplantation, few AML cells (estimated at 
1x105 to 1x106 mononuclear cells in the marrow) had complete self-renewal 
capabilities and multi-potency. Further immunophenotypic analysis of this 
population demonstrated that these AML cells displayed known HSC 
markers (CD34+/CD38-) consistent with the least differentiated stem cell 
state. In contrast, AML cells that exhibited a slightly more differentiated 
immunophenotype, CD34+/CD3S+ were unable to proliferate effectively. 
These data strongly suggest that the heterogeneous population of blast cells 
exhibiting various stages of maturation, as seen in leukemia patients, can be 
derived from a single leukemic stem cell (LSe) which, in tum, can sustain 
the leukemic disease. Importantly, this hierarchical LSC population 
organization in terms of both numbers and levels of maturity mirrors the 
commonly accepted paradigm of normal adult hematopoiesis. In addition, 
the slow rate of proliferation, which is characteristic of HSCs, is also 
exhibited by LSCs. In fact, LSCs slow proliferation rate is thought to be a 
contributing factor to the overall refractiveness of leukemic disease to 
conventional chemotherapy strategies targeting rapidly dividing cells (210-
213). 
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SLs and Leukemia 
Acute myelogenous leukemia (AML) 
AML is mostly associated with acquired genetic alterations that 
inhibit terminal differentiation and result in replacement of normal marrow 
elements with largely undifferentiated blast cells. The traditional in vitro 
cellular model to study this disease is the HL-60 cell line (203), which was 
obtained by leukopheresis from a patient with acute promyelocytic leukemia 
(214). Many early studies using HL-60 cells revealed that alterations of SL 
metabolism in leukemic cells can induce cellular processes such as apoptosis 
and differentiation which can be further exploited for therapeutic benefit. 
Early studies showed that increased ceramide correlated with HL-60 
cells differentiation induced by vitamin D3 treatment (30). In these studies, 
ceramide was shown to be derived from SM hydrolysis; equal masses of 
ceramide and phosphorylcholine were produced after vitamin D3 treatment, 
and increased neutral SMase activity in cell extracts was detected. Similar to 
the behavior of "signaling" molecules, ceramide returned to basal levels by 4 
hours. These observations suggested the existence of a "SM cycle", a 
mechanism of SM hydrolysis and regeneration intimately linked to cellular 
processes such as differentiation. 
Subsequent studies corroborated ceramides' role in HL-60 
differentiation by illustrating enhanced vitamin D-mediated differentiation 
upon addition of cell-permeable ceramide (synthetic ceramide with a shorter 
fatty acid chain) or purified soluble bacterial neutral SMase (31). Ceramide 
has also been shown to recapitulate the ability of TNF-a or interferon y to 
induce monocytic differentiation in HL-60 cells (215). Mechanistic studies 
later established that TNF-a stimulation (leading to ceramide generation) 
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resulted in de-phosphorylation of Rb (216) due to PPI activation (217). 
Ceramide accumulation during differentiation is not only observed in HL-60 
cells (30,31,215), but also is seen in a number of other cell types, such as 
EL4 thymoma cells (218), cerebral Purkinji cells (219), and U937 
monoblastic leukemia cells (220). 
Subsequent experimentation revealed that ceramide could induce a 
cytotoxic effect consistent with the apoptotic phenotype (32). The fact that 
SL modulation can induce apoptosis was substantiated by additional studies 
showing SM hydrolysis followed by apoptosis in response to a variety of 
different cytokines and known stress-inducers such as TNF -u, interferon y, 
and IL-l in numerous cell types. Furthermore, the biological effect of many 
of these agents was reproduced upon exogenous addition of either cell-
permeable ceramide analogues or bacterial SMase [for excellent reviews on 
this topic please refer to (92,221,222)]. 
Because AML is characterized by the inability of stem cells to 
properly differentiate, the ability of ceramide to either revert the 
undifferentiated phenotype of AML blasts or suppress them (alone or in 
combination with chemotherapeutic agents) has prompted investigators to 
consider SL metabolism manipulation as a novel therapeutic approach. 
Moreover, recent developments have established a link between drug 
resistance and alterations of the SL pathway. It has long been established 
that treatment of parent HL-60 cells with doxorubicin results in increased 
ceramide and subsequent apoptosis (223). In contrast, HL-60 cells positive 
for the multidrug resistance genes MDR1 or MRPI(224), failed to respond 
to doxorubicin or etoposide and did not accumulate ceramide (225). It was 
proposed that the key difference in SL metabolism between parent and MDR 
HL-60 cells was SKI expression, which was low in parent HL-60 and 
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significantly elevated in MDR HL-60 cells. Importantly, forced SKI 
expression in sensitive parent cells resulted in blockade of apoptosis whereas 
inhibition of SKI activity in MDR HL-60 by the pharmacological inhibitor 
F-12509a overcame this resistance by inducing mitochondrial-dependent 
apoptosis. In another study, granulocyte macrophage colony-stimulating 
factor (GM-CSF) fused to the catalytic and translocation domains of the 
diphtheria toxin (DT388-GM-CSF) induced cell death in MDR HL-60 cells. 
DT388-GM-CSF treatment induced a strong ceramide accumulation 
concomitant to SM hydrolysis (226). Because the GM-CSF receptor is only 
present on AML blasts, the engineered diphtheria toxin is preferentially 
delivered to AML cells, thereby killing them, likely by affecting SL 
metabolism. The effectiveness of DT388-GM-CSF as a novel therapeutic 
approach for AML was initially determined in a phase I clinical trial 
conducted on drug-resistant AML patients. In this trial, DT388-GM-CSF was 
found to promote partial or complete remission, although hepatotoxicity 
prevented widespread drug use (226). 
Recently, the therapeutic potential of the modulation of bioactive SLs 
as a way to potentiate other therapies was investigated in conjunction with 
resveratrol (3,5,4'-trans-trihydroxystilbene), a natural compound known to 
exhibit anti-tumor activities through an undetermined mechanism. It was 
observed that elevation of endogenous ceramide in HL-60 cells promoted by 
either cell permeable C8-ceramide treatment, pharmacological inhibition of 
glucosylceramide synthases with l-phenyl-2-decanoylamino-3-morpholino-
I-propanol (PDMP) or SKI inhibition in combination with resveratrol was 
followed by significantly greater apoptosis compared to any of the 
treatments given in isolation (227). These observations support the idea that 
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induction of ceramide accumulation might be a viable avenue for sensitizing 
cells to other cytotoxic agents. 
Acute lymphoblastic leukemia (ALL). 
ALL represents a group of neoplasms defined by accumulations of 
precursor B or T-Iymphocytes commonly called lymphoblasts (203). In 
particular, T-ALL is a highly aggressive leukemia and represents 15% of 
childhood ALL and 25% of adult ALL (228). Model systems of lymphoid-
derived cell lines have allowed reseachers to uncover the potential of SLs as 
mediators of chemotherapeutics through apoptosis. For example, cytarabine 
(Ara-C) and fludarabine induced apoptosis in lymphoid leukemia cell lines 
by increasing ceramide via SM hydrolysis as well as de novo ceramide 
synthesis (229). The correlation between ceramide and apoptosis is also 
supported by ceramide accumulation in ALL cells in response to 
doxorubicin (230) and the vinca alkaloid, vincristine (VCR) (231,232). 
Ceramide accumulation-driven apoptosis is a proposed pathway to 
cytotoxicity in addition to the ones originally described for these agents. In 
T -ALL cells, the apoptotic mechanism invoked for doxorubicin depends 
upon ceramide upregulation, specifically through stimulation of the CD9S 
(APO-l/Fas) death receptor as demonstrated by increased CD9S-ligand, 
cleavage of caspases and apoptosis, and by activation of the tyrosine kinase, 
Lck (233). Likewise, inhibition of the CD95 death pathway either by anti-
sense-mediated downregulation of CD95-L, dominant negative Fas 
Associated protein via Death Domain (FADD), or by using cells deficient in 
aSMase (Niemann-Pick A [NPA] fibroblasts) inhibited ceramide-induced 
apoptosis. Finally, ceramide's role in this process was also supported by the 
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observations that upon exogenous ceramide addition in NP A fibroblasts, a 
restoration of apoptosis and CD95-L expression was observed. Collectively, 
these results provide a link between doxorubicin-stimulated ceramide and 
C095 death signaling (230). 
The relationship between CD95 activation and ceramide has been the 
topic of intense investigation and one of the most popular cellular models 
employed has been the T -ALL cell line, Jurkat. Although not without 
controversy (76,230,234-245), the current model for this relationship 
involves the activation of aSMase (246). In particular, upon initial 
stimulation of the CD95 receptor, the recruitment and activation of a small 
percentage (--2%) of the adaptor protein FADD and caspase 8 to the receptor 
is sufficient to induce translocation of aSMase to the plasma membrane. 
ASMase, in tum, produces ceramide which coalesces into ceramide-rich 
platforms, favoring CD95 oligomerization and the assembly of the DISC for 
the full activation of the CD95 signaling cascade. The importance of this 
process is demonstrated in experiments with lurkat cells in which 
pharmacological inhibition of raft formation (by cholesterol extraction or 
chelation), inhibition of aSMase activation, or sequestration of surface 
ceramide with anti-ceramide antibody caused resistance to CD95-induced 
apoptosis (243-245). Finally, inhibition of nuclear SMS activity has been 
shown to be an additional contributing factor to ceramide accumulation and 
apoptosis in response to CD95 stimulation (108). Inhibition of SMS activity 
was found to be a caspase-dependent event (109). Cleavage and inactivation 
of SMS1 occurred early in the signaling cascade and caused the re-
localization of the enzyme from the Golgi, where it normally resides, to the 
cytoplasm. 
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In line with the importance of activation of aSMase for CD95-
signaling, recent observations have also demonstrated the fundamental role 
for plasma membrane SM in this process. In fact, a mutant line of murine T 
cell lymphoma WR19L devoid of SMS1 (hence of SM in the outer leaflet of 
the plasma membrane where SM naturally is concentrated), failed to 
undergo apoptosis in response to CD95 ligation because of the inability of 
the receptor to cluster. Restored expression of SMS 1., and thus of SM in the 
plasma membrane, enabled formation of the CD95-initiated death-inducing 
signaling complex., allowing caspase 3 and 8 activation and the full 
execution of the apoptotic program (175,187,247). 
Over the years, lurkat cells have been a popular model for studying 
the relationships between SLs and T-cell ALL, in particular. In fact, in 
addition to investigations to address the role of SLs as signaling molecules 
downstream of CD95 activation, lurkat cells have been employed to study 
the SL response after a variety of other stimuli, such as gamma and UV-C 
radiations, photodynamic therapy (PDT), cannabinoids, and galectin-l 
(107,248-254). Apoptosis is the most common ceramide-mediated response 
observed in these cells., although necrosis due to loss of mitochondrial 
membrane potential, formation of reactive oxygen species, and loss of 
intracellular ATP has also been observed (255,256). For instance, apoptosis 
has been observed after treatment with gamma radiation, and ceramide 
accumulation, resulting initially from SM hydrolysis and subsequently from 
de novo synthesis, preceded the onset of caspase-dependent death. 
Interestingly, after irradiation, ceramide accumulated in different cellular 
compartments at different times: an early peak was observed in the plasma 
membrane (minutes), followed by an Increase of ceramide In the 
mitochondria (hours) (249,250,254). Importantly, the addition of SL 
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metabolism inhibitors which favor the accumulation of endogenous 
ceramide maximized mitochondrial dysfunction and apoptosis (251). 
Modulation of ceramide metabolism by inhibition of ceramidases or GCS 
potentiated apoptosis also in response to the cationic antimicrobial peptide 
bovine lactoferricin (257) and in lurkat cells, as in AML blasts, SKI 
inhibition with BML-258 was sufficient for inducing caspase-dependent cell 
death (258). Similar to CD95 stimulation, exposure of lurkat cells to UV-C 
induced a rapid translocation of aSMase to the plasma membrane where it 
promoted ceramide formation and raft fusion (244). Different from CD95 
stimulation, the UV -C-induced aSMase activation was caspase independent, 
but nevertheless critical to UV -C-induced cell death. Activation of aSMase 
in these cells has been observed in response to a number of apoptotic stimuli 
such as the histone deacetylase inhibitor LAQ824 and the B-galactosidase-
binding protein galectin-l (78,253). 
Exposure to PDT was also found to be cytotoxic for lurkat cells, and 
after PDT, ceramide was found to accumulate due to inhibition of SMS and 
GCS . (107). Indeed, over-expression of SMS 1 decreased ceramide 
accumulation and apoptosis after PDT treatment (259) whereas RNAi-
mediated down-regulation of SMS 1 resulted in the opposite effect, 
potentiating apoptosis through caspase activation (260). 
In Jurkat cells, ceramide-induced apoptosis generally proceeds in a 
caspase-dependent fashion although the precise ordering of the signaling 
cascade is unclear. For example, caspase 8 has been proposed to act 
upstream of mitochondrial damage upon treatment with ceramide or 
etoposide (261) whereas it was shown to be downstream of the mitochondria 
after ceramide accumulation in response to cannabinoid treatment (252). 
Recently, research into the effects of ceramide on gene transcription 
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indicated the tumor suppressor gene thioredoxin-interacting protein (Txnip) 
as a novel distal effector (262). Similar to ceramide, etoposide induced 
Txnip expression and apoptosis, and both events were prevented by 
inhibition of ceramide production. According to this study, Txnip, by 
binding to thioredoxin, promotes its dissociation from the apoptosis signal-
regulating kinase 1 (ASKl) which, in tum, gets activated. Active ASK! 
promotes phosphorylation of p38 mitogen-activated protein kinase and JNK 
and induces ER stress, events that collectively lead to apoptosis. 
In addition to Jurkat, Molt~4 cells have been employed as an 
additional model for T -ALL, and they have been instrumental for the 
discovery of the functional link between ceramide and cell cycle arrest. Prior 
to cell cycle arrest induced by serum withdrawal, sustained cerami de 
accumulation due to SM hydrolysis through the action of an nSMase was 
observed. Addition of C6-ceramide recapitulated the serum withdrawal 
phenotype (263). Later studies in other cell types showed that ceramide-
induced cell cycle arrest was caused by dephosphorylation of Rb (217) and 
inactivation of the eyelin-dependent CDK2, but not CDK4 (264). 
Chemotherapeutics and their ability to activate apoptosis have also 
been studied in this cell line. Etoposide was shown to induce apoptosis 
through activation of SPT (41), and increased ceramide due to activation of 
aSMase and nSMase prior to caspase 3 activation was observed after 
treatment with the folate analog and thymidylate synthase inhibitor, 
GW1843 (265). 
Molt-4 cells were also used to investigate the relationship between 
p53, a known tumor suppressor, and ceramide; this relationship was 
analyzed based upon the seemingly functional similarities of these two 
molecules. These studies revealed that upon treatment with either 
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actinomycin D or gamma-irradiation, there was an induction of p53-
dependent ceramide accumulation followed by cell death (266). The 
biochemical pathways responsible for ceramide accumulation after p53 up-
regulation were recently revisited, and it was shown that gamma-irradiation 
of Molt-4 cells and consequential p53-upregulation led to de novo ceramide 
synthesis of primarily C]6-ceramide due to increased activity of ceramide 
synthase (267). 
Evidence for in vivo regulation of SLs in AML, ALL and Large 
Granular Lymphocytic Leukemia 
SKI and nSMase2 expression (measured by quantitative peR) were 
found to be altered in bone marrow specimens collected from patients with 
acute leukemia (148). Corresponding to signaling functions of these two 
enzymes, SKI expression was IO-fold greater in leukemic specimens 
compared to normal bone marrow, whereas nSMase2 expression was 10-
fold lower in leukemia when compared to normal counterparts. 
In line with these observations, the nSMase2 gene was reported to be 
the target of inactivating mutations in human ALL and AML specimens 
(268). In fact, 11 different mutations were reported., targeting the nSMase2 
gene in 8 of 131 (6%) ALLs and 5 of 92 (5%) AMLs examined, but no 
mutations on nSMase2 were found in other cancers examined. Of these 
mutations, 9 corresponded to amino acids conserved in all known vertebrate 
animal sequences of nSMase2, with 2 recurrent mutations. Functional 
analysis of two mutations revealed lower nSMase2 protein expression and/or 
its mislocalization; the effect of the other mutations was not readily evident 
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(148). Support for SKI '8 contribution to AML is validated by investigations 
demonstrating a potent induction of apoptosis upon SKI specific inhibition 
in AML leukemic blasts isolated from patients (258). Importantly., this study 
identified and subsequently utilized the first potent and water-soluble 
pharmacological inhibitor specific for SKI (BML-258). Results revealed 
that BM-258 treatment and subsequent apoptosis were specific to leukemic 
blasts because they were relatively non-cytotoxic to normal peripheral blood 
mononuclear leukocytes. Furthermore, BM-258 was suggested to be a 
potential therapeutic agent for ameliorating AML because its use in an AML 
xenograph model suppressed tumor growth, and decreased cell proliferation 
and induced apoptosis within the tumor (258). Based on the evidence 
previously presented for the regulatory functions of SLs and ceramide in cell 
culture models for AML and ALL, these results substantiate the potential 
targeting of the SL pathway as an effective therapeutic intervention. 
Promise for manipulating ceramide levels to induce apoptosis of 
leukemic cells is impressively demonstrated in a recent investigation with 
large granular lymphocytic leukemia (LGL) cells derived from natural killer 
(NK) cells (269). NK-LGL can be an extremely aggressive disease, with 
survival upon diagnoses limited to only days or weeks. Notably, NK-LGL 
pathogenesis is relatively unknown and no therapeutics exist for this disease. 
In this study, high expression of survivin., a member of the inhibitor of the 
apoptosis protein (lAP) family, was reported in both chronic and aggressive 
NK leukemia cells isolated from patients (but not in normal tissues), and this 
demonstrated the dependence of primary human NK-LGL on this protein for 
survival. Treatment of the RNK-16 cell line, a rat model for NK-LGL, with 
cell permeable C6-ceramide administered in nanoliposomes resulted in 
inhibition of constitutive phosphorylation of ERK and a time- and dose-
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dependent decrease of survivin protein. The relevance of these studies to in 
vivo NK-LGL was validated because systemic, intravenous delivery of 
nanoliposomal ceramide induced complete remission of aggressive NK-LGL 
leukemia in a rat model (transplantation of spleen cells from aged F344 rats 
with spontaneous LGL leukemia in young syngeneic rats). In addition, C6-
ceramide induced caspase-dependent cell death in human primary NK-LGL 
but not in the normal counterparts. Collectively, these data suggest that 
effective ceramide delivery can target leukemia mediators that are 
dysregulated, such as sUfvivin, serving as a unIque approach for specific 
therapy directed to leukemic versus normal cells. 
Disrupted SL signaling during LGL derived from T-cells (T-LGL) 
was also demonstrated (270) with an approach that utilized microarray data 
and "theme-based" bioinfonnatics such as Expression Analysis Systematic 
Explorer (EASE) and Gene Set Enrichment Analysis (GSEA) collected from 
mononuclear cells in peripheral blood (PBMC) of normal versus T -LGL 
patients. This analysis revealed a dramatic dysregulation of apoptotic gene 
expression in PBMCs of T-LGL patients. Additionally, there was evidence 
of a balance shift between SL-mediated pro-apoptotic signaling versus anti-
apoptotic signaling, with a critical role for acid ceramidase and SKI, both 
upregulated in PBMCs of T-LGL patients. Upon validation of the 
bioinformatic results, it was discovered that inhibition of acid ceramidase 
(by NO E) and of SIP-mediated signaling with the SIP antagonist FTY720, 
resulted in significantly higher apoptosis in T -LGL PBMCs versus normal 
PBMCs. 
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Chronic myelogenous leukemia (CML). 
Myelogenous neoplasms are hematopoietic stem cell disorders 
resulting from the clonal expansion of one or more of the myeloid stem or 
precursor cells (201). CML is one of the best characterized myelogenous 
leukemias and one of the first malignancies known to result from a specific 
genetic abnormality, the Philadelphia chromosome (Ph). This abnormality 
arises from the reciprocal translocation between the long arms of 
chromosome 9 and 22 creating a fusion gene between BCR (breakpoint 
cluster region) and ABL (Abelson leukemia virus-derived kinase). BCR-
ABL is subsequently transcribed and translated into a constitutively active 
tyrosine kinase protein similarly named, Bcr-abl (Figure 4) (271-274). Bcr-
abl encodes three different Bcr-abl proteins depending upon the location of 
the translocation breakpoint located on chromosome 22: p190 kD, p210 kD 
(the most common), and p230 kD [reviewed in (275-278)]. 
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Figure 4. Reciprocal translocation of Bcr-abl. Reciprocal translocation of 
chromosomes 9 and 22 resulting in der 9 and the Philadelphia chromosome. 
Translocation results in the fusion gene between BCR (breakpoint cluster region) and 
ABL (Abelson Leukemia virus-derived kinase), Bcr-abl. 
In the clinical setting, CML is characterized by three distinct phases: a 
chronic phase, an accelerated phase, and a blast phase (or blast crisis). The 
chronic phase is characterized by expansion of the granulocytic cell lineage 
and, if untreated, it lasts two to five years. The accelerated phase is 
characterized by an increase of basophils or blasts, abnormality of platelet 
counts, and the presence of clonal evolution, and it may last up to one year. 
Disease progression from the accelerated phase to the blast phase is 
associated with an increase in cytogenetic mutations and a block of cell 
differentiation that results in the presence of 30% or more myeloid blast 
cells in peripheral blood or bone marrow, and eventually the presence of 
infiltrates outside the bone marrow. The survival time for patients in blast 
phase is 3 to 6 months (276,278,279). 
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The fusion of the Ber and Abl genes produces a protein that retains 
the tyrosine kinase activity of Abl, but it has lost its regulation and is now 
constitutively active. At early stages of CML, the kinase activity of Bcr-abl 
is necessary for its oncogenic function, and a number of factors have been 
identified as potential direct or indirect targets of its disregulated kinase 
activity. Bcr-abl promotes the formation of a multicomplex via binding to 
GRB2 (growth factor receptor-bound protein 2) that in turn binds to SOS (a 
guanine-nucleotide exchanger of RAS) which activates Ras. GRB2 also 
binds to Gab2 (GRB2-associated binding protein 2) which is phosphorylated 
by Bcr-abl and activates the PI3K1AktJMAPK pathway (274,280,281). Other 
targets of Bcr-abl are the RAe GTPases (RAe1, 2, and 3) and janus kinase 
2. Ultimately, a number of transcription factors are activated by Bcr-abl such 
as STATs, c-Myc, NF-kB, c-Jun and c-Fos. Activation of these factors 
promotes transcription of anti-apoptotic genes, such as bel2 and bel-xl, and 
of positive regulators of cell cycle progression, such as cyclin D (for a 
review (273,275,277)). It has been postulated that the anti-apoptotic effect of 
Bcr-abl favors inaccurate DNA repair whereas in normal cells DNA damage 
would induce apoptosis. As a result, genetic changes (occurring in 50-75% 
of patients) would accumulate on p53, c-myc, ras, Rb and p16, further 
favoring enhanced proliferation, survival, and arrest of differentiation. These 
events are thought to promote progression to the blast phase in a newly 
acquired Bcr-abl-independent manner. 
With the identification of Bcr-abl as a CML initiator and the 
uncovering of its kinase activity, targeted therapy followed, and Bcr-abl is 
the prototype for such pharmacological approaches .. Indeed a competitive 
inhibitor of the A TP-binding site of Ber-abl was developed by Novartis 
(imatinib mesylate; Gleevec, Glivec, or STI571) (282-284). Imatinib was 
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first administered to patients In 1998, and SInce that time has been 
remarkably successful in patients with chronic phase CML (80% complete 
cytogenetic response in newly diagnosed chronic phase patients) (285). In 
contrast, imatinib treatment does not cure the disease because it does not 
eradicate Bcr-abl-positive hemopoietic stem cells. So, long-term treatment 
with imatinib favors relapse due to acquired resistance arising from point 
mutations in the Bcr-abl A TP-binding site, overexpression of Bcr-abl itself 
or mutations of the p-glycoprotein pump (286). Imatinib treatment for 
patients in the advanced phase of the disease has been far less beneficial than 
for patients in the chronic phase, probably due to an acquired independence 
from Bcr-abl arising from additional genetic mutations. These patients are 
given standard chemotherapy (anthracycline, anthracenedione, cytarabine, 
etoposide, carboplatin, hydroxyurea alone or in combination) and they have 
a response rate, in myeloid blast crisis, of less than 30% (287-291). 
SLsandCML 
Lately the role of SLs in Bcr-abl-mediated signaling is becoming 
more apparent. In fact, initial evidence has led to contrasting conclusions. In 
particular, whereas Bcr-abl expression was shown to impart total or partial 
resistance to treatment with exogenous short chain ceramide analogues (C 2 
or C6-ceramide), Bcr-abl also accelerated ceramide-mediated apoptosis by 
these same analogues (292-295). In contrast, the consensus opinion appears 
to converge on the role of SKI in Bcr-abl positive cells. Increased basal SKl 
activity was observed in Bcr-abl positive, compared to negative cells, 
suggesting that the expression of Bcr-abl is sufficient to drive SKI activity 
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(296). Moreover, it was shown that an SKI target seemed to be Mcl-l 
because inhibition of SKI in CML lead to decreased Mel-I. An additional 
target of SKI in CML cells might be the anti-apoptotic protein bel2; 
overexpression of neutral CDase in K562 cells induced up-regulatioll of bel2 
via SIP (297). Recently, in two important studies, accumulat.ion of 
endogenous ceramide and decreases in the anti-apoptotic SL, SIP, were 
shown to be partly responsible for the cytotoxic effect exerted by imatinib 
treatment in CML-derived cell lines. Also, a balance shift between 
endogenous ceramide and SIP in favor of SIP was purported to be critical in 
the acquisition of imatinib resistance to CML cells (298,299). The first of 
these studies employed K562 cells as an in vitro model of CML and 
demonstrated that. imatinib treatment resulted in a substantial and time-
dependent increase of C 18-ceramide, most likely generated via CerSI. The 
importance of ceramide in inducing apoptosis after imatinib treatment was 
further exemplified by results showing that inhibition of CerS 1 caused a 
complete block of C]8-ceramide generation which was, in turn, followed by 
decreased apoptosis. To understand the mechanism of imatinib resistance, 
K562 cells were continuously exposed to increasing amounts of imatinib 
followed by selection of apoptotic resistant clones, termed K562IIMA 0 .. 2 or 
-1.. Interestingly, these imatinib-resistant clones failed to increase C 18-
ceramide after imatinib treatment and CerS lover-expression in K562/IMA 
cells successfully restored C 18-ceramide accumulation and enhanced 
sensitivity to imatinib. Moreover, detection of enhanced SKI expression 
and SIP generation in K562/IMA cells further suggested an imbalance of the 
C]8-ceramide/SlP ratio in favor of SIP, thus promoting cell survival in these 
cells (298). 
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The role of SKI as an indicator of chemoresistance of CML cells has 
also been explored using the CML cell model LAMA84 (300). In contrast to 
imatinib-resistant LAMA84 cells, imatinib-sensitive LAMA84 displayed 
marked SKI inhibition paired with decreased SIP and increased ceramide 
content. Furthermore, it was demonstrated that SKI over-expression 
protected LAMA84 cells from imatinib-induced cytotoxicity, by blocking 
the release of cytochrome c and Smac/Diablo from mitochondria. The 
potential relationship between SKI and the anti-leukemic drug Ara-C, was 
also investigated. Ara-C was shown to induce cell death by inhibiting SKI, 
suggesting that cell death induced by either imatinib or Ara-C may converge 
on SKI as a regulatory checkpoint. Additionally, these studies identified a 
rapid and transient increase in ceramide, not only following imatinib 
treatment but also upon treatment with Ara-C as well as other anti-leukemic 
therapeutics such as farnesyltransferase (FTI), UOI26 (a MEK inhibitor), 
and F-12S09a (an SKI inhibitor) supporting the idea that an increase in 
ceramide is a common event in response to several chemotherapeutics also 
in CML-derived cells. Notably, pharmacological or RNAi-mediated 
inhibition of SKI resulted in increased ceramide and decreased SIP in 
imatinib-resistant LAMA84 cells, followed by apoptosis as measured by 
caspase-3 activation and strong nuclear fragmentation. Interestingly, 
treatment with F-I2509a in both resistant and sensitive clinical patient 
samples resulted in significant decreases in cellular viability indicating the 
potential of this type of therapeutic in the future. A concurrent study 
conducted in a different laboratory, while failing to quantify lipids upon SKI 
inhibition, still demonstrated that with pharmacological inhibition of SKI, 
there was an early and substantial SKI inhibition in K562 cells, followed by 
impaired cell cycle progression and apoptosis, further supporting the 
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therapeutic potential of SKl(301). Ilnportantly, the combination of imatinib 
and SKI inhibition resulted in a strong synergistic effect on cellular growth 
and survival (302). 
Interestingly, the link between ceramide and Bcr-abl may involve 
PP2A. It has been demonstrated that the cytotoxic effect of the SIP 
antagonist FTY720 to CML cells occurs through activation of PP2A (303). 
Interestingly, it was recently shown that FTY720 treatment induces 
accumulation of ceramide (304) and, as previously discussed, ceramide is 
known to activate PP2A by binding to IPP2A and dissociating it from PP2A 
(115). Therefore a novel link between FTY720/ceramide 
accumulation/activation of PP2A and inhibition of Bcr-abl may exist. 
For a summary of the roles of different SLs and SL-nletabolizing 
enzymes in CML cells, please see Figure 5. 
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Figure 5. Roles of the different SLs and SL metabolizing enzymes in CML cells. A. 
Bcr-abl increases the expression of the SL-metabolizing enzymes SKI and SMS 1 causing 
an increase of the pro-proliferative lipids, SIP and DAG and the decrease of ceramide 
levels. The particular SL profile contributes to the proliferative advantage and pro-
survival characteristics of CML cells. B. Pharmacological inhibition of BCT-abl by 
Imatinib activates CerS 1 and inhibits SMS and SKI with consequent accumulation of 
C18-ceramide levels and decrease of DAG and SIP levels. This particular profile 
contributes to the cytotoxic effect of this drug in CML cells (See text for details). 
DAGandCML 
It is very surprising that the relationship between Bcr-abl and DAG 
has not been documented in the literature. Indirect evidence of the 
involvement of DAG as a downstream signaling molecule of Bcr-abl come 
from reports showing that activation of phospholipase C (PLC) yl and of the 
PI3K1Akt pathway are required for Bcr-abl signaling through mTOR/p70S6-
kinase (305,306). The regulation of mTOR/p70S6-kinase by PLCyl seems 
to occur via modulation of both calcium signaling (CaMKII) (presumably 
through formation of IP3) and classical and novel protein kinase C (likely 
through production of DAG). In our system, we observed a very significant 
drop of DAG levels when either Bcr-abl or SMS/SMS 1 were inhibited. 
Being SMS 1 regulated by Bcr-abl, it is possible that part of the observed 
drop of DAG levels after inhibition of Bcr-abl is due to the decrease of 
SMS/SMSI activity, In addition to inhibition of PLCyl. 
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Chapter 1 
Specific Aim 1: Determine the function ofSMSl in maintaining the 
cancerous phenotype exhibited by Bcr-abl positive blast cells 
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oncogene." 
Tara Ann Burns I, Marimuthu Subathra 1, Paola Signorelli 3, Young Choi 1 , Xiaofeng 
Yang2, Yang Wang2 , Maristella Villani lA, Kapil Bhallas,Daohong Zhou6, and Chiara 
LUbertol. 
Departments of 1 Biochemistry and Molecular Biology, and 2Pathology and Laboratory 
Medicine, Medical University of South Carolina, Charleston, South Carolina, USA; 
3Laboratory of Biochemistry and Molecular Biology, San Paolo University Hospital, 
Medical School, University of Milan, Italy; 4Polispecialistica Bios, 88900 Crotone, Italy; 
5The University of Kansas Cancer Center, Kansas City, KS, USA; 6Division of Radiation 
Health, Department of Pharmaceutical Sciences, and Winthrop P. Rockefeller Cancer 
Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. 
Abbreviated Title: SMS 1 expression is regulated by Bcr-abl 
Abbreviations: SMS, sphingomyelin synthase; DAG, diacylglycerol; SM, 
sphingomyelin; PC, phosphatidylcholine~ TNF, tumor necrosis factor; CML, chronic 
myelogenous leukemia; NBD, N-(7-nitrobenz-2-oxa-l,3-diazol-4- yl)amino; FACS, 
fluorescence activated cell sorter; PARP, Poly (ADP-ribose) polymerase; SIP, 
sphingosine-I-phosphate; PP2A, protein phosphates 2A; PLC, phospholipase C. 
Supplementary key words: sphingomyelin synthase, ceramide, diacylglycerol, Bcr-abl, 
imatinib mesylate. 
INTRODUCTION 
Sphingomyelin synthase (SMS) represents an important class of 
enzymes responsible for the biosynthesis of sphingomyelin (SM), a critical 
structural component of the plasma membrane. While producing SM from 
ceramide and phosphatidylcholine (PC), SMSs also form diacylglycerol 
(DAG) (307-313). Therefore the biological importance of SMSs may reside 
not only in the biosynthesis of SM but also in the regulation, in opposing 
directions, of the levels of ceramide, a bioactive molecule which mainly 
exerts a negative effect on cell proliferation, and DAG, a well-established 
mitogenic lipid (314). 
Indeed, increased SMS activity was observed in conditions of 
enhanced cell proliferation (such as regenerating rat liver or stimulation of 
quiescent astrocytes with basic FGF) (192,193) and during cell 
transformation (such as hepatocellular carcinoma versus normal liver and 
SV-40 transformed fibroblasts versus their normal counterpart) (314,315). 
Vice versa, inhibition of SMS activity, in a caspase-dependent manner, has 
been shown to precede the onset of apoptosis induced by either TNF in 
Kym-1 cells or FAS ligand in lurkat T-cells (108,194). 
Two genes have been identified as responsible for SMS activity in 
mammalian cells, SMS1 and SMS2 (174,175). The amino acidic sequence of 
the proteins encoded by these two genes mainly differs in their N-termini, 
with SMS 1 carrying a sterile alpha motif that is absent in SMS2. In 
agreement with previous biochemical studies assessing the intracellular 
distribution of SMS activity, SMS 1 localizes at the Goigi whereas SMS2 
localizes at the Golgi and plasma membrane (165,174,182,183). Modulation 
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of SMS1 or SMS2 activity In most tested cell types has resulted in an 
alteration of ceramide levels whereas changes in DAG levels have been 
elusive (165,184,185,259,260,316). On the other hand, in Hela cells it has 
been shown that, in spite of the absence of significant changes of total DAG 
levels upon modulation of SMSs, intracellular DAG pools (in particular at 
the Golgi) appeared to be altered (165). 
Whereas inhibition of SMS 1 by direct caspase cleavage has been 
shown after treatment with Fas ligand in lurkat cells (317), no molecular 
factors that are able to stimulate SMS1 or SMS2 expression/activity have 
been identified so far. One of the conditions in which total SMS activity was 
found to be increased, was a pool of samples isolated from patients with 
acute lymphoblastic leukemia, acute myeloid leukemia and chronic 
myelogenous leukemia (CML) (10). 
CML is a myeloproliferative disorder of hemopoietic stem cells and 
occurs in 1 to 1.5 per 100,000 accounting for 15-20% of adult leukemia. 
CML is directly linked to a chromosomal abnormality caused by the 
reciprocal translocation of chromosomes 9 and 22 resulting in a shortened 
chromosome 22, termed the Philadelphia chromosome. This chromosomal 
translocation generates a fusion product between the breakpoint cluster 
region (Bcr) and the Abelson kinase (Abl) genes (275-278). The chimera 
now encodes for a constitutively active tyrosine kinase, Bcr-abl which 
initiates the leukemic transformation (273,274). In the clinical setting, CML 
is identified by three distinct phases: chronic phase, accelerated phase, and 
blast phase (279). The chronic phase is characterized by a slight increase of 
granulocytic progenitors and a substantial increase of granulocytes in the 
peripheral blood. At this stage, pharmacological inhibition of the Bcr-abl 
tyrosine kinase activity by Imatinib mesylate has proven key for the 
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containment of the disease (282,283,318). Nevertheless, the insurgence of 
mechanisms of resistance to current therapy, most commonly mutations in 
the A TP-binding pocket of Bcr-abl after long-term treatment with tyrosine 
kinase inhibitors, are causing disease progression from the chronic phase to 
the terminal blast phase (286). The blast phase is characterized by a block of 
differentiation resulting in 30% or more myeloid or lymphoid blast cells in 
the peripheral blood or bone marrow, from where the blast cells eventually 
infiltrate other organs such as spleen, liver, or lymph nodes (276). These 
blast cells are refractory to current treatments and the survival time for 
patients affected by blast crisis CML is 3 to 6 months (287,288,291). In this 
study, we provide evidence of a link between the expression of the BCR-
ABL oncogene, its activity and elevated SMS activity. We show that 
elevated expression of SMS 1 and not SMS2 is responsible for the elevated 
SMS activity and that elevated SMS 1 is important for sustaining 
proliferation of Bcr-abl positive cells. Inhibition of Bcr-abl, SMS activity or 
SMSl expression results in an alteration of the ceramide to DAG ratio 
consistent with a negative effect on cell proliferation. All together these 
results establish the first molecular link between a well-established oncogene 
and SMS 1 expression. 
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MATERIALS AND METHODS 
Materials 
RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and 
Trypan Blue dye solution were from Gibeo/Invitrogen Corp., Carlsbad, CA. 
NBD-C6-Ceramide and NBD-C6-sphingomyelin were purchased from 
Molecular Probes. All other lipids were purchased from A vanti Polar Lipids 
(Alabaster, AL). D609 was purchased from Biomol International; and 
Imatinib Mesylate was obtained from Novartis. 
Cell culture 
K562, HL-60, U937, Jurkat, and MCF-7 cell lines were originally 
purchased from the American Type Culture Collection (Rockville, MD). 
Human acute myeloid leukemia HL-60 cells stably expressing p18S Bcr-abl 
(HL~60/Bcr-abl) or the empty vector (HL-60 ct) were a generous gift from 
Dr. K. Bhalla (Medical College of Georgia, Augusta, Georgia, USA) (292). 
Human leukemic SupT13 T cells were obtained from Dr. J.S. Thompson at 
the University of Kentucky. All cell lines were grown in RPMI-1640 
supplemented with 10% FBS, 100 Vlml penicillin and 100 J.lg/ml 
streptomycin, and were maintained at 37°C at 5% CO2. Cells were routinely 
counted after staining with the Trypan blue dye. Pharmacological inhibition 
of SMS and Bcr-abl was achieved by incubation of cells with D609 and 
Imatinib mesylate as indicated in the individual experiments in complete 
growth medium (in absence of antibiotics) using O.lxl06 cells/ml cultures. 
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Methods 
Downregulation of SMSl and SMS2 with siRNA 
The siRNA for human SMSI targeted the sequence CAe ACT ATG 
Gee AAT CAG CAA (165) and the one for SMS2 targeted the sequence 
ACe GTe ATG ATe ACA OTT GTA (316). In preliminary experiments, 
the effects on SMSs RNA expression, SMS activity, and cell viability of the 
AIIStars Negative Control siRNA (Qiagen) was compared to that of the 
transfection reagent by itself and found no difference, therefore the Alistars 
Negative Control was used in subsequent experimentation as baseline. K562 
were transfected with siRNAs by electroporation using the Amaxa 
Nucleofector device (Amaxa) according to the manufacturer's instructions. 
The protocol was optimized regarding the concentration of SMS 1 siRNA, 
transfection and post-transfection conditions in preliminary dose-response 
experiments (1-10 ).lg SMS 1 siRNA). Consequently, the following optimal 
conditions were employed. Cells (lxl06 K562 cells or 2xl06 HL-60 cells) 
were transfected with 2-5 Ilg of siRNA. After 30 minutes of incubation at 
37°C, 5% CO2 in 500 J.lI of complete growth medium, cells were initially 
seeded at O.5x 106 cells/ml, and subsequently diluted 1:4 once control cells 
reached 1.3xl06 cells/ml concentration. At the indicated time points after 
transfection, cells were washed twice with ice cold PBS and processed 
according to the required analysis. 
RNA isolation and reverse transcription for real time peR. 
To analyze the expression of SMS 1 or SMS2 in U937, HL-60/ct, HL-
60IBcr-abl, and K562 cells, total RNA was first isolated from Ix106 cells 
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using the RNeasy Mini Kit according to manufacturer's protocol, including 
optional DNase digestion (Qiagen, Gmbh, Hilden, Germany). Further DNase 
digestion was performed using the Turbo DNA free kit according to 
manufacturer's protocol (Applied Biosystems). The first strand eDNA 
synthesis was prepared from 1 f.lg of RNA using Superscript III (Invitrogen) 
according to the manufacturer's recommendations. Real-time peR 
amplification was carried out as described by Villani et a1. (165). 
Lentiviral-mediated downregulation of SMSl 
For lenti-viral experiments, K562 cells were transduced with either 
non-targeting control particles (shRNA-NTCP) or Mission lentiviral 
transduction particles (both from Sigma-Aldrich) that contained the 
pLKO.l-puro vector including the SMSI targeting sequence, 5'-CCG Gee 
AAC TGC GAA GAA TAA TGA ACT eGA GTT CAT TAT TCT TCG 
CAG TTG GTT TTT TG-3' (sh-RNA-SMSl). During transduction, 3xl04 
K562 cells/ml fe-suspended in RPMI-1640 containing 10% FBS and 10 
J..lg/ml of Hexabromide (Sigma) were infected at a Multiplicity of Infection 
(MOl) of 10 with the appropriate lenti-viral particles. Cells were incubated 
at 37°C, 5% CO2 and 3 days post-transduction, 10 f.lg/ml of puromycin 
(Sigma) was added to the media to select for pLKO.1-puro positive clones 
and fe-added every 3-4 days to maintain selection. The concentration of 
puromycin needed to select for vector expressing clones was based on a kill-
curve analysis showing 70-80% cell death after 3 days in non-transduced 
K562 cells (data not shown). SMSI down-regulation (approximately 50%) 
was confirmed by quantitative real time peR. 
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[3H]-Thymidine incorporation assay 
K562 cells stably transduced with either shRNA-SMS 1 or shRNA-
NTCP lentivirus particles were used for transient siRNA transfections. 
K562/shRNA-SMSl and K562/shRNA-NTCP were transiently transfected 
with SMSI siRNA or Allstars Negative control respectively, and their 
cellular proliferation rates were compared by thymidine incorporation. The 
transient transfections were accomplished by the same electroporation 
protocol as described above and were diluted 48 hours post transfection by 
1.25 dilution factor in complete medium. The thymidine incorporation assay 
was optimized for K562 cells to determine the cell concentration and total 
cell number, as well as the amount of [3H]_ Thymidine (American 
radiolabeled chemicals; 1 JJ.Ci/J..lI specific activity) needed for maximum 
[3H]_ Thymidine incorporation within the linear range of the assay (data not 
shown). At the indicated time points after transient transfection, IJ.lCi of 
[3H]-Thymidine was added to 500 J.!ls serum free RPMI-1640 containing 
2xl05 K562 cells in each of the experimental groups (as above) and 
incubated for 4 hours at37°C and 5% CO2- After incubation, cells were 
centrifuged at lOOOg for 5 minutes at 4°C and the supernatant was removed. 
The cell pellets were washed twice with ice-cold PBS to remove all excess 
of unincorporated [3H]-Thymidine followed by a 30 minute incubation in 
5% ice cold trichloroacetic acid (TeA, 700 f.lls). The suspensions were 
centrifuged as above, TeA removed, and pellets were subsequently 
solubilized in O.SN NaOH containing 0.5% SDS (500 f.!ls). For analysis, 
150 J.!ls of the solubilized pellets were counted in 4ml of scintillation fluid 
(MP Biomedicals) and incorporated [3H]_ Thymidine was measured as 
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counts per minute in a Beckman-Coulter scintillation counter. CPM values 
were normalized to the total 500 Ills of solubilized pellets. 
Downregulation of BCR-ABL 
Bcr-abl was transiently down-regulated with a validated siRNA, 
targeting the sequence 5'-AAG CAG AGT TeA AAA Gce CTT-3' (319). 
HL-60/Bcr-abl cells were electroporated with 2 J.!g of either BCR-ABL 
targeting siRNA or the Allstar Negative Control siRNA according to the 
conditions described for SMS 1 and SMS2 down-regulation with the 
following modifications. Twelve hours post transfection, cells were diluted 
to O.2xl06 cells/ml in complete medium and 36 hours post transfection, cells 
were harvested, washed twice with ice cold PBS and processed for lipid 
analysis. Effective down-regulation of Bcr-abl was determined by western 
blotting and an aproximate 70% reduction of Bcr-abI in BCR-ABL siRNA 
treated cells was observed (data not shown). 
Sphingomyelin synthase activity assay 
SMS activity was performed as previously described with few 
modifications (165). Briefly, three to four million cells were harvested on 
ice, washed in PBS and resuspended in 150 III of homogenization buffer 
containing 250 mM Tris, 50 mM EDT A pH 7.4, Pierce Halt phosphatase 
inhibitor, Pierce Halt protease inhibitor (Pierce, Rockville, 11) and 5 mM 
PMSF. Cells were then lysed by sonication at 11 % power for 20 seconds 
(preliminary optimization experiments showed 95% cell lysis with these 
conditions). Unbroken cells were pelleted by centrifugation at 400g for 5 
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minutes at 4°C and supernatant was collected and assayed for protein 
concentration using the Bio-rad protein determination assay reagent (Bio-
Rad, Hercules, CA). Fifty micrograms of proteins were used for SMS 
activity which was carried out and analyzed as previously described (165). 
Total membrane preparation and SMSI western blotting 
Twenty million cells were harvested on ice, washed in PBS and 
resuspended in 800 J.lI of homogenization buffer containing 250 mM Tris, 50 
mM EDT A pH 7.4, Pierce Halt phosphatase inhibitor, Pierce Halt protease 
inhibitor (Pierce, Rockville, 11) and 5 mM PMSF. Cells were then lysed as 
indicated for SMS activity and centrifuged at 1000g for 10 minutes at 4°C. 
Supernatants were collected and centrifuged at 120,000g for 1 hour at 4°C. 
Membrane pellets were re-suspended in 200 J-!l of homogenization buffer 
and passed through a 21 gauge needle until uniform. Membrane protein 
concentration was determined using the Bio-fad protein determination assay 
reagent (Bio-rad, Hercules, CA). Membranes were diluted with 4X sample 
buffer and incubated at 37°C for 30 minutes~ Cell membrane proteins (80 
J-!g) were separated by 10% SDS-PAGE under reducing conditions and 
transferred to nitrocellulose membranes. Membranes were blocked with 5% 
milk PBS-Tween 0.1 % for 1 hour at room temperature. Membranes were 
then incubated with SMS 1 antibodies raised against the full-length protein 
(1:1000) (Ex-alpha Biologics, Maynard, Ma) for 4 hours at room 
temperature in 5% milk PBS-Tween 0.1 %. After extensive washings, 
membranes were next incubated with peroxidase-conjugated goat-anti-rabbit 
(1:3500, Santa Cruz) in 5% milk PBS-Tween 0.1% for 1 hour at room 
temperature. Signals were visualized using Super Signal (Pierce Chemical 
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Co) and exposure to Kodak BioMax MR Film (Eastman Kodak Co., 
Rochester, NY). 
Detection of PARP cleavage as an indicator of apoptosis 
Analysis of P ARP cleavage was conducted on totallysates (20 J.lg) on 
a 7.5% SDS-PAGE under reducing conditions. After transfer to 
nitrocellulose membranes and blocking as indicated above, P ARP and its 
cleaved fragment were visualized using primary rabbit polyclonal antibodies 
(Santa Cruz, 1: 1500) and secondary peroxidase-conjugated goat-anti-rabbit 
(1:10000, Santa Cruz) both in 5% milk PBS-Tween 0.1 %. Signals were 
visualized using EeL (GE Healthcare) and exposure to Kodak BioMax MR 
Film (Eastman Kodak Co., Rochester, NY). 
Lipid Analysis 
Ceramide, DAG and SM species were measured by the Lipidomics 
Core Facility at MUSe 
(http://www.musc.edu/BCMB/lipidomics/index.shtml). For the lipid 
measurements, lxl06 K562 cells or 2x106 HL-60/ct or HL-60IBcr-abl cells 
were used for each experimental condition. Aliquots of lipid extracts were 
used to measure inorganic phosphate which was used as normalization factor 
(320). 
Statistical Analysis 
Statistical analysis of the data was performed using Student's t-test, 
and p<0.05 was considered statistically significant. 
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RESULTS 
Expression ofBcr-abl increased SMS activity 
In a published report, it was shown that a pool of mononuclear cells 
isolated from peripheral blood or bone marrow of chemoresistant patients 
with different leukemias presented elevated SMS activity along with 
decreased ceramide levels (10). Therefore to assess if increased SMS 
activity was associated with specific hematological malignancies, a 
screening was carried out in different leukemic cell lines in vitro. As shown 
in Figure 6A, K562 cells exhibited a significantly higher SMS activity (by 
approximately lO-fold) compared to the other cell lines. The enzymatic 
activity of SMS was linear with the amount of cell lysates and time of 
reaction (data not shown), indicating that the differences were not an artifact 
of the assay conditions. Notably, K562 cells originate from a pleural 
effusion of a patient with chronic myelogenous leukemia (CML) in blast 
crisis, and are characterized by the expression of the BCR-ABL oncogene, 
whose expression is present in 95% of cases of CML. 
Therefore in order to determine if the increase of SMS in K562 was a 
direct result of BCR-ABL expression, SMS activity was then measured in 
HL~60 cells stably transfected with the BCR-ABL gene (HL-60/Bcr-abl) in 
comparison to cells transfected with the empty vector (HL-60/ct) (292,316) 
(Figure 6B). It was found that the expression of Bcr-abl in HL-60 cells 
induced a 9-fold increase of SMS activity, not due to the assay experimental 
conditions (data not shown). As a complementary approach, the effect of 
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inhibition of Bcr-abl tyrosine kinase activity on SMS activity was 
determined in K562 cells. As shown in Figure 6C, inhibition of Bcr-abl 
activity by Imatinib mesylate induced a dose- and time-dependent inhibition 
of SMS activity which became significant by 24 hours of incubation, and 
continued through 36 hours of treatment. Importantly, the inhibition of SMS 
activity by Imatinib at 24 and 30 hours was observed when no significant 
effect of the drug on cell proliferation could be observed. Inhibition of cell 
proliferation by Imatinib started at 36 hours of treatment with all 
concentrations tested (Supplementary Figure 1), and it was accompanied 
by the presence of 3.7% of dead cells at O.2J.lM, 8.3% at O.4J.lM, and 10% at 
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Figure 6A-C. Expression of Bcr-abl increased SMS activity 
B 





.~ ...J 8 .~ x 
* 
1 
-(J 0 m- 6 en"'C 
:E ~ 















Z' 80 ._ "C > (1) .- .c: ... (,) 
(,) ... 
60 ~ ~ 
en E 
:JEI 
en E 40 
~ ..... 20 0 
~ 0 - 0 
24 30 36 
Time of incubation (hours) 
Figure 6. Expression of Bcr-abl increased SMS activity. (A) In vitro SMS activity 
was measured in a panel of exponentially growing leukemic cell lines as described in the 
"Materials and Methods" section. The SMS activity was normalized to that of HL-60 
cells. (B) In vitro SMS activity was measured in exponentially growing HL-60 cells 
stably expressing the BCR-ABL oncogene (p185) (HL-60 Bcr-abl) and control cells 
carrying the empty vector (HL-60 ct) as described in the "Materials and Methods" 
section. (C) K562 cells (0.1 x 106 cells/ml) were incubated in the presence of the 
indicated concentrations of Imatinib (1m) or vehicle control (CT) for different periods of 
time. At the reported time points, 3x 106 cells were collected for SMS activity. Data 
represents the average and standard deviation of at least 3 separate experiments. Where 
standard deviations are not visible, the standard deviation is too small compared to the 
scale of the y-axis. Asterick indicates significant to HL-60/ct or to control (CT) (p-
value). 
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All together these results suggest that, in K562 cells, SMS activity is 
regulated by the tyrosine kinase activity of Bcr-abl. 
Bcr-abl-induced increase of SMS activity is attributable to the up-
regulation ofSMSl 
Two SMSs have been identified in mammalian cells. In order to 
determine which of these SMSs is responsible for the observed increase in 
SMS activity, the effect of Bcr-abl on the expression of SMSl and SMS2 was 
determined by Real Time peR. Interestingly, as shown in Figure 7A, the 
expression of SMSl mRNA in K562 and HL-60/Bcr-abl was significantly 
higher than that in Bcr-abl negative cells (HL-60/ct or U937). The results 
obtained by real-time peR were also confirmed by northern blot analysis of 
total RNA collected from HL-60/ct and HL-60/Bcr-abl cells, using the full-
length SMSl eDNA as probe (data not shown). On the other hand, the 
expression of Bcr-abl caused a reproducible and significant drop of SMS2 
mRNA level (Figure 7 A). Notably, the absolute expression level of SMS2 
mRNA in HL-60/ct is significantly lower than that of SMSl (1.32xlO-3 
versus 6.24xlO-4 MNE) and, by dropping in Bcr-abl-positive cells, it became 
almost undetectable. 
To confirm that increased expression of SMSl in Bcr-abl positive cells 
led to elevated SMS 1 protein, western blotting was performed on the total 
membrane fraction isolated from Bcr-abl-negative and positive cell lines. As 
shown in Figure 7B and in line with the mRNA expression pattern (Figure 
7 A), the levels of SMS 1 in Bcr-abl negative cells were barely detectable 
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whereas they were significantly elevated in Bcr-abl positive cells (K562 and 
HL-60/Bcr-abl). The identification of the SMS 1 band in leukemia cells was 
based on the comparison with Hela cells treated with SMSl siRNA (Figure 
7C). On the other hand, no commercially available antibodies for SMS2 
(ExAlpha or Santa Cruz) were able to detect any band in any of these cell 
lines (whereas they were able to detect SMS2 in Hela cells, data not shown). 
All together these data suggest that SMS 1 may indeed be responsible for the 
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Figure 7. Bcr-abl induced upregulation of SMSI. (A) Expression of BCR-ABL (HL-
60lBcr-abl and K562) caused an approximate 35 fold increase of SMS 1 expression 
compared to Bcr-abl negative cells (HL 60 CT and U937) whereas it caused a drop of 
SMS2 expression compared to Bcr-abl negative cells. Expression of SMSl and SMS2 
were determined by real-time PCR as indicated in the "Materials and Methods" section 
and normalized against ~-actin. (B) Total membrane fractions were collected from 
exponentially growing cells, and Western blotting analysis using 80 ug of proteins was 
performed as described in "Materials and Methods" section using non-purified polyclonal 
antibodies raised against recombinant full-length SMS 1 protein (Exalpha Biologicals). 
Equal loading was confirmed by Ponceau staining (see the loading control panel). (C) 
the identity of the SMS 1 band was determined based on the specific disappearance of the 
same molecular weight band in Hela cells after siRNA mediated SMSI downregulation 
as compared to cells transfected with a scrambled siRNA (CT siRNA) or a siRNA against 
SMS2 (SMS2 as siRNA). These results are representative of 2 separate experiments. 
Where error bars are not visible, the error bars too small compared to the scale the y-axis. 
Asterisk indicates significance to HL-60/CT (p<0.05). MNE:Mean of Normalized 
Expression. 
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To further test if Bcr-abl regulates SMS activity by promoting SMSl 
expression and activity, SMSl was down-regulated by transient treatment 
with siRNA in K562 cells. Down-regulation was achieved by 
electroporation of SMSl specific siRNA followed by both expression and 
activity analysis at various time points. As shown in Figure 8A, down-
regulation of SMSl caused a significant reduction of the expression of SMSl 
mRNA already after 24 hours (Figure 8B). Importantly, the SMSl siRNA 
showed target specificity since no change of SMS2 mRNA expression was 
observed (Figure 8e). Similarly, treatment of K562 cells with a validated 
SMS2 siRNA (316) caused SMS2 expression to reach levels below detection 
(data not -shown) while not affecting SMSI expression (data not shown). 
Differently from SMSl, down-regulation of SMS2 did not affect SMS 
activity (Figure SD). 
All together these observations demonstrate that SMS 1 is the main 
contributor to Bcr-abl-induced increase of SMS activity. 
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Figure 8. SMSI is the main contributor to SMS activity in K562 cells. SMSl (SMS 1-) 
and SMS2 (SMS2-) were down-regulated in K562 cells by treatment with siRNA (40nM 
up to 72 hours). Treatment with SMSl siRNA significantly decreased SMSl expression as 
measured by Real-Time peR (A) without significantly affecting SMS2 expression (C). 
The siRNA-induced SMSl decrease caused a decrease of total in vitro SMS activity (B). 
SMS2 siRNA did not affect in vitro SMS activity (D). These results are representative of 
at least 3 separate experiments. AU: Arbitrary Fluorescence Units. MNE: Mean of 
Normalized Expression. Asterisk indicates significance to SCR control (p<O.05). 
Inhibition of SMS activity caused accumulation of ceramide and 
decrease ofDAG 
Since SMS promotes the formation of DAG by consuming ceramide, 
and DAG sustains cell proliferation whereas ceramide has generally a 
negative effect on cell growth (32,42,95,167,168,170,321-325), lipid 
analysis upon modulation of SMS activity was conducted to determine its 
impact on the levels of these bioactive lipids. To this aim, lipid levels were 
determined upon inhibition of SMS activity by either treatment with the 
SMS pharmacological inhibitor, D609 (50j.lg/ml) (Figures 9A and 9B) or 
siRNA-mediated down-regulation of SMSl (Figure 9C and 9D) in K562 
cells. Cells for each experimental condition were collected after 24 and 48 
hours of treatment. Since the basal levels of the lipids (for these and all 
subsequent lipid measurements) were variable among separate experiments 
whereas the pattern of changes for each experiment was similar as compared 
to other repeat experiments, results are reported as fold of time-matched 
controls. Absolute values of all detected ceramide, SM and DAG molecular 
specIes for a representative experiment are provided in Supplementary 
Tables 1 and 2. As shown in Figure 9A, pharmacological inhibition of 
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SMS induced a significant accumulation of representative ceramide species 
C18:0 and e22:1 at both 24 and 48 hours of treatment. On the other hand, 
the levels of representative DAG species C14:0/C18:0 and C16:0/C18:0 
significantly decreased upon inhibition of SMS after both 24 and 48 hours 
of treatment (Figure 9B). The overall lipid changes cause a shift of the ratio 
between total ceramide levels over total DAG levels from 0.11 of control 
cells to 0.45 of D609 treated cells at 24 hours and from 0.09 of control cells 
to 0.50 of D609 treated cells at 48 hours (Supplementary Table 1). 
Similarly, although in a less pronounced manner, C18:0 and C22: 1 ceramide 
levels accumulated after 48 hours of down-regulation of SMSl (Figure 9C) 
whereas C14:0/C18:0 and C16:0IC18:0 DAG levels decreased significantly 
already after 24 hours (Figure 9D). In this case, the ratio between total 
ceramide levels over total DAG levels goes from 0.17 in control cells to 0.26 
in SMS 1- cells after 24 hours and from 0.46 to 0.64 after 48 hours 
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Figure 9. Effect of inhibition of SMS on ceramide and DAG levels. K562 cells were 
treated either with D609 (50 ).lg/ml) (A and B) or with control siRNA (SCR) or SMSl 
siRNA (SMS 1-) (C and D) for 24 and 48 hours. One million cells were collected for each 
time point and experimental condition and analyzed by mass spectrometry for ceramide 
(A and C) and DAG (B and D) levels and species by the Lipidomics Core Facility at 
MUSC. Reported in the graphs are representative ceramide and DAG species. Levels are 
reported as fold changes versus time-matched control. Where standard deviations are not 
visible, the standard deviation is too small compared to the scale of the y-axis. CT: 
vehicle control. Asterisk indicates significance to time-matched control (p<0.05). 
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All together these results indicate that inhibition of SMS/SMSI 
induced changes in some ceramide and DAG molecular species that shift the 
ceramide/DAG ratio in favor of ceramide. 
Modulation of Bcr-abl expression and activity caused lipid changes 
consistent with down-stream regulation ofSMSl 
If Bcr-abl promotes SMS 1 expression and activity, then modulation of 
Bcr-abl activity should cause lipid changes consistent with changes in SMS 
activity. To investigate this relationship, we first determined the effect of 
Bcr-abl expression on basal levels of DAG, ceramide and SM by mass 
spectrometry. HL-60/ct and HL-60/Bcr-abl cells (Figure 10) were grown 
under standard conditions and collected once the cells reached the 
logarithmic phase of growth. Importantly, cells with similar passage 
numbers were used to control for lipid changes resulting from cell culture 
aging, potentially disguising the lipid changes specifically mediated by Bcr-
abl expression. The levels of several DAG and SM species were found 
increased in HL-60IBcr-abl cells as compared to HL-60/ct (Figure 10 and 
Supplementary Table 3). In particular, the same representative DAG 
species that were decreased upon down-regulation of SMSl, C14:0/C16:0 
and C14:0/C18:0, were also elevated in BCR-ABL expressing cells (Figure 
lOA). Moreover, the majority of SM species were significantly elevated in 
HL-60/Bcr-abl cells as compared to HL-60/ct (Figure lOB and 
Supplementary Table 3C). This is in agreement with the enhanced SMS 
activity observed in HL-60/Bcr-abl cells as compared to HL-60/Ct (Figure 
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6B). Interestingly, Bcr-abl expression did not decrease ceramide levels 























Figure lOA+B. Effect of overexpression of Bcr-abl in HI-60 cells 
on the lipids regulated by SMSI 
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Figure 10. Effect of overexpression of Bcr-abl in HL-60 cells on the lipids regulated 
by SMSI. Two million HL-60IBcr-abl or HL-60/ct cells of similar passage were allowed 
to reach the logarithmic phase of growth and were harvested at the same time for lipid 
analysis. The levels and species of DAG (A) and SM (B) were analyzed from two 
independent experiments by mass spectrometry at the Lipidomics Core Facility at 
MUSC. Reported in the graphs are representative DAG and SM species. Levels are 
reported as fold change versus time-matched control (HL-60/ct). Asterisk indicates 
significant difference (p<O.05) of HL-60/Bcr-abl versus control cells (HL-60/ct) once the 
fold of time-matched control was calculated. 
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Next, in a complementary approach, the effect of siRNA-mediated 
down-regulation of BCR-ABL was determined on SMS-regulated lipids. The 
amount of siRNA, time of incubation, and cell culture conditions were 
optimized in preliminary experiments and conditions were selected based 
upon both maximum BCR-ABL down-regulation, as measured by western 
blotting, and decreased SMS activity (data not shown). HL-60/Bcr-abl cells 
were either treated with siRNA targeting BCR-ABL (Bcr-abl-) or with the 
scrambled siRNA Allstar control (SCR) and cells from each experimental 
condition were harvested 36 hours post siRNA treatment for lipid analysis. 
Absolute lipid levels from one representative experiment are reported in 
Supplementary Table 4 and representative lipid species are reported in 
Figure 11. These results showed that reduction of BCR-ABL expression 
induced a significant increase of the levels of representative ceramide 
species, C 18:0 and e22: 1 and a decrease of representative DAG species, 
C14:0IC18:0 and C16:0/C18:0 (Figures l1A and lIB and Supplementary 
Table 4). These changes resulted in an overall shift of the total ceramide 
over total DAG ratio from 0.34 of control cells to 1.34 of BCR-ABL down-
regulated cells. Furthermore, Bcr-abl inhibition resulted in a significant 
decrease of total SM levels, as the levels of several molecular species were 
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Figure llA-D. Inhibition of Bcr-abl induced accumulation of 
ceramide and reduction of DAG levels 
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Figure 11. Inhibition of Bcr-abl induced accumulation of ceramide and reduction of 
DAG levels. Panels A and B: HL-60IBcr-abl cells were treated with either scrambled 
siRNA control (SCR) or BCR-ABL siRNA (Bcr-abl -) for 36 hours. Two million cells 
were collected from each experimental condition and the levels and species of cerarnide 
(A), and DAG (B) were analyzed from three independent experiments by mass 
spectrometry by the Lipidomics Core Facility at MUSC. Panels C and D: K562 cells 
were treated with Imatinib (1m, 0.4 or 1 I-lM) for 24 and 30 hours and the levels of 
different species of ceramide (C) and DAG (D) were measured by mass spectrometry at 
MUSC. Levels are reported as fold changes versus time-matched control (SCR or CT). 
Where standard deviations are not visible, the standard deviation is too small compared to 
the scale of the y-axis. Asterisk indicates significant difference between HL-60/Bcr-abl( -) 
and SCR control or Imatinib-treated and control cells (p< 0.05). CT: control~ 1m: 
Imatinib-treated cells. Reported in the graphs are representative ceramide and DAG 
speCIes. 
The effect of loss of active Bcr-abl on DAG, ceramide and SM levels 
was also determined in K562 cells after pharmacological inhibition of Bcr-
abl with Imatinib. K562 cells were treated with O.4Jj.M and If.lM Imatinib for 
24 and 30 hours (concentrations of Imatinib and time of incubation which 
effectively inhibited SMS activity prior to affecting cell proliferation, 
Supplementary Figure 1). Cells for each experimental condition were 
collected and lipids extracted for mass spectrometry analysis. As shown in 
Figure IIC, accumulation of the representative C18:0 and e22:1 ceramide 
species was observed already after 24 hours and more pronouncedly after 30 
hours of treatment with both concentrations. On the other hand, C14:0/C18:0 
and C16:0IC18:0 DAG levels were greatly suppressed already after 24 hours 
of treatment with both Imatinib concentrations and they remained low after 
30 hours of incubation. In the presence of 1 JlM Imatinib, the reported lipid 
changes cause a shift of the ratio between total ceramide over total DAG 
from 0.64 of control cells to 1.21 of Imatinib treated cells after 24 hours and 
from 0.34 to 1.03 after 48 hours. Absolute lipid values from one 
representative experiment are reported in Supplementary Table 5. 
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All together these results are consistent with modulation of SMS 
activity by Bcr-abl. 
Inhibition ofSMSl caused a significant defect in cell growth ofBcr-
abl-positive cells 
Since down-regulation of SMSI caused a decrease of DAG and an 
increase of ceramide, and DAG and ceramide are involved in regulation of 
cellular proliferation and/or cell death (32,42,95,167,168,170,321-325), the 
effect of SMS 1 inhibition was next determined on these cellular processes. 
K562 cells were first treated with D609, and its effect on cell proliferation 
was tested by measuring incorporation of tritiated thymidine (Figure 12A). 
A significant inhibitory effect of D609 was observed already after 24 hours 
and it continued after 48 and 72 hours of treatment. Next, the effect of 
specific down-regulation of SMSl was determined. Initially, transient down-
regulation of SMS 1 with siRNA produced variable results depending on the 
extent of SMSI reduction (inhibition of cellular proliferation was only 
observed in case of suppression of SMSl by more than 75%). We reasoned 
that this might be due to the high basal SMSl expression in these cells and to 
a possible threshold effect. Thus, to obtain a more reproducible effect, we 
aimed at achieving maximal down-regulation of SMSI. To this aim, K562 
cells were first transduced with viral particles containing short hairpin RNA 
targeting SMSl (shRNA-SMSI) followed by selection of stably expressing 
cells (this ensured a basal 50% reduction of SMSl expression, data not 
shown). Subsequently, to further down-regulate SMSl, K562 cells stably 
transduced with shRNA-SMS1 were transfected with SMSl siRNA (shRNA-
SMS1/SMSI) and those transduced with control shRNA (shRNA-NTCP) 
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were transiently transfected with Allstar Scrambled siRNA (shRNA-
NTCP/SCR). As shown in Figure 12B, sustained inhibition of SMSl in 
K562 cells (shRNA~SMSI/SMSI) resulted in reduced [3H]-thymidine 
incorporation as compared to control cells (shRNA-NTCP/SCR) already at 
24 hours, and significantly after 48 and 72 hours. On the other hand 
inhibition of SMSl expression by more than 75% in HL-60/ct cells did not 
affect their cell growth (Supplementary Figure 2).These results suggest 
that sustained inhibition of SMSI expression/activity in K562 cells 
significantly impairs cell proliferation. 
On the other hand, down-regulation of SMSl did not cause 
cytotoxicity or apoptosis. In fact no significant increase in trypan blue 
positive cells and no positivity to propidium iodide was detected by FACS 
analysis (data not shown). Moreover, no evidence of caspase-induced 
apoptosis was observed in K562 cells upon treatment with D609 or after 
















Figure 12A +B. Inhibition of SMS activity in K562 cells 
significantly reduced cell proliferation 
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Figure 12. Inhibition of SMS activity in K562 cells significantly reduced cell 
proliferation. Changes in proliferation after pharmacological (A) or siRNA~mediated 
inhibition of SMS 1 (B) were measured by 3H-Thymidine incorporation after 24, 48, and 
72 hours. A: 3H_ Thymidine incorporation was determined after inhibition of total SMS 
with D609 (50 ~g/ml). B: cells were transduced with lenti-virus containing either control 
particles (shRNA-NTCP) or viral particles containing sequences to induce partial stable 
down-regulation of SMSl (shRNA-SMSl). 3H-Thymidine incorporation was then 
measured in shRNA-NTCP transiently transfected with Allstar scrambled siRNA control, 
(shRNA-NTCP/SCR) and shRNA-SMS 1 cells transiently transfected with SMSl siRNA. 
Results represent the average and standard deviation of a minimum of 4 separate 
experiments. Where standard deviations are not visible, the standard deviation is too 
small compared to the scale of the y-axis. Asterisk indicates significant difference versus 
Control or shRNA-NTCP/SCR (p< 0.05). ShRNA: short-hairpin RNA. NTCP: Non-
Transducing Control Particles. CPMs: Counts Per Minute. 
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All together these results implicate SMS 1 in specific regulation of cell 
proliferation, and not cell death, of Bcr-abl-positive cells. 
DISCUSSION 
In this study, we provide evidence of a link between the expression of 
the Bcr-abl oncogene, its activity and elevated SMS activity. We further 
show that enhanced expression of SMS 1 and not SMS2 is responsible for the 
elevated SMS activity and that elevated SMS 1 is important for sustaining 
proliferation of Bcr-abl positive cells. Moreover, modulation of Bcr-abl, 
SMS activity or SMS 1 expression results in a similar alteration of the ratio 
of the bioactive lipids ceramide and DAG. Finally, inhibition of SMSI 
significantly affects cell proliferation of Bcr-abl positive cells consistent 
with the shift of the ceramide to DAG ratio in favor of ceramide. 
These results are significant since up to date no molecular factors that 
are able to stimulate SMS 1 or SMS2 expression/activity have been 
identified. In particular, increased SMS activity has been associated with 
some transformed phenotypes (10,314,315), thus the herein reported 
regulation of SMS 1 by Bcr-abl represents the first molecular link between a 
well-known oncogene and an SMS to support that association. 
Up to date, the involvement of SMS 1 as a potential downstream target 
of Bcr-abl was unknown, and in general the role of ceramide in Bcr-abl-
mediated signalling was unclear. In particular, whereas Ber-abi expression 
was shown to impart total or partial resistance to treatment with exogenous 
short chain ceramide analogues (C2 or C6-ceramide), Bcr-abl was also 
found to accelerate ceramide-mediated apoptosis by these same analogues 
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(292-294). Recently., accumulation of endogenous ceramide and decrease of 
the antiapoptotic sphingolipid, sphingosine 1 phosphate (SIP) was shown to 
be in part responsible for the cytotoxic effect exerted by imatinib treatment 
in CML derived cell lines (298). Moreover, it was also shown that a shift of 
the balance between endogenous ceramide and SIP in favor of SIP might be 
of critical relevance for imparting imatinib resistance to CML cells 
(298,299). In our experimental model, we observed similar changes in 
ceramide levels after treatment with Imatinib as those reported in the 
literature (298), and these lipid changes were also observed in case of 
pharmacological or siRNA-mediated inhibition of SMSI. Together with the 
fact that inhibition of Bcr-abl causes a significant block of SMS activity 
(Figure 6C), this suggests that, at least in part, ceramide accumulation upon 
inhibition of Bcr-abl might be due to inhibition of SMS 1 activity. 
Interestingly, down-regulation of SMSl induced accumulation of specific 
ceramide molecular species such as C16:0, C18:0, C20:0 and e22:1 which 
were also accumulated upon pharmacological inhibition with D609 
(Supplementary Tables lA and 2A). D609 treatment also caused 
accumulation of other ceramide species, and this maybe due to either or both 
the more rapid and sustained inhibition of SMS activity compared to siRNA 
and the activation of other ceramide-generating pathways, such as the de 
novo pathway (326). Importantly, C18:0., C20:0 and e22: 1 ceramides were 
also increased upon pharmacological inhibition of Bcr-abl., and this is 
consistent with SMS 1 being a down-stream target of Bcr-abl. Also in the 
case of Bcr-abl inhibition, other ceramide species were also increased and 
this maybe the result of activation of certain ceramide synthases, such as 
CerS 1 (298). 
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The fact that ceramide accumulation upon inhibition of Bcr-abl might 
be in part due to SMS 1 inhibition is also supported by the analysis of both 
SM and DAG levels. Indeed, we found that upon inhibition of Bcr-abl or 
SMS/SMS 1, there was a tendency for several species of SM to decrease, 
although some changes were not statistically significant (Supplementary 
Tables Ie, 2C, and 5C). Additionally, over-expression of Bcr-abl in HL-60 
cells induced a significant accumulation of various species of SM 
(Supplementary Table 3C) and siRNA-mediated downregulation of the 
oncogene significantly lowered SM levels (Supplementary Table 4C). 
Notably, inhibition of Bcr-abl or SMS/SMS 1 induced a significant 
drop of several DAG species, and these changes were even more 
pronounced than those in ceramide levels (Supplementary tables IB, 2B 
and 3B). Pharmacological and siRNA-mediated inhibition of SMS 1 induced 
a significant decrease of specific DAG molecular species, such as low 
abundant C14:0/C16:0 and C14:0/18:0 DAGs, and highly represented 
C16:0/18:0, C16:0/18:1, C18:0/18:1 and Di-C16:0 DAGs. These same 
species were also decreased upon inhibition of Bcr-abl (Supplementary 
Table SB), suggesting that there might be a specific pattern of DAG changes 
induced by modulation of SMS1. These results were also observed upon 
siRNA mediated down-regulation of BCR-ABL in HL-60/Bcr-abl cells 
(Supplementary Table 4B). 
As already mentioned In the general introduction, the relationship 
between Bcr-abl and DAG has not been documented in the literature. 
Indirect evidence of the involvement of DAG as a downstream signaling 
molecule of Bcr-abl come from reports showing that activation of 
phospholipase C (PLC) yl and of the PI3KJAkt pathway are required for 
Bcr-abl signaling through mTOR/p70S6-kinase (305,306). The regulation of 
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mTOR/p70S6-kinase by PLCyl seems to occur VIa modulation of both 
calcium signaling (CaMKII) (presumably through formation of 1P3) and 
classical and novel protein kinase C (likely through production of DAG). In 
our system, we observed a very significant drop of DAG levels when either 
Bcr-abl or SMS/SMS 1 were inhibited. Being SMS 1 regulated by Bcr-abl, it 
is possible that part of the observed drop of DAG levels after inhibition of 
Bcr-abl is due to the decrease of SMS/SMS 1 activity, in addition to 
inhibition of PLCy 1. 
Importantly the changes of cerami de (accumulation) and DAG 
( decrease) levels observed upon inhibition of Bcr-abl or SMS/SMS 1 are 
both consistent with the inhibition of cell proliferation observed in response 
to these treatments, and these concomitant lipid changes may work in 
concert to cause this phenotype. Interestingly, down-regulation of SMSl did 
not cause a change in proliferation of the Bcr-abl negative cell line HL-60 
(Supplementary Figure 2), indicating a specific role for SMS 1 in 
supporting proliferation of Bcr-abl positive K562 cells. The difference in the 
requirement of SMSl expression for proliferation between Bcr-abl positive 
and negative cells may be linked to the expression of SMS2 and the ability of 
SMS2 to compensate for the loss of SMS 1. In fact, SMS2 is almost 
undetectable in Bcr-abl positive K562 but expressed in HL-60 to a similar 
level as SMSI (data not shown). This scenario would imply that whenever 
SMS 1 is the only SMS expressed in a certain cell type, then its activity is 
crucial for survival of those cells. 
An interesting observation is the fact that SMSl mRNA is increased in 
Bcr-abl positive cells opening up the question of the mechanism by which 
SMSl expression is stimulated by Bcr-abl (transcriptional regulation or 
mRNA stability). Preliminary results support the first mechanism thus in the 
84 
near future it is our intention to characterize the transcriptional regulation of 
SMSI by Bcr-abl in order to elucidate the signaling pathway, down-stream 
of Bcr-abl, responsible for up-regulation of SMS1. 
Interestingly, even if K562 cells are blast phase CML, and therefore 
characterized by a block of differentiation potentially due to the 
accumulation of mutations in addition to the formation of the Bcr-abl 
chimaera, SMS 1 activity is still under the control of the Bcr-abl tyrosine 
kinase activity. Therefore it is unlikely that SMS 1 may represent a 
"druggable" target to contain newly diagnosed blast phase CML. On the 
other hand, in spite of the success obtained in controlling the chronic phase 
of CML, the increase in resistance to Bcr-abl inhibitors is starting to 
represent a significant medical challenge. Thus, establishing SMS 1 as an 
important down-stream regulator of Bcr-abl may provide the basis for future 
work set to test SMS 1 as a potential novel pharmacological target for CML, 
in particular for those cases that arise from resistance to Bcr-abl inhibitors. 
In summary, the discovery of the Bcr-abl/SMSl connection provides 
the first molecularly-characterized model for a better understanding of 
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Supplementary Figure 1. Effect of Imatinib on cell number. K562 cells (O.Ix 106 
cell/ml) were incubated in the presence of the indicated concentrations of Imatinib (1m) 
or vehicle control (CT) for different periods of time. At the reported time points, cells 
were counted and cell viability was determined by Trypan blue staining. The cell number 
reported in the Figure represents total cells (Trypan blue positive + Trypan blue negative 
cells). Data represent the average and standard deviation of at least 3 separate 
experiments. Where standard deviations are not visible, the standard deviation is too 
small compared to the scale of the y-axis. Asterisk indicates significant difference to 
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Supplementary Figure 2. Down-regulation of SMSI did not affect cell proliferation 
of HL-60/ct cells. HL-60/ct cells were transfected with either the All Star Scrambled 
control siRNA (SCR) or SMSl siRNA (SMSl-). Aliquots of cells were counted and 
stained with Trypan blue after 24, 48, and 72 hours. Treatment with SMSl siRNA 
induced an average 70-80% down-regulation of SMSl expression after 48 hours. Data 




Supplementary Figure 3. Inhibition of SMS activity in K562 cells 
did not induce apoptosis 
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Supplementary Figure 3. Inhibition of SMS activity in K562 cells did not induce 
apoptosis. Treatment of K562 cells with either D609 (50 ~g/ml) or SMSl siRNA 
(SMS 1-) for 72 hours did not induce PARP cleavage (as determined by western blotting). 
MCF-7 cells treated with InM TNFa for 18 hours were used as positive control for 









Supplementary Table 1. Effect of inhibition ofSMSl by D609 treatment on lipid levels 
Effect of inhibition of SMSI by D609 treatment on lipid levels. Reported are the levels of individual species of cerami de (A), 
DAG (B) and SM (C) as measured by mass spectrometry during treatment with D609 (50 J..!g/ml) after 24 and 48 hours. Since basal 
levels of lipids were variable among the different experiments whereas the pattern of changes between experimental conditions was 
similar (Figure 13A and B), reported are the absolute values of one representative experiment. In bold are the values that were 
significantly different compared to the time-matched control once the fold change versus the appropriate control was calculated 
among three independent experiments (p<O.05 versus CT). CT: Control cells. 
Supplementary Table lA. Ceramide species (pmoleslnmole of Pi) 
I C14-Cer C16-Cer C18-Cer C18:1-Cer C20-Cer C20:1-Cer C22-Cer C22:1-Cer C24-Cer C24:1-Cer C26-Cer C26:1-Cer 
0.018 0.117 0.020 0.007 0.014 0.003 0.082 0.030 1.13 0.445 0.015 0.035 
0.097 0.323 0.073 0.025 0.082 0.008 0.213 0.073 1.15 0.502 0.042 0.053 
0.012 0.063 0.017 0.003 0.010 0.002 0.047 0.018 0.73 0.300 0.013 0.015 







Supplementary Table lB. DAG species (pmoleslnmole of Pi) 
Samples 
C14:0/16:0· C14:0/18:0· C14:0/18:1· C16:0/18:0· C16:0/18:1· C16:0/20:0- C16:0/24:1- C16: 1/18:0- CI6:1/18:1-
DAG DAG DAG DAG DAG DAG DAG DAG DAG 
CT24h 0.620 0.225 0.127 3.82 5.39 0.182 0.217 0.072 0.393 
D60924h 0.177 0.050 0.080 0.84 1.32 0.005 0.008 0.115 0.602 
CT48h 0.497 0.298 0.142 3.59 3.14 0.275 0.267 0.022 0.285 
D60948h 0.068 0.050 0.075 0.69 0.78 0.020 0.020 0.003 0.237 
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Supplementary Table lB. DAG species (pmoleslnmole of Pi), continued 
C18:0118:1- C18:0118:2· C18:0/20:4· Di·C14:0· Di·C16:0- Di·C18:0· Di·C18:1- Total 
Samples DAG DAG DAG DAG DAG DAG DAG DAG 
CT24h 0.92 0.28 1.08 0.080 2.54 0.207 0.121 16.27 
D60924h 0.65 0.48 0.66 0.060 0.45 0.178 0.225 5.89 
CT48h 2.05 0.16 0.58 0.068 2.01 0.093 0.288 13.77 
D60948h 0.61 0.14 0.90 0.022 0.23 0.197 0.195 4.24 
Supplementary Table Ie. SM species (pmoleslnmole of Pi) 
Samples C14·SM C16~SM C18~SM C18:1~SM C20~SM C20:1~SM C22-SM C22:1·SM C24·SM C24:1-SM C26-SM C26:1-SM Total SM 
CT24h 0.505 21.25 3.16 2.23 1.07 0.28 6.67 2.86 7.59 16.59 0.09 0.37 62.67 
D60924h 0.735 22.23 2.71 1.62 0.98 0.22 3.93 1.80 4.56 8.37 0.25 0.41 47.82 
CT48h 0.725 27.02 3.31 3.09 0.81 0.14 7.14 2.40 7.68 17.01 0.07 0.20 69.60 







Supplementary Table 2. Effect of inhibition ofSMSl by siRNA treatment on lipid levels 
Effect of inhibition of SMSI by siRNA treatment on lipid levels. Reported are the levels of individual species of ceramide (A), 
DAG (B) and SM (C) as measured by mass spectrometry during down-regulation of SMSl (SMSI-) with siRNA as compared to a 
scrambled control sequence (SCR) after 24 and 48 hours. Since basal levels of lipids were variable among the different experiments 
whereas the pattern of changes between experimental conditions was similar (Figure 13C and D), reported are the absolute values of 
one representative experiment. In bold are the values that were significantly different compared to the time-matched control once the 
fold change versus the appropriate control was calculated among three independent experiments(p<O.05 versus SCR). 
Supplementary Table 2A. Ceramide species (pm o Ie sin m ole of Pi) 
I C14-Cer C16-Cer C18-Cer C18:1-Cer C20-Cer C20:1-Cer C22-Cer C22:1-Cer C24-Cer C24:1-Cer C26-Cer C26:1-Cer 
0.008 0.140 0.155 0.012 0.021 0.001 0.072 0.043 1.137 0.907 0.038 0.026 
0.001 0.118 0.160 0.004 0.014 0.001 0.070 0.042 0.802 0.904 0.015 0.021 
0.036 0.307 0.124 0.021 0.026 0.004 0.112 0.065 1.532 1.427 0.053 0.067 







Supplementary Table 2B. DAG species (pmoleslnmole of Pi) 
CI4:0/16:0- CI4:0/18:0- C14:0/18:1- CI6:0/18:0- CI6:0/18:1- C16:0/20:0· CI6:0/24: 1- CI6:1/18:0- C16:1/18:1-
Samples DAG DAG DAG DAG DAG DAG DAG DAG DAG 
SCR24h 0.774 0.399 0.062 7.208 2.132 0.288 0.090 0.087 0.060 
SMSl- 24h 0.559 0.146 0.036 3.172 1.695 0.095 0.077 0.051 0.045 
SCR48h 0.277 0.122 0.053 2.908 1.766 0.105 0.061 0.060 0.048 
SMSl· 48h 0.178 0.062 0.037 1.856 1.499 0.080 0.058 0.044 0.052 
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Supplementary Table 2B. DAG species (pmoleslnmole of Pi), continued 
Samples 
C18:0/18:1- C18:0/18:2- C18:0/20:4- Di-C14:0- Di-C16:0- Di-C18:0- Di-C18:1-
Total DAG 
DAG DAG DAG DAG DAG DAG DAG 
SCR24h 1.102 0.034 0.072 0.041 2.534 0.106 0.103 15.09 
SMSl- 24h 0.567 0.019 0.037 0.028 1.637 0.028 0.086 8.28 
SCR48h 1.413 0.082 0.432 0.019 0.667 0.064 0.120 8.20 
SMSl- 48h 1.262 0.103 0.351 0.014 0.452 0.029 0.134 6.21 
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Supplementary Table 2C. SM species (pmoleslnmole of Pi) 
Samples I CI4-SM C16-SM CI8-SM CI8:I-SM C20-SM C20:I-SM C22-SM C22:I-SM C24-SM C24:I-SM C26-SM C26:I-SM Total SM 
SCR24h 1.17 22.0 2.96 0.301 0.687 0.195 2.94 1.50 3.98 8.38 0.035 0.204 44.35 
SMSI-24h 1.06 19.0 2.69 0.305 0.702 0.224 2.64 1.46 3.04 7.39 0.042 0.174 38.73 
SCR 48h 1.22 22.5 2.77 0.260 0.681 0.186 2.34 1.31 3.77 7.18 0.077 0.197 42.49 
SMSl-48h 0.96 13.0 1.84 0.249 0.663 0.172 2.28 1.31 2.86 6.21 0.027 0.118 29.69 
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Supplementary Table 3. Effect of over expression ofBCR-ABL in HL-60 cells on lipid levels. 
Effect of overexpression of BCR-ABL in HL-60 cells on lipid levels. Reported are the levels of individual species of ceramide (A), 
DAG (B), and SM (C) extracted from HL-60/ct and HL-60IBcr-abl cells as measured by mass spectrometry. Cells from each 
experimental condition were harvested after the same amount of time in culture and during the logarithmic stage of growth. Since 
basal levels of lipids were variable among the different experiments whereas the pattern of changes between experimental conditions 
were similar (Figure 14), reported are the absolute values of one representative experiment. In bold are the values that were 
significantly different compared to the time-matched control once the fold change versus the appropriate control was calculated 





Supplementary Table 3A. Ceramide species (pmoleslnmole of Pi) 
C14-Cer C16-Cer C18-Cer C18:1-Cer C20-Cer C20:1-Cer C22-Cer C22:1-Cer C24-Cer C24:1-Cer C26-Cer C26:1-Cer Total Cer 
.08 0.83 0.07 0.03 0.02 BOL 0.08 0.02 1.81 1.39 0.07 0.16 4.56 
.09 0.97 0.10 0.05 0.04 0.01 0.25 0.10 3.68 3.71 0.13 0.28 9.41 
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Supplementary Table 3B. DAG species (pmoleslnmole of Pi) 
C14:0/16:0- C14:0/18:0- C14:0/18:1- C16:0/18:0- C16:0/18:1- C16:0/20:0- C16: 1/18:0- C16: 1/18:1-
Samples AG DAG DAG DAG DAG DAG DAG DAG 
HL60/ct 0.11 0.49 0.83 3.22 0.02 0.08 1.60 
HL60lBcr-abl 11.53 0.52 0.26 5.95 8.53 0.32 0.25 0.45 







































Supplementary Table 3C. SM species (pmolelnmole of Pi) 
























Supplementary Table 4. Effect of down-regulation ofBCR .. ABL on lipid levels ofHL-60IBcr-abl cells. 
Effect of down-regulation of BCR-ABL on lipid levels of HL-60IBcr-abl cells. Reported are the levels of individual species of 
ceramide (A), DAG, (B), and SM (C) from HL-60IBcr-abl cells after down-regulation of BCR-ABL. HL-60fBcr-abl cells were treated 
with either BCR-ABL targeting siRNA [HL-60/Bcr-abI/Bcr-abl( -)] or scrambled Allstar RNAi control [HL-60IBcr-abl/SCR] and cells 
from each condition were collected after 36 hours and lipids were extracted for analysis. Since basal levels of lipids were variable 
among the different experiments whereas the pattern of changes between experimental conditions was similar (Figure 13A and B), 
reported are the absolute values of one representative experiment. In bold are the values that were significantly different compared to 
the time-matched control once the fold change versus the appropriate control was calculated among three independent experiments 
(p<O.05 versus HL-60IBcr-abI/SCR). BDL: below detection limit. 
Supplementary Table 4A. Ceramide species (pmoleslnmole of Pi) 
Samples C14-Cer C16-Cer C18-Cer C18:1-CerC20-Cer C20:1-Cer C22-Cer C22:1-Cer C24-Cer C24:1-Cer C26-Cer C26:1-Cer Total Cer 
HL-60/Bcr-abUSCR .10 0.72 0.07 0.03 0.07 0.01 0.24 0.11 2.42 2.27 0.08 0.13 6.25 
HL-60IBcr-abllBcr-abl( -) 10.15 0.53 0.11 0.07 0.07 0.03 0.18 0.15 1.12 1.78 0.03 0.06 4.28 
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Supplementary Table 4B. DAG species (pmoleslnmoZe of Pi) 
C14:0/16:0 C14:0/18:0 C14:0/18:1 C16:0/18:0 C16:0/18:1 C16:0/20:0 C16:1/18:0 C16:1/18:1 C18:0/18:1-
Samples AG DAG DAG DAG DAG DAG DAG DAG DAG 
HL-60IBcr-abl/SCR 1.24 0.56 0.20 7.09 4.48 0.26 0.06 
HL-60IBcr-abllBcr-abl (-) 0.05 0.02 0.01 0.58 0.57 0.23 0.48 



































HL-60IBcr-abI/SCR 10.72 55.52 3.56 




































Supplementary Table 5. Effect of inhibition of BCR-ABL activity with Imatinib on lipid levels in 
K562cells. 
Effect of inhibition of Bcr-abl activity with Imatinib on lipid levels in K562 cells. Reported are the levels of individual species of 
ceramide (A), DAG (B) and SM (C) as measured by mass spectrometry during pharmacological inhibition of Bcr-abl in K562 cells 
with different concentrations of Imatinib (0.4 and 1 JlM, 1m) after 24 and 30 hours of incubation. Since basal levels of lipids were 
variable among the different experiments whereas the pattern of changes between experimental conditions was similar (Figure 13C 
and D), reported are the values of one representative experiment. In bold are the values that were significantly different compared to 
the time-matched control once the fold change versus the appropriate control was calculated among three independent experiments 
(p<O.05 versus CT). BDL: below detection limit. 
Supplementary Table SA. Ceramide species (pmoleslnmole of Pi) 
C14- C16- C18- CI8:1- C20- C20:1- e22- C22:1 .. C24· C24:1 C26· C26:1· Total 
I Cer Cer Cer Cer Cer Cer Cer Cer Cer Cer Cer Cer Cer 
0.051 0.56 0.038 0.02 0.043 0.004 0.19 0.062 2.63 2.18 0.049 0.111 5.94 
1m (O.4uM) 24h 0.089 0.57 0.051 0.087 0.061 0.008 0.24 0.107 2.36 2.83 0.038 0.1 6.54 
1m (tuM) 24h 0.107 0.65 0.061 0.073 0.071 0.009 0.20 0.102 2.24 2.80 0.033 0.067 6.41 
CT30h 0.068 0.99 0.031 0.026 0.053 0.003 0.26 0.080 3.15 2.73 0.058 0.115 7.56 
1m (O.4uM) 30b 0.170 1.02 0.109 0.119 0.106 0.017 0.34 0.202 2.85 3.89 0.045 0.120 8.99 
1m (luM) 30h 0.181 0.92 0.109 0.118 0.089 0.019 0.27 0.163 2.53 3.75 0.038 0.092 8.28 
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Supplementary Table SB. DAG species (pmoleslnmole of Pi) 
-,amples 
I CI4:0/16:0- CI4:0/18:0- C14:0/18:1- CI6:0/18:0- CI6:0/18:1- C16:0/20:0- C16: 1/18:0- C16: 1/18:1-
DAG DAG DAG DAG DAG DAG DAG DAG 
CT24h 0.29 0.23 0.024 4.15 1.60 0.19 0.12 0.07 
Illl (O.4uM) 24h 0.03 0.04 0.015 1.49 0.83 0.03 0.03 0.02 
1m (luM) 24h 0.02 0.03 0.01 1.14 0.62 SOL 0.02 0.02 
CT30h 0.69 0.65 0.073 10.61 3.03 0.57 0.30 0.19 
1m (O.4uM) 30h 0.07 0.20 0.015 3.73 1.12 0.12 0.06 0.05 
1m (luM) 30h 0.02 0.06 0.013 1.45 0.97 0.03 0.04 0.03 
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Supplementary Table SB. DAG species (pmoleslnmole of Pi), continued 
Samples 
C18:0/18:1- C18:0/18:2- C18:0/20:4- Di-C14:0- Di-C16:0- Di-C18:0- Di-C18:1-
Total DAG 
DAG DAG DAG DAG DAG DAG DAG 
CT24h 0.72 0.08 0.35 0.007 1.07 0.16 0.24 9.30 
1m (Op4uM) 24h 0.53 0.04 0.84 0.002 0.21 0.08 0.19 4.38 
1m (luM) 24h 0.73 0.20 2.01 0.001 0.10 0.13 0.26 5.29 
CT30h 1.75 0.21 0.74 0.013 2.36 0.39 0.47 22.05 
1m (O.4uM) 30h 1.09 0.36 1 .. 96 0.003 0.35 0.23 0.36 9.72 
1m (luM) 30h 1.15 0.45 3.07 0.002 0.13 0.13 0.49 8.04 
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Supplementary Table se. SM species (pmoleslnmole of Pi) 
Samples 
Cl4- Cl6- C18- CI8:I- C20- C20:l- e22- e22:1- C24- C24:I- C26- C26:l-
Total SM 
8M SM 8M SM SM SM SM SM 8M SM SM SM 
CT24h 0.056 15.7 3.42 0.33 0.67 0.063 4.75 2.38 4.34 12.8 0.009 0.043 44.56 
1m (O.4uM) 24h 0.059 11.9 1.95 0 .. 16 0.14 0.040 2.47 1.42 2.36 9.0 0.002 0.027 29.53 
1m (luM) 24h 0.075 14.5 2.35 0.23 0.17 0.052 3.25 1.90 3.15 11.3 0.001 0.034 37.01 
CT30h 0.074 21.5 4.18 0.39 0.80 0.071 6.02 2.85 5.47 15.9 0.012 0.055 57.32 
1m (O.4uM) 30h 0.093 19.7 3.04 0.32 0.29 0.067 4.22 2.58 4.07 14.8 0.005 0.047 49.23 
1m (luM) 30b 0.091 19.2 3.00 0.28 0.21 0.060 3.95 2.29 4.13 14.1 0.001 0.043 47.36 
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APPENDIX A: Effect of pharmacological inhibition ofSMS on the 
differentiation ofK562 cells, and SMS profile in circulating CD34+ 
blasts isolated from CML patients. 
The following results are included as part of Specific Aim 1, but were not 
included for either manuscript, "Sphingomyelin synthase 1 activity is regulated by 
the BCR-ABL oncogene," or "Transcriptional regulation of SMSI by the Bcr-abl 
oncogene", because more clinical samples including control blasts are necessary 
for adequate statistical analysis and significance. 
Materials and Methods 
Materials 
RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and Trypan 
Blue dye solution were from Gibeo/Invitrogen Corp., Carlsbad, CA. K562 was 
originally purchased from the American Type Culture Collection (Rockville, MD). 
Cells were routinely counted after staining with the Trypan blue dye. 
Phannacological inhibition of SMS was achieved by incubation of cells with D609 
in complete growth medium needed per cell line. Peripheral Blood Mononuclear 
Cells (PBMC) isolated from two patients with CML during the blast stage of the 
disease were obtained from the Hollings Cancer Center Biorepository. 
CD34( +) cell culture 
CD34(+) and (-) cells were maintained at 37°C at 5% CO2. CD34(+) and (-) 
cells were grown in complete media containing the following: StemSpam serum 
free expansion medium (SFEM) (StemCell Technologies, Vancouver, Canada), 
including 200/0 FBS, StemSpan cytokine cocktail (1 ml added for each 99mls of 
106 
media) (StemCell Technologies, Vancouver, Canada), 8ull O.5mls of low density 
lipoprotein (0.032-0.068 mg protein/ml) (Sigma-Aldrich, St. Louis, MO) and 1 % 
of penicillin/streptomycin. 
CD34( +) cell isolation 
CD34( +) cells were separated from frozen PBMCs uSIng the CD34 
microbead kit according to the suggested manufacturer protocol (Milltenyi 
Biotech, Aubom, CA). Specifically, 1 x 108 frozen PBMCs containing 20% blast 
cells were used. One ml of 1 mg/ml DNAse 1 (1000-1500 U) (Stem cell 
technologies, Vancouver, Canada) was added to cells upon thawing. Dead cells 
were removed from the preparation using Ficoll-Plaque Premium according the 
manufacturer's protocol (Pharmacia, New Yark, NY) and fe-suspended in de-
gassed CD34 buffer [PBS (no Mg+2 or Ca+2) pH 7.2,0.5% BSA and 2 mM EDTA]. 
Subsequently, further removal of dead cells was obtained by using pre-separation 
filters (Milltenyi Biotech, Auborn, CA) followed by centrifugation at 300g for 10 
minutes at 4°C. The supernatant was completely removed and cells were re-
suspended in 600ul of CD34 buffer. To this cell suspension, 200ul of 
crystallizable fragment receptor (FeR) blocking reagent and 200ul of CD34 
phycoerythrin (PE) conjugated microbeads were added. The above mixture was 
subsequently incubated for 30 minutes at 4°C. Cell were washed in 20mls of cold 
CD34 buffer, centrifuged at 300g for 10 minutes at 4°C, supernatant was aspirated 
completely and each pellet was resuspended in 500ul of CD34 buffer. Cell 
mixture was added to the prepared column placed in a magnetic field (autoMACS 
separator) and processed according to the manufacturer's recommendation. 
CD34( +) cells remain in the autoMACs separator when they are within the 
magnetic field and flowthrough of cells represent CD34( -). CD34( -) cells are 
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stored at -20°C for further assays of mRNA expression or SMS activity. Column 
is then removed from the magnetic field and the flowthrough contains CD34( +) 
cells. These cells are then stored at -20°C for further assays of mRNA expression 
or SMS activity. 
In some cases, following elution of either CD34( -) or CD34( +) cells from 
the magnetic column as described above, cells were subsequently centrifuged at 
300g for 10 minutes at 4°C and resuspended in 200ul of complete medium for cell 
growth experiments. 
Flow cytometry 
Standard flow cytometry procedure was used according to manufacturer's 
suggested protocol (Becton Dickinson) with I x 105 cells using CDI1b conjugated 
to fluoresceine isothiocyanate (FITC), CD14 conjugated to allophycocyanin 
(APC), and CD34 conjugated to phycoerythrin (PE). Flow cytometry was 
analyzed using the FACSCaliber (Becton Dickinson) and results were provided by 
the flow cytometry core facility at MUSC. 
SMS activity and D609 
For experiments testing optimal CD34( +) growing conditions or for D609 
experiments, CD34( +) or CD34( -) cells purified as above were resuspended in 1 ml 
of complete media in a 12 well plate at a concentration of 5 x 104 cells/ml. Cells 
were cultured for 24 hours before testing SMS activity or treating with D609. To 
inhibit SMS activity, D609 was added and cellular proliferation was determined by 
cell counting with trypan blue exclusion at 24 and 72 hours post-treatment. 
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QRT-PCR and SMS activity assay 
SMS activity assay, mRNA and QRT -peR were performed as described in 
the "Materials and Method" section in Chapter 1. 
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Results 
Effect of pharmacological inhibition ofSMS on differentiation ofK562 
cells. 
To further characterize the biological implications of the effect of SMS 
inhibition on K562 cells, the effect of D609 was determined on K562 cellular 
differentiation. To this aim, K562 and control cells (vehicle only treatment) were 
treated with 50ug/ml D609 for 96 hours and were analyzed for expression of the 
myeloid/monocytic surface antigen markers, CD 14, and CD 11 b by flow 
cytometry. As shown in Figure 13, D609 treatment caused a significant shift from 
CDllb/CD14 negative K562 control cells to approximately 15% eDI1b and 60% 
CD 14 positive cells. These results illustrate that pharmacological inhibition of 
SMS not only decreases cellular proliferation but is capable of causing cellular 
differentiation towards the myeloid/monocytic lineage. 
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Figure 13. Inhibition of SMS activity induces myelocytic/monocytic 
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Figure 13. Inhibition of SMS activity induces myelocytic/monocytic differentiation in K562 
cells. Differentiation markers are characterized by immunophenotypic analysis by flow 
cytometric analysis (FACSCaliber, Becton Dickenson, Germany) with antibodies directly 
labeled with fluorochromes PE for CD 14 and FITC for CD 11. Data is displayed as the % of total 
cells staining positive for the antigens CD14 and CD11b as analyzed by flow cytometry. Arrows 
pointing to the right indicates representative cells from each treatment group. Cells were stained 
with Wright -Giemsa and magnified 40X for visualization using a standard light microscope. 
Abbreviations: CD-Cluster of Differentiation, FITC, fluoresceine isothiocyanate, PE 
phycoerythrin. 
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Effect of pharmacological inhibition. 
To confirm the increased SMS activity observed in Bcr-abl positive cell 
lines, SMS activity was also measured in Bcr-abl positive/CD34+ progenitor cells 
isolated from CML patients in blast crisis as compared to CD34( -) cells. Increased 
SMS activity in CD34( +) cells closely reflected the data obtained from Bcr-abl-
positive cell line (Figure 14). In addition, SMSl expression levels from Bcr-abl 
positive/CD34( +) cells were analyzed by QRT -peR, and it was found that there 
was a substantial increase of SMSl expression in CD34( +) cells as compared to 
CD34( -) cells (Figure 15). 
Finally, the effect of addition of various dosages of D609 (50ug/ml and 
75ug/mJ) on cellular proliferation of CD34( +) cells was determined showing both a 
time and dose dependant decrease of CD34( +) cell proliferation (Figure 16). All 
together these data corroborate the observations collected from ber-abl-positive 
cell lines. 
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Figure 14. SMS1 activity is elevated in CD34+ cells isolated/rom CML 
patient in blast crisis 
04----
CD34 negative CD34 positive 
Figure 14. SMSI activity is elevated in CD34+ cells isolated from CML patient in blast 
crisis. SMS activity was measured as described in "Materials and Method" section from CD34 
negative and positive cells.Abbreviations: CD, Cluster of Differentation, ug, microgram. 
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Figure 15. SMSI expression is elevated in CD34+ cells from CML patient 
in blast crisis 
CD34 negative CD34 positive 
Figure 15. SMSI expression is elevated in CD34+ cells from CML patient in blast crisis. 
mRNA gene expression was determined from CD34 positive and negative cells. All mRNA 
levels were normalized to B-actin expression. Abbreviations:MNE, Mean Normalized 
Expression, CD, Cluster of Differentiation. 
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Figure 16. Pharmacological inhibition of SMS results in decreased 
























Figure 16. Pharmacological inhibition of SMS results in decreased CD34+ cellular 
proliferation. CD34+ cells were treated with the above indicate ugs of D609 for 24 and 72 
hours. Cellular proliferation was measured by trypan blue exclusion. Data represents cell 
number X 10-4. Abbreviations:CD, Cluster of differentiation 
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Chapter 2. Establish SMSI transcriptional activation upon 
Bcr-abl expression. 
Manuscript 2: 
"Transcriptional regulation of SMSl by the Bcr-abl oncogene" 
Tara Ann Burns1 and Chiara Luberto1,2. 
Department of tBiochemistry and Molecular Biology, Medical University of South 
Carolina, Charleston, South Carolina, USA and 2 Department of Physiology and 
Biophysics, Stony Brook University, Stony Brook, New York, USA. 
INTRODUCTION 
Sphingomyelin synthase (SMS) is a class of enzymes responsible for 
the production of sphingomyelin in mammalian cells. This enzyme uses 
phosphatidylcholine and ceramide as its precursors and produces 
sphingomyelin (SM) and diacylglycerol (DAG). In particular, SMS 
transfers the phosphorylcholine moiety from phosphatidylcholine onto 
ceramide thereby producing SM and as a byproduct, DAG (1-5,7). 
Interestingly, both ceramide and DAG are widely known as bioactive 
sphingolipids with opposing functions. Namely ceramide has been widely 
studied during cellular stress response such as cell death and differentiation 
(5,11,13-18,26,28,33-37). On the other hand, DAG cellular responses are 
mainly studied In cellular processes such as proliferation and 
transformation(8). The ability of this enzyme to modulate the levels of these 
two different bioactive sphingolipids makes this enzyme an interesting target 
for further investigation. In previous studies conducted by our lab (Burns 
and Luberto, manuscript accepted with minor revisions), we have shown that 
SMS activity is increased in the K562 celL K562 cells are derived from the 
pleural effusion of a patient with chronic myelogenous leukemia (CML). 
CML is a hematopoietic stem cell disorder and occurs in 1 to 1.5 out of 
100,000 and accounts for 15-20% of all adult leukemias. The initiating 
event of CML is the reciprocal translocation of Chromosomes 9 and 11 and 
this event results in a chromosomal fusion between the breakpoint cluster 
region (BCR) and the Abelson kinase (ABL) genes resulting in a shortened 
chromosome termed "Philadelphia chromosome." (275-278). The shortened 
Philadelphia chromosome chimera carries a constitutively active tyrosine 
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kinase, Bcr-abl (273,274). Increased SMS activity was due to increased 
expression of the SMSl isoform and increased SMS 1 was critical for 
sustaining the cell proliferation of BCR-ABL positive cells (Bums et aI, 
manuscript accepted with minor revisions). Still unknown is the mechanism 
by which Bcr-abl stimulates SMSl expression. 
Recently, the SMSl locus has been somewhat characterized. The 
putative structure of SMSl mRNA consists of 3734 nucleotides with 11 
exons and a hypothetical coding region of 1239 nucleotides flanked by an 
extended 5'-and 3'-UTRs (Figure 17A). The 5'-UTR is 954 nucleotides-
long and it comprises exons 1-6 and a portion of exon 7. Upstream open 
reading frames (uORFs) are located within exons 1, 5 and 6 corresponding 
to ATGs located at nucleotide positions 13-15, 523-525, and 646-648. The 
coding region is predicted to start at the weak A TG codon at 955- 957 
nucleotide positions and to stop with the T AA codon at positions 2194-2196 
and encodes a transmembrane protein of 413 amino acids (327). The 3'-
UTR of the transcript is 1538 nucleotides long (328). 
In this paper we provide evidence of transcriptional regulation of 
SMSI by Bcr-abl and we characterize the SMSl promoter under the control 
of Bcr-abl. We show that although Bcr-abl upregulates different SMSl 
transcripts, the transcription of SMSl is maximally upregulated at sites 
located downstream of intron 6. Thus we propose that Bcr-abl expression 
results in the use of an alternative transcription start site (TSS) within exon 7 
of SMSl and we characterize the first validated promoter (Promoter C) for 
SMS1. We also demonstrate that the identified Promoter C is under the 
control of Bcr-abl. Finally, we produced a series of 5' promoter C deletions 
and we demonstrated that the essential cis-element(s) necessary for Bcr-abl-
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mediated upregulation of this promoter is located between -113 and -110 
from the TSS C. 
MATERIALS AND METHODS 
Materials 
RPMI media, fetal bovine serum (FBS) and penicillin/streptomycin 
were from Gibco/Invitrogen Corp., Carlsbad, CA. 
Methods 
Cell culture 
K562 and HL-60 cell lines were purchased from the American Type 
Culture Collection (Rockville, MD). Human acute myeloid leukemia, HL-60 
cells stably expressing p185 Bcr-abl (HI-60IBcr-abl) and HL-60 stably 
expressIng the empty vector control (HL-60ICt) were generated as 
previously described (292). All cell lines were grown in RPMI-1640 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 
lOOug/ml streptomycin, and were maintained at 37°C at 5% CO2• 
RNA isolation and reverse transcription for real time peR 
RNA isolation and first strand eDNA synthesis were performed as 
described previously (165). Primers were designed to specifically amplify 
SMSl heteronuclear RNA (the first transcribed RNA; hnRNA) at various 
regions within SMS1. Amplification of genomic DNA was prevented by 
treating all RNA samples with DNAse using both on and off-column 
digestion (Qiagen, Valencia, CA) and Ambion Turbo DNAse (Invitrogen, 
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Carlsbad, CA). Furthennore., controls were added consisting of RNA 
purified from each cell line and not treated with superscript reverse 
transcriptase. Both RNA treated with and without superscript reverse 
transcriptase were amplified using Quantitati ve Real-Time reverse 
Polymerase Chain Reaction (QRT-PCR) using primers described below. 
RNA control samples did not amplify during QRT-PCR thus demonstrating 
the absence of genomic DNA. All primer sequences and their specific 
annealing temperatures used during QRT-PCR are provided in Table 1. 
QRT-PCR was performed using the Bio-Rad icycler (Bio-Rad, Hercules, 
CA) and syber green mixture according to the suggested protocol (Bio-Rad, 
Hercules., CA). Bio-Rad icycler parameters are as follows, one cycle of 3min 
at 95°C, 40 cycles of lOs at 95°C and 45s at the appropriate annealing 
temperatures for each primer set (as indicated in Supplementary Table 6), 
one cycle of lmin at 95°C, one cycle of Imin at the appropriate annealing 
temperature and 78 cycles., with each cycle increasing by O.soC for 10 s 
starting from each primer set's appropriate annealing temperature. For 
QRT-PCR experiments to measure mRNA expression, primers were 
designed to span exonJexon junctions thus preventing amplification of 
genomic DNA and/or hnRNA with the following exception, Exon7FIR. 
Results were normalized to an internal control gene., f3-actin (165) and 
amplification efficiency. QRT -peR results were analyzed using Q-Gene® 
software, a software that expresses data as means of normalized expression 
(329). 
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SMSI mRNA message stability 
K562 cells, HL-60/ct, and HL-60/Bcr-abl cells were fe-suspended in 
5ml of complete medium (RPMI containing 10% FBS and 1 % PIS) at a 
concentration of 0.3xl06 cells Iml with either the addition of sterile double 
distilled water (ddH20) or 5 ug/ ml of actinomycin D. Cells were treated for 
30 minutes, l, 2, and 4 hrs and collected by centrifugation at 900 RPM for 5 
minutes and fe-suspended in RTL buffer containing f3 mercaptoethanol. One 
ug of RNA was extracted as indicated above (Qiagen Valencia CA) and 
eDNA was prepared as indicated above (Invitrogen, Carlsbad, CA). eDNA 
was diluted lIla and was used for RT-qPCR. RT-qPCR cycling conditions 
were as follows: 95°C for 3min, and 40 cycles of 95°C for lOs, 61°C for 
45s, 95°C for lmin and a melt curve analysis was performed by 78 cycles 
each increasing by O.5°C from 61 DC. RT-qPCR results were normalized to 
B-actin and analyzed using Q-Gene® software (329). 
5' RACE 
RNA Ligase Mediated Rapid Amplification of cDNA ends (RLM-
RACE) was used to identify the transcriptional start site of SMSl in the Bcr-
abl positive K562 cells according to the manufacturer's specified protocol 
for Ambion FirstChoice RLM-RACE (Invitrogen, Carlsbad, CA). In 
summary, lug of RNA was purified from K562 cells using the Qiagen 
RNAeasy total RNA kit (Qiagen, Valencia, CA) as previously described 
(165) and was subsequently de-phosphorylated with calf intestine 
phosphatase (CIP) at 37°C for lhr, control mRNA was treated 
simultaneously but without the addition of CIP. For all the following 
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enzymatic reactions, enzymes were inactive by the addition of 
phenol/chloroform and RNA was subsequently extracted as suggested by 
manufacturer. Seven microliters of either elP treated versus non-treated 
RNA were incubated with tobacco acid pyrophosphatase (TAP), to remove 
the mRNA Cap structure, at 37°C for 1 hour. Seven microliters of CIP 
treated mRNA was also added to a reaction without TAP as an additional 
control. Both eIP (-) and TAP ( -) control reactions were used in all 
subsequent RLM-RACE steps using the same amount of uls as for each non-
control reactions. Six microliters of the dephosphorylated, decapped mRNA 
was added to the GeneRacer RNA oligo and incubated with T4 RNA ligase 
at 37°C for Ihr. The deeapped, full-length mRNA ligated to the GeneRacer 
RNA oligo was used for reverse transcription of mRNA into eDNA using 
Superscript III reverse transcriptase and random primers following the 
standard protocol (Invitrogen, Carlsbad, CA). One microliter of this 
prepared cDNA was used as a template for an initial outer peR to amplify 
cDNA ends. The outer peR was performend using 0.25U of platinum high 
fidelity Taq polymerase and all primers were used at O.4uM for a standard 
50~L peR reaction as suggested by the manufacturer (Invitrogen, Carlsbad, 
CA). The primers used for the outer peR included the GeneRacer 5' primer 
(kit component) and the following gene specific primer (GSP2R), 5'CAA 
GAA CGG CCA TGC CAA TGG-3'. The following negative controls were 
added: peR reaction without template eDNA, peR reaction without GSP2, 
and a peR reaction without the GeneRacer 5' primer. Additionally to 
ensure fidelity of the kit and all its enzymes, l~L of HeLa eDNA was used 
as template with the GeneRacer 5'primer and control primer B.l provided 
with the kit. Two additional peR reactions were used as positive controls 
for verification of the presence of the target RNA and for testing RLM-
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RACE procedure. These PCR reactions utilized prImers synthesized 
upstream to GSP2 and far enough downstream to produce a resolvable peR 
product as visualized by agarose gel electrophoresis. The combination of 
primers used for these positive control reactions are as follows, GSP/outerlF 
(5'-TOC CAA ACA AGT CTC TOe TC-3') with GSPR, or GSP/outerlF 
with GSP3R (5'-AAG Tee TOG CCT GTG AAA TG-3'). peR 
amplification conditions followed for the outer PCR were as follows: 94°C 
for 3min and 35 cycles of 94°C for 30s, 60°C for 30s, 72°C for 30s, 
followed by an extension at 72°C for 7min. One microliter of the outer PCR 
was used as template for the inner 5' RLM-RACE peR with the following 
primers, GSP3R and 5'RACE inner primer provided with kit. Negative 
controls were added as above for inner peR and peR application was 
performed using the same peR amplification conditions as above. 
Following both outer and inner peR reactions, IOJ-lL of the reactions and all 
above mentioned controls were added to a 2% agarose gel containing 100 
ug/mL ethidium bromide for visualization of peR products. PCR products 
were excised from gel, and purified under standard conditions (Qiagen, 
Valencia CA). Four microliters were used for ligation with the pCR-2.1-
TOPO cloning vector, transformed into DH5a cells according to standard 
protocol (Invitrogen, Carlsbad CA) and grown overnight on LB plates 
containing 100 ug/ml ampicillin for selection. Bacterial colonies were 
selected and DNA was purified from these colonies according to 
manufacturer recommended protocol (Qiagen, Valencia CA). Two 
micrograms of purified DNA were used for sequencing with both M13F and 
M13R primers and sequencing results were analyzed with jellyfish software. 
The entire 5' RLM RACE protocol was repeated twice. 
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Genomatix Analysis 
Computational analysis of the SMSl gene (SGMSl) with the 
Genomatix Software (www.genomatix.de) predicted a proximal promoter 
within intron 6 and 1068 bp upstream from exon 7 which we named 
Promoter C. The analyzed sequence included human genomic sequences 
from chromosome 10 approximately 18 Kb upstream to SMSl and 
overlapping with 31 Kb of SMSl genomic sequence. 
Genomic DNA preparation 
Genomic DNA was obtained from 15 X 106 exponentially growing 
K562 cells. Cells were centrifuged at 3000 RPM for 5 minutes at 4°C and 
resuspended in 500 ul of freshly prepared lysis buffer containing 50 mM 
EDTA pH 8, 1 % SDS, 50 mM Tris pH 7.4, 100 mM NaCl2 and 750 ug/rnl 
Proteinase K (Roche Molecular Biochemical, Indianapolis, Indiana). K562 
cell lysate was then incubated for 1 hour at 60°C, vortexed briefly, and then 
incubated at 60°C overnight. Following overnight incubation, 200 ul of ice-
cold 5M KOAc was added, the lysate was vortexed for 30s and incubated on 
ice for 11/2 hours, centrifuged at 12,000 RPM for 15 minutes and 500 ul of 
the supernatant was removed. To precipitate DNA, 1 rnl of ice cold EtOH 
was added to the top of supernatant and the mixture was gently rocked a few 
times at 90°C. DNA was spooled from the interface of the supernatant, 
washed first with 70% EtOH and then with 100% EtOH. DNA precipitate 
was air-dried for 10 minutes and resuspended in 100ul of sterile ddH20. 
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peR amplification of Promoter C 
Promoter C was amplified from K562 genomIc DNA by peR 
amplification using primers as indicated in Supplementary Table 7, in a 
100 ul volume reaction containing approximately 40 ng of DNA and the 
following peR conditions: 0.2 mM dNTP, 1.5 mM MgCI2, 0.75 uM of 
primers, and 2.5U Tag DNA polymerase (Invitrogen Life Technologies, 
Carlsbad CA). peR amplification conditions for Promoter C isolation were 
as follows: 95°C for 5 min and 35 cycles of 95°C for 50 s, S2°e for 50 s, and 
72°C for 2 min, followed by an extension at 72°C for 10 min. 
Generation of luciferase reporter plasm ids 
Full length promoter C and all deletion constructs were obtained using 
the same reverse primer, Promoter CR-5'-AAG Tee TGG CCT GTG AAA 
TG-3' by standard PCR (as above) and TaKaRA LS Taq hot-start DNA 
polymerase (Clontech Laboratories, Mountain View, CA) with the forward 
primers listed in Supplementary Table 7. Promoter C peR amplicons were 
cloned into the pCR 2.1 TOPO~ T A sub cloning vector and transformed into 
DHA5a bacterial cells using standard conditions (Invitrogen, Carlsbad, CA). 
The plasmids were extracted from ampicillin resistant bacterial colonies, and 
inserts were excised from the peR 2.1 TOPO-T A vector using Kpnl and 
ZhoI (Invitrogen Life Technologies, Carlsbad, CA) and cloned into the final 
pGL3-basic vector (Promega, Madison, WI, USA). All sequences were 
verified by sequencing (Genewiz, Southplainfield, NJ) with either the 
Promoter CR primer and/or the gene specific Promoter CR primer, 
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ProCRs-5' (Supplementary Table 7). Sequence analysis and verification 
was carried out using the Jellyfish software. DNA was prepared for 
transfections using the Endofree Plasmid Maxi Kit (Qiagen, Valencia, CA). 
Transient transfection and luciferase assay 
K562 cells and/or HL-60/Ct cells transfections were performed by 
electroporation in a 12 well plate with either Ixl06 K562 cells or 2xl06 HL-
60 cells per well using the Nucleofector 2b solution, according to the 
protocol, including electroporation settings, as recommended by the 
manufacturer (Amaxa, Allendale, NJ). Cells were electroporated with 2.5ug 
of pGL3-basic vector or pGL3-basic/human promoter C constructs and 
2.5ug of pCMV -~-galactosidase reporter gene. Cells were harvested 24 
hours after transfection, washed once in ice cold PBS, lysed with IX 
reporter lysis buffer (RLB), and luciferase activity was measured using a 
Promega kit (Promega, Madison, WI). For the luciferase activity assay, 
either 5ul of K562 cell lysate plus 15ul of IX RLB or 20ul of HL-60 cell 
lysate were used. Luciferase activity assay reagent (Promega, Madison, WI) 
was mixed briefly with the appropriate amount of cell lysate (as above) and 
luciferase activity was measured using a Sirius Luminometer (Bethold 
Technologies, GMBh & Co. KG, Germany) programmed with a 2-second 
measurement delay followed by a IO-second measurement read. 13-
Galactosidase activity was used to normalize for cell transfection efficiency 
determined by using a colorimetic method as suggested by the manufacturer 
(Promega, Madison, WI). Specifically, 20 uls of K562 cell lysate plus 130ul 
of RLB or 150ul of HL-60 cell lysate was briefly mixed with 150ul of 2X 13-
galactosidase assay buffer, incubated at 37° C for 1 hour and read at 420 nrn. 
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Promoter activity from K562 or HL-60 lysates was calculated after 
normalization with the amount of cell lysate used for the luciferase activity 
assay, to the B-Galactosidase activity of each sample and by subtraction of 
background values (as determined from pGL3 vector only controls). Data 
were expressed as average + SO or for experiments measuring promoter 
activity and data from deletion constructs the data was expressed as fold 
change of luciferase activity to full-length promoter C. All data were from a 
minimum of three independent experiments. 
Imatinib treatment of K562 cells and luciferase activity 
K562 cells were treated with Imatinib mesylate (STI-571) using 0.2, 
0.4, 1.0 uM or vehicle (H20) only control for 30 hours in complete medium 
and electroporated following the same conditions as above with either 2.5ug 
of pCMV -~-galactosidase, 2.5ug of pGL3/promoter C or 2.5ug of pGL3-
basic vector only control. K562 cells were treated for 30 hours with STI -
571 according to previously optimized experiments demonstrating no 
appreciable effect on cell proliferation (Bums and Luberto, manuscript 
accepted with minor revisions). K562 cells treated with STI-571 were 
harvested, lysed and luciferase activity assays along with the p-galactosidase 
colorimetric assays were carried out as described above. Data represents a 
minimum of 3 independent experiments normalized as above + SD. 
RESULTS 
Bcr-abl positive cells have increased SMS1 gene expression 
In our previous studies, (Bums and Luberto, manuscript accepted with 
minor revisions) we have demonstrated increased SMS activity in Bcr-abl 
positive, K562 and HL60/Bcr-abl cells compared to Bcr-abl negative, HL-
60/ct and U937 cells. In particular, a significant increase of SMSl 
expression was observed in Bcr-abl positive (K562 and HL-60/Bcr-abl) 
versus negative cells (HL-60/ct and U937) when primers complementary 
exon-exon junction of ex on 10/11 to part of exon 11 were used (Figure 
17A). 
Figure 17 A +B. Bcr-abl mediated up-regulation of SMS1 
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Figure 17. Bcr-abl mediated up-regulation of SMSI. (A) Schematic representing the 
putative exon structure of human SMS1 mRNA. Light gray boxes represent the 5' UTR; 
translated SMSl is indicated on the schematic as dark gray boxes; white boxes represent 
the 3' UTR region. (B) BCR-ABL positive cells (HL-60IBcr-abl and K562) have an 
approximate 35-fold increase of SMS1 expression compared to BCR-ABL negative cells 
(HL-60/ct and U937). Expression of SMSl was determined by QRT -peR as indicated in 
the "Materials and Methods" section and normalized against fj-actin. Data represents a 
minimum of 3 independent experiments + SD. * indicates significance to H-L60/ct (p< 
0.05). Where error bars are not visible, the error bars are too small compared to the scale 
the y-axis. MNE: Mean of Normalized Expression. 
Ber-abi transcriptionally regulates expression of SMSI 
In order to further elucidate the mechanism by which Bcr-abl causes 
increased SMSl expression, the effects of Bcr-abl expression on SMSI 
transcription was determined by measuring the amount of heteronuclear 
RNA (hnRNA) by QRT- peR. Since hnRNA is the very first RNA 
transcribed from DNA, its expression is indicative of gene transcription. 
Conversely, mRNA expression is indicative of both gene transcription as 
well as RNA processing. Total RNA was extracted from K562, HL-60/Bcr-
abl, HL-60/ct and U937 cells and treated with DNase. SMSl hnRNA 
transcription from both Bcr-abl positive and negative eells was measured by 
QRT-PCR using primer pairs designed to target a region between intron 7 
and exon 8 (Figure 18A). As shown in (Figure 18A), SMSl hnRNA 
transcription was 35-70-fold higher in Bcr-abl positive, HL-60/Bcr-abl and 
K562 compared to Bcr-abl negative HL-60/ct and U937 cells. Importantly, 
SMS 1 hnRNA was undetectable from control eDNA. Control cDNA was 
synthesized from total RNA without the addition of reverse transcriptase, 
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therefore lack of SMS 1 hnRNA in these samples ensured that all DNase 
treated samples were not contaminated with genomic DNA. 
Figure 18. Ber-abl transcriptionally regulates expression of SMSI 
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Figure 18. Bcr-abl transcriptionally regulates expression of SMSI. (A) BCR-ABL 
positive cells (HL-60/Bcr-abl and K562) have increased SMSl hnRNA gene expression 
compared to BCR-ABL negative cells (HL-60/ct and U937). Lack of SMSl expression 
from hnRNA obtained from cDNAs synthesized without reverse transcriptase 
demonstrates lack of genomic contamination. (B) MNE expression of SMSl in Bcr-abl 
negative HL-60/ct cells and Bcr-abl positive cells, HL-60/Bcr-abl K562 upon treatment 
with 5 ug/ml of actinomycin D for 30 min, Ihr, and 2 hrs. Data points represent the 
percent of remaining mRNA at each indicated time point. Expression of SMSl was 
determined by QRT -peR as indicated in the "Materials and Methods'" section and 
nonnalized against p-actin. These results are representative of two separate experiments. 
MNE: Mean of Normalized Expression. 
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Increased mRNA stability represents an additional mechanism that 
could potentially contribute to enhanced SMSl expression as observed in 
Bcr-abl positive versus negative cells (Figure 17B). To investigate this 
potential mechanism, we measured the half life of SMS 1 in Bcr-abl positive 
or negative cells. Data were calculated by normalizing all SMSl mRNA 
expression levels to f3-actin from K562, HL-60/Bcr-abl and HL-60/ct 
(Figure 18B). Each time point was used to calculate linear regression and 
data were displayed as percent of remaining mRNA. This analysis indicated 
no significant differences in mRNA stability in Bcr-abl positive versus 
negative cells. 
Bcr-abl promotes SMSI transcription at specific transcription start 
sites 
To further examine the effect of Bcr-abl on SMSl transcription, 
different primer pairs located closer to either the 5' or the 3' ends of SMSl 
were designed and QRT-PCR was performed to quantify relative levels of 
SMSl hnRNA (Figure 19A) or mRNA (Figure 19D) normalized to ~-actin. 
SMSI normalized hnRNA data are shown in Figures 19B and 19C and 
SMSl normalized mRNA data are shown in Figures 19E and 19F. These 
results revealed that SMSl mRNA is approximately 5-fold higher in Bcr-abl 
positive compared to negative cells when measured at exon 5/exon 6 
(Figure 19E) and similarly, SMSl gene transcription is approximately 5-fold 







Figure 19A-F. Bcr-abl promotes SMSI transcription at different 
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Figure 19A-F. Bcr-abl promotes SMSI transcription at different transcription start 
sites. (A) Schematic representing the putative genomic organization of SMS1. Black, 
solid line numbered with Roman numerals indicate intron regions, white numbered boxes 
indicate transcribed/untranslated exons, and black numbered boxes indicate 
transcribed/translated exons. Bcr-abl positive, HL-60/Bcr-abl and K562 cells, have an 
approximate 5-fold increase of SMSl hnRNA expression as compared to Bcr-abl 
negative, HL 60/ct and U937 cells when measured at intron5/exon6 (B) versus a 35-70-
fold increase of SMSI hnRNA expression when hnRNA is measured at intron7/exon8 
(C). (D) Schematic representing the putative mature gene organization of SMSl, colors 
representation same as in (A). (E) SMSl mRNA expression is 5-fold higher in Bcr-abl 
positive HL 60lBcr-abl and K562 cells versus Bcr-abl negative HL 60/ct and U937 cells 
when measured at exon 5/exon6 versus an approximate 35-fold higher SMSI expression 
level when measured at exon 10lexon 11 (F). Arrows indicate primer placement; primer 
sequence infonnation as in "Methods and Materials" section. Expression of SMSl was 
determined by QRT-PCR as indicated in the "Materials and Methods" section, 
nonnalized to f3-actin expression and expressed as fold change over HL-60/ct. Figures 
(B) and (C) are representative of two separate experiments. Figures (E) and (F) represent 
the average of 3 independent experiments + SD. * indicates significance to HL-60/ct (p< 
0.05). hnRNA: heteronuclear RNA. 
By contrast, QRT-PCR analyzing SMSl expression/transcription 
closer to the 3' ends demonstrated that SMSl normalized transcription is 
approximately 35 fold higher in Bcr-abl positive compared to negative cells 
when measured at intron 7/exon 8 (Figure 19C) and SMSl mRNA is 
approximately 40-75-fold higher when measured at exon 10/exon 11 
(Figure 19F). Collectively, these results indicate that Bcr-abl mediates 
upregulation of both SMSl expression and transcription and that Bcr-abl 
preferentially promotes transcription downstream of exon 6 (Figure 20). 
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Figure 20. Proposed Bcr-abl-mediated regulation of SMSI transcription. SMS1. 
Exons are indicated by numbered squares and introns are numbered with Roman 
numerals. 5' and 3' UTRs are indicated by light gray colored squares. Data from in silico 
analysis and from QRT -peR data (Figure 19) suggest that Bcr-abl regulates transcription 
of SMS 1 at both the 5' and 3' end but to the highest extent downstream from exon 6. 
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Identification of SMSI transcription start sites in Ber-abl positive 
cells 
To identify the Bcr-abl dependent 5' end transcription start sites of 
SMSl we performed RLM-RACE in Bcr-abl positive, K562 cells, using 
reverse primers in exon 7 (GSP-exon 7) or exon 5/6 (GSP-exon 5/6) (Figure 
21). RLM-RACE revealed 5 different transcript products identified as SMSI 
5' RACE products (Figure 21A). Sequence alignment of the SMSl locus 
(ensemble-ENSG0000019864) with transcript products obtained by RLM-
RACE revealed 4 different TSS named (A, B, C, and D). Importantly, TSS 
C and TSS D were both downstream of exon 6 and thus these TSSs were the 
once most likely to be utilized in Bcr-abl positive cells. Importantly 
bioinformatic analysis of human genomic sequences from chromosome 10 
approximately 18 Kb upstream to SMSl and overlapping with 31 Kb of 
SMSl genomic sequence predicted the presence of 3 different promoters, 
one of 540bp at -480bp from exon 1 (promoter 1), a second one of 228bp 
that started within exon 2 (promoter 2) and a third of 1068 bp starting in 
intron 6, 735 bp upstream to exon VII and expanding into exon VII 
(promoter 3). The predicted promoter 3 being downstream of exon 6 and 
upstream of the coding region, matched our prediction based on the TSS 
analysis. The transcript upregulated in Bcr-abl cells, as identified by RLM-
RACE, has its TSS (TSS C) on intron 6, specifically 97 bps upsteam from 
exon 7 (Figure 21A). The putative promoter upstream to this TSS was 
named Promoter C (Figure 2IB). Other identified transcripts and their 
putative promoters were named Promoter A, Promoter B, and Promoter D 
and are shown in (Figure 21A and Table 3). 
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Relative abundance of the differellt predicted mature messages of 
SMSI in Bcr-abl positive cells 
To determine the relative abundance of the different SMSl mRNAs in 
Bcr-abl positive versus negative cells, and to confirm that the mRNA 
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Figure 21 A +B. Identification of transcription start sites of SMS1 
in Bcr-abl positive cells 
A SMS1 5' RACE products B Predicted common hnRNA transcripts with 
putative promoter 
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Figure 21A+B. Identification of transcription start sites of SMSI in Bcr-abl positive 
cells. (A) Schematic of the 5' RLM-RACE products in K562 cells identified by aligning 
RACE products with human SMSl (SGMSl) using basic local alignment search tool 
(BLAST). As a note, transcripts previously described as introns in other cell lines and 
tissues (328,330) are illustrated using large, dashed lines and numbered with Roman 
numerals and exons are illustrated with numbered boxes. (B) Schematic of predicted 
common hnRNA transcript and putative promoter based on SMSl 5' RLM-RACE 
products. TSS: Transcription Start Site. RLM-RACE: RNA ligase Mediated Rapid 
Amplification of cDNA ends. 
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originated from TSS C is predominant, QRT -peR was performed by 
designing primers to detect SMSI mRNA originating from the following 
putative TSSs: A, A+B, A+B+C+D, or D. (Figure 22). All results were 
normalized to J3-actin expression. SMSl expression from TSSs A and D 
were each calculated each independently. Expression of SMSl mRNA from 
TSSs B or C could not be analyzed in isolation due to their locations within 
SMSI. Therefore, mRNA from TSS B's contribution to SMSl's overall 
expression was determined by comparing mRNA from TSS B to the 
combination of A+B. Likewise, mRNA from TSS C's contribution to 
SMSI's overall expression was calculated by comparing A+B+C+D to 
mRNA from A, A+B, and D. Mature SMSl from TSS C had an approximate 
33-fold relative expression compared to HL-60/ct mRNA. In contrast, there 
was only an approximate 5-fold increase of SMSI expression from TSS B 
and less than I-fold increase of mRNA from TSS D compared to HL-60/ct 
mRNA. Message RNA from TSS A was undetectable in HL-60/ct cells and 
its mean normalized expression in Bcr-abl positive cells was less than 0.003 
on average. 
These results confirmed that the mRNA originated from TSSC is the 
most abundant in Bcr-abl positive cells. 
Identification of core promoter C 
Since in Bcr-abl positive cells, the mRNA from TSS C was the most 
represented, it is speculated that a putative promoter region upstream of TSS 
C (named Promoter C) was activated in these cells as compared to Bcr-abl 
negative cells. The predicted promoter 3 from the Genomatix analysis 
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Figure 22. Relative abundance of the different mature messages of SMSI in Bcr-abl 
positive cells (A) SMSl expression was measured by QRT -PCR as described in the 
"Materials and Methods" section from both Bcr-abl positive, HL 60lBcr-abl and K562 
cells and Bcr-abl negative, HL 60/ct cells. Specifically, SMSl gene expression from each 
TSS was measured by designing primers based on the identified RLM-RACE 
transcription product (for specific primer sequence information see "Materials and 
Methods"). To analyze the contribution of each putative promoter to overall SMSl gene 
expression in Bcr-abl positive cells, SMSl gene expression from Bcr-abl positive cells 
was compared to their negative counterparts from all putative promoters (A+B+C+D) 
versus SMSl gene expression originating from either putative promoters A, D, or from 
the combination of A+B thus revealing that the mass majority of SMSl gene expression 
in Bcr-abl positive cells results from putative Promoter C. (B) Genomic organization of 
SMS1. See legend box for full description of schematic. TSSs identified by RLM-RACE 
are indicated on the schematic using both arrows and corresponding letters. Data 
represent the mean of a minimum of 3 independent experiments + SD normalized to ~­
actin expression. TSS: Transcription Start Site; int: Intron; ex: exon; RLM-RACE: RNA 
Ligase Mediated Rapid Amplification of cDNA ends. 
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Genomatix predicted core promoter of 1068 bp starting on intron 6 
and overlapping exon 7. This core promoter was cloned in the pGL3-basic 
luciferase reporter vector (pGL3-ProC). In all luciferase experiments, the 
resulting PGL3-basic luciferase construct was co-transfected with the 
pCMV -p-galactosidase plasmid and for each set of experiments, empty 
pGL3-vector was transfected separately. Results were normalized to p-
galactosidase activity to account for differences in transfection efficiency 
and the pGL3-vector only control was used to normalize for any background 
luciferase activity signal. The plasmid pGL3-ProC was transfected into Bcr-
abl negative, HL-60/ct cells and Bcr-abl positive, HL-60/Bcr-abl and K562 
cells. Results from this experiment are shown in Figure 23A. Bcr-abl 
positive HL-60/Bcr-abl and K562 cells have an approximate 40 fold increase 
of luciferase activity compared to Bcr-abl negative, HL-60/ct cells. 
To ensure that increased luciferase activity from pGL3-Pro C 
transfections were mediated by Bcr-abl, K562 cells were treated with the 
Bcr-abl inhibitor, Imatinib (also STI-571) (Figure 23B). Specifically, K562 
cells were transfected with pGL3/Pro C and with 0.2, 0.4, or 1.0 uM of STI-
571 or vehicle control. Luciferase activity was decreased in all 
concentrations approximately 2-fold supporting the dependence of Promoter 
C activity on Bcr-abl. 
In order to locate the core promoter sequence of promoter C, 6 
progressive 5 f deletion constructs were generated (Figure 23C). The 
original Promoter C cloned into the pGL3-basic vector is termed "Promoter 
C-full-length". The remaining deletion constructs were numbered according 
to their location in regards to the TSS C identified by RLM-RACE. These 
constructs were transfected into HL-60 and K562 cells as described in 
"Materials and Methods." Relative luciferase activity of deletion constructs 
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Figure 23. Identification of the core Promoter C. Luciferase activity from celllysates 
measured after electroporation with 2.5ug of Promoter C cloned with the pGL3-basic 
luciferase reporter vector (pGL3-Promoter C) and 2.5ug of pCMV -B-galactosidase 
reporter vector measured from Bcr-abl negative cells, HL-60 and Bcr-abl positive cells, 
HL-60IBcr-abl and K562 cells collected 24 hours after electroporation (A), from K562 
cells treated with 0.2, 0.4, or 1.0 uM of STI-571 for 30 hours of treatment (B), and from 
K562 or HL-60/ct cells lysed 24 hours after electroporation with either full-length or 5' 
progressive deletions of full length pGL3-Promoter C (C). Numbers associated with 
each deletion construct refers to the distance of the first 5' base pair of the deletion 
fragment to the Transcription Start Site (TSS). Data in (C) are expressed as fold-change 
compared to full-length pGL3-Promoter C. Data represents luciferase activity 
normalized to pCMV -B-galactosidase activity and pGL3-vector only control. All 
experiments represent the mean ± SD of at least 3 independent experiments. STI -571: 
Imatinib mesylate. RLU: Relative Light Units. B-gal: B-galactosidase. 
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in both cell lines were compared to that of pGL3/ProC and expressed as fold 
change over Promoter C. As seen in Figure 23C, transfections in Bcr-abl 
positive K562 cells with the deletion construct -110 resulted in a near 
complete abolishment of luciferase activity, while the -113 deletion 
construct maintained luciferase activity. These results indicate that the 
fragment between -113 and -110 contains cis-elements that are essential to 
drive high-level transcription of the SMS 1 gene. These experiments were the 
result of a minimum of 3 independent experiments performed on different 
days. Smaller deviations could be obtained by doing all the deletions on the 
same day in triplicate since the effect of transfection with each deletion 
construct varies to some degree from day-ta-day, possibly from differences 
in growth state, health and transfection efficiency of cells. But experiments 
were chosen based on independent experiments even though larger standard 
deviations are obtained. In contrast, transfection in HL-60 cells (Bcr-abl 
negative), with the -110 deletion constructs resulted in no appreciable 
change of luciferase activity_ In fact, there was no loss of luciferase activity 




This study investigated the mechanism responsible for the effect of 
Bcr-abl on SMSI transcription. We provide evidence of a unique Bcr-abl 
dependent mechanism of SMSl transcriptional regulation via the use of an 
alternative transcriptional start site within SMSI. Multiple transcription start 
sites and their putative promoters within SMSl are identified. This includes 
TSS C and Promoter C., both most likely regulated specifically through Bcr-
abI. Finally, the region of Promoter C, regulated by Bcr-abl., has been 
identified. This region is predicted to contain the cis-elements necessary for 
Ber-abl regulation. 
Previously, we have demonstrated that Bcr-abl induces increased 
SMSl expression (Burns and Luberto., manuscript accepted with minor 
revisions) but the mechanism of the increased expression has as yet, been 
undescribed. Therefore in order to analyze SMSl transcription we measured 
hnRNA by QRT -peR. To analyze hnRNA, primers were designed to have 
at least one primer, either forward or reverse, inside introns. By this method, 
primers would preferentially amplify precursor transcripts, and not mature 
mRNA or excised introns. Precursor transcript levels reflect transcription. 
This is a more accurate method to analyze gene transcription then by 
measuring mRNA transcript levels, since precursor transcripts are more 
rapidly and consistently processed by pre-mRNA splicing. Changes in 
precursor transcript levels are reflective of changes in transcription rather 
than changes in RNA stability (331-334). In opposition, measuring mRNA 
overall gene expression is an indicator of gene expression after post-
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transcriptional processIng. U sing this approach, evidence is provided 
showing a 35-70 fold increase of normalized SMSl hnRNA transcription in 
the presence of Bcr-abl. This data therefore suggest that elevated SMSl 
expression seen in Bcr-abl positive cells as compared to their negative 
counterparts is due to increased SMSl transcription. 
An additional mechanism that could contribute to elevated SMSl 
expression is increased mRNA stability. The 3' end of SMSl has been 
analysed by Vladychenskaya, et a1. in 2004 (330). This study investigated 
SMS1's 3' UTR by in silico analysis and concluded that SMSl had 3' UTRs 
approximately lh as long as the estimated average 1027 nucleotides found in 
humans (330,335). In addition, SMS1's 3' UTR is comprised 0[70% poly-
A and poly-T tracts versus the general composition of UTRs with an average 
of 55% (330,335). Furthermore, SMSl has six ATTTA motifs found within 
the 3'-UTR. These motifs possibly correspond to the functional domains of 
adenylate/uridylate-rich elements (AREs). Importantly, ARE motifs are 
known determinants of mRNA instability_ These motifs are normally found 
within a number of labile, short-lived mRNAs which encode for regulatory 
proteins, such as growth factors and their receptors, proto-oncoprotein's, 
inflammatory mediators and cytokines (336,337). Considering the increased 
SMSl gene expression observed in Bcr-abl positive compared to negative 
cells and in light of SMS]'s complex 3' UTR, mRNA stability/instability as a 
post-transcriptional mechanism was explored. These studies were based on 
the use of actinomycin D, a strong inhibitor of transcription and they 
revealed no difference in mRNA stability in Bcr-abl positive compared to 
negative cells. Overall, transcriptional analysis combined with mRNA 
stability studies strongly suggests that increased SMSl expression in Bc-abl 
positive cells is due to increased SMSl transcription. 
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In the process of determining the effect of Bcr-abl on SMSl 
transcription, different primer pairs closer to either the 5' or the 3' ends were 
used for QRT-PCR analysis. Interestingly, using primers probing either 
hnRNA or mRNA downstream to ex on 6, we found a much larger fold 
increase of either SMSl expression or transcription (Figures 19C and F) 
than when probing SMSl upstream to intron 6 (Figures 19B and E). These 
results suggested to us that perhaps Bcr-abl was promoting SMSl 
transcription at least at two different TSSs and that the TSS proximal to exon 
7 was stronger (Figure 20). This hypothesis was in agreement with 
promoter analysis of the SMSl locus performed using the Genomatix 
software. Genomatix analysis revealed the presence of 3 predicted 
promoters, two at the 5' end of SMSl and one overlapping intron 6 and exon 
7. Therefore according to the prediction that SMSI may have multiple TSSs, 
we concluded that it was essential to identify the correct TSSs and 
appropriate promoter in order to further analyze Bcr-abl regulation on SMS1 
expressIon. 
Identifying the correct TSS is essential in order to ensure that the 
region under investigation is appropriate. To this aim, we used RLM-RACE 
to first identify the Bcr-abl dependent TSS of SMS1. This method is 
advantageous to other types of methods seeking to identify the TSS of genes 
because RLM-RACE is designed to only detect transcripts containing a 7-
methylguanylate cap structure at the S' end. Since the structure is only found 
in authentic Sf ends of RNA polymerase II, artificial 5' end resulting from 
RNA degradation or reverse transcriptase pausing are not detected 
(338,339). In addition, degraded mRNAs are not detected as a result of the 
initial phosphatase treatment of the RNA sample. Controls were added to 
the RLM-RACE procedure without the addition of phosphatase to ensure 
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that phosphatase treatment on RLM-RACE products was successful, 
therefore confirming that degraded mRNAs were not analyzed. This 
technique was specifically selected instead of other methods used to detect 
TSS such as primer extension, RNase protection and S 1 nuclease since the 
structure of SMSl is known to be complex. This complexity is demonstrated 
by a previous study analyzing SMSl transcripts from cerebellum. This study 
predicted two TSS by primer extension, one at 700bps and another at 350bp 
upstream from the employed primer located within exon 6 (330). 
Unfortunately, primer extension analysis cannot easily reveal actual 
sequence information on complex genes with multiple TSS, but instead since 
the size of the eDNA corresponds to the distance from the 5' end of the 
primer, predictions of the TSS can be made from calculating distance of base 
pairs from the reverse primer. Likewise, RNase protection and Sl nuclease 
methods reveal the size of a probe fragment resistant to cleavage by RNase 
or S 1. This size corresponds to the distance from the 5' end of the labeled 
probe to the 5' end of mRNA, if the probe hybridizes to the sequence within 
the first exon. Yet, if the probe hybridizes to sequences within the second 
exon or intron for example, resistant products will not correspond to the 
desired distance (340). These complications are eliminated by choosing 
RLM-RACE for the reasons mentioned above and because products of 
RLM-RACE can be sequenced and compared to genomic information 
available on public websites, such as NCBI and EnsembL 
This technique revealed four different TSSs. Importantly, a TSS was 
identified within exon 7 upstream to the ATG (TSS C). The position of TSS 
C is also in agreement with the QRT -peR data on SMSl gene transcription 
and expression that predicted an alternative TSS driven by Bcr-abl, 
downstream of exon 6 and proximal to exon 7 (Figure 19), as well as the 
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Genomatix predicted putative promoter starting in introD 6 and spannIng 
exon 7. Since more than one TSSs was identified in Bcr-abl positive cells, 
the relative abundance of the different mature messages of SMSl was 
determined by QRT -peR. This analysis revealed quantitative information 
of each of the identified putative transcripts and suggested that Bcr-abl is 
preferentially regulating TSS C and its corresponding Promoter C as 
compared to all other identified transcripts and putative promoters (Figures 
22A and B). 
The proper identity of TSS C and its putative promoter C was 
confirmed by luciferase reporter analysis in Bcr-abl positive cells as well as 
by the changes of hnRNA and mRNA (Figures 22 and 23A). Transient 
transfectians in Bcr-abl positive compared to negative cells revealed a 
similar pattern of promoter C transcriptional activity (40-fold increase in 
Bcr-abl positive cells) (Figure 23A). 
Experiments were also conducted to identify the region of promoter C 
containing the minimal base pairs needed for Bcr-abl dependent SMSl 
transcription. When base pairs were deleted between -113 and -110 from 
TSS C, promoter C driven luciferase activity was reduced to mere 
background (Figure 23C). These results suggest that the important cis-
elements in Promoter C are likely to exist between -110 and -113. Other 
deletions showed somewhat reduced luciferase activity (i.e. -119 and -113, 
Figure 23C) but the differences between these deletions and the full length 
Promoter C activity are minimal when standard deviations are considered. 
Importantly, the dependence of SMSl transcription from Bcr-abl was 
validated by both experiments demonstrating the lack of any significant 
difference in luciferase activity with any of the deletion constructs in the 
Bcr-abl negative HL-60 cells (Figure 23C) and by the inhibitory effect of 
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Imatinib on the transcription activity of Promoter C in Bcr-abl positive cells 
(Figure 23B). 
For the first time, these results provide evidence that a known 
oncogene, Bc-abl regulates SMSl transcription through a unique mechanism. 
Specifically, Bcr-abl is capable of directing SMSI transcription via the use 
of TSS C within exon 7 of SMS1. Future studies will be conducted to 
unequivocally identify the potential trans-acting factors within Promoter C 
that mediate this Bcr-abl-dependent mechanism. These studies will 
definitively connect this unique mechanism of Bcr-abl regulation to 
sphingolipid metabolism, a connection to this author's knowledge, 
previously unknown. In addition to the identification of the trans-acting 
factor, future studies should address the potential benefit in having a much 
shorter SMSl transcript in Bcr-abl cells when transcription starts within exon 
7 (instead of introD I or II). One possible benefit for Bcr-abl cells in utilizing 
Promoter C could be that the resulting mRNA might be more efficiently 
post-transcriptionally regulated, perhaps leading to a faster translation. 
Interestingly, translational regulation of SMSl has been predicted (330) and 
Bcr-abl has been linked to aberrant translation. In particular, Bcr-abl 
expression is involved in altered expression of RNA binding proteins (such 
as La and hnRNP K) which in tum ultimately enhance translation of pro-
proliferative and pro-survival proteins [for a review (303)]. 
In summary, this paper has shown for the first time a unique 
mechanism utilized by Bcr-abl in regulating SMSl transcription. This 
mechanism is unique to Bcr-abl positive cells, and results from this paper 
constitute evidence of a Bcr-abl-regulated mechanism that alters the TSS 
and promoter activity of SMS1. 
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APPENDIX B: Identification of the transcription (actor 
responsible for Bcr-abl-mediated upregulation of SMSl 
transcription. 
The following results are included as part of Specific Aim 2, but 
currently they are not included in the manuscript "Transcriptional regulation 
of SMSl by the Ber-abl oncogene", because they are very preliminary and 
they require further validation. 
Materials and methods 
Materials 
RPMI media, fetal bovine serum (FBS), penicillin/streptomycin and 
Trypan Blue dye solution were from Gibeo/Invitrogen Corp., (Carlsbad, 
CA). 
Cell culture 
K562 cells were originally purchased from the American Type 
Culture Collection (Rockville, MD). All cell lines were grown in RPMI-
1640 supplemented with 10% FBS, 100 D/ml penicillin and 100 Jlg/ml 
streptomycin, and were maintained at 37°C at 5% CO2• 
Downregulation of STATS 
The siRNA used to knockdown human STAT5 was from a pool of 3 
target-specific 20-25 nucleotides (Santa Cruz Biotechnologies, Santa Cruz, 
CA). The Allstar Negative Control was used in experiments as baseline. 
K562 cells were transfected with siRNA by electroporation using the Amaxa 
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Nucleofector device (Amaxa) according to the manufacturer's instructions. 
The protocol was optimized regarding the concentration of STAT5 siRNA, 
transfection and post-transfection conditions in preliminary dose-response 
experiments (1-10 J.lg STAT5 siRNA). Consequently, the following optimal 
conditions were employed. Cells (lxl06 K562 cells) were transfected with 
2.2 ~gof siRNA. After 30 minutes of incubation at 37°C, 5% CO2 in 500 J.lI 
of complete growth medium, cells were seeded at O.5xl06 cells/ml in 2 mls 
of complete media. Twenty-four hours after transfection, cells were 
harvested for mRNA extraction. Successful downregulation of STAT5 was 
confirmed by peR analysis (data not shown) using standard peR conditions 
with primers provided with the siRNA kit (Santa Cruz, CA) as suggested by 
the manufacturer (Invitrogen, CA). 
Downregulation of YYl 
For the knockdown of endogenous YY1, Mission shRNA 
pLKO.l-puro shRNA vector plasmid was used targeting endogenous YYl 
sequence-5'-CCG GCe TeC TGA TTA TTC AGA ATA TCT CGA GAT 
ATT CTG AAT AAT CAG GAG OTT TTT-3'(341) (Sigma-Aldrich, MO). 
YYl shRNA was provided as a bacterial stab, bacterial cells were grown on 
an LB plate containing 100 ug/ml of carbenicillin for selection. One isolated 
clone was selected from the LB plate and grown in Terrific broth (Sigma-
Aldrich, MO) with 100 ug/ml of carbenicillin (Sigma-aldrich, MO) 
overnight. Overnight cultures (1700 mls) were used for DNA extraction of 
YYJ-shRNA plasmids using the GenElute HP Endotoxin-Free Maxiprep Kit 
(Sigma-Aldrich, MO). ShRNAVector backbone pLKO.l was used as a 
negative control for knock-down validation (342). Transfections with YYJ-
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shRNA were optimized regarding the concentration of YYJ-shRNA plasmid, 
transfection and post-transfection conditions in preliminary dose-response 
experiments (1-15 Jlg YYJ-shRNA plasmid). Consequently, the following 
optimal conditions were employed. Cells (lxl06 K562 cells) were 
transfected with 15 J..lg of YYJ-shRNA plasmid. After 30 minutes of 
incubation at 37°C, 5% CO2 in 500 J.lI of complete growth medium, cells 
were seeded at O.5x106 cells/ml in 2 mls of complete media. Cells were 
collected at 24, 48, 72 and 96 hours and processed for RNA extraction, see 
below. 
RNA isolation and reverse transcription for real time peR 
To analyze the expression of SMSl in K562 cells after STAT5 siRNA 
and YYJ-shRNA transfection, total RNA was first isolated from 1x106 cells 
using the RNeasy Mini Kit according to manufacturer's protocol, including 
optional DNase digestion (Qiagen, Gmbh, Hilden, Germany). Further DNase 
digestion was performed using the Turbo DNA free kit according to 
manufacturer's protocol (Applied Biosystems). The first strand eDNA 
synthesis was prepared from 1 ~g of RNA using Superscript III (Invitrogen) 
according to the manufacturer's recommendations. Real-time peR 
amplification was carried out as described by Villani et al. (165) using the 
following primers targeting SMSI hnRNA at intron 7F, 5'-ATT GAG TeA 
TTG AAA AAT TAC AG-3' and exon 8R, 5'-GCC AAC TAT GCA GAA 
AAA TC-3'. 
Nuclear Extraction 
For nuclear extraction, 4xl06 K562, HL-60/Bcr-abl and HL-60/ct cells 
were harvested during the log phase of growth. Cells were centrifuged at 
3000rpm at 4°C for 5 minutes and after the medium was removed, cell 
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pellets were subsequently washed with ice cold PBS, and centrifuged as 
above. Pellets were re-suspended in 400ul of ice~cold lysis buffer [10 mM 
HEPES, pH 7.9, 10 mM KC1, 100 mM EGTA, 100 mM EDTA, ImM 
dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF)], and 
incubated 10 minutes on ice. Just before centrifugation, 5ul of 10% Nonidet 
40 was added, the cell suspension was pipetted gently 4-5 times, and nuclei 
were pelleted by centrifugation for 10 minutes at 1300 g at 4 cC. 
Supernatants were removed, and nuclei were resuspended in 40ul of ice-cold 
extraction buffer [20 mM HEPES pH 7.9, 400 rnM NaCI, 25% (v/v) 
glycerol, 1 mM EDTA, 1mM EGTA, ImM DTT, 0.5 mM PMSF]. The 
suspension was rotated gently for 30 minutes at 4°C and centrifuged at 
18,000 g for 15 minutes at 4°C. The supernatants were flash-frozen and 
stored at -80cC. Protein concentration was determined using the Bio-fad 
protein assay (Biorad, Hercules, CA). 
Electrophoretic Mobility Shift Assay (EMSA) 
Assays were performed as previously described (343) with 
minor modifications. Assays were performed in a final volume of 20ul using 
18ug of protein nuclear extracts and incubated in HDKE buffer [20 mm 
Hepes, pH 7.9,50 mm KCI, 5% (v/v) glycerol, 1 mm EDTA, 5 mm DTT] 
containing 1 flg poly( dI -de), 1 ~g poly( dN 6), and 10 f-lg of bovine serum 
albumin. One JlI of radiolabeled oligonucleotide probe (60,000-100,000 
cpm) was added to each reaction and incubated at room temperature for 20 
min before the addition of the loading buffer. 
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Oligonucleotides 
The following oligonucleotide was used corresponding to 
sequences within Promoter C spanning -133 to -96 as numbered from the 
identified TSS C: 5'-AAG TAC AGe ATe TTG ATA TTT TCT CTT GeT 
TTC ACA G-3'. This oligonucleotide was end-labeled using polynucleotide 
T 4 kinase (Promega, Wi) and [ y-32p ]A TP (American Radiolabeled 
Chemicals, MO) and purified on a microspin G25 column (Amersham, PA). 
Evi-l 
The oligonucleotide containing the core Promoter C (initially 
identified between -133 and -97 nucleotides) was predicted to carry a 
putative consensus sequence for Evi -1. Thus, in order to determine if Evi-l 
is responsible for activation of Promoter C in Bcr-abl positive cells, we 
produced an Evi-I mutated Promoter C and tested it for luciferase reporter 
activity in K562 cells. With the support of the Genomatix software, 
nucleotides substitutions were made to mutate the Evi-l consensus sequence 
(Promoter C/Evi -1-M) without generating or deleting any other potential 
transcription factor binding site. Therefore, the following oligonucleotides 
were generated for site directed mutagenesis, EVIIF, 5'-TAA TTT GGA 
AGT ACA GCA TCT TGA Tee TTT eTC TTG CTT TCA CAG AAG 
GAA G-3', and EVIIR-, 5'-CTT CCT TCT GTG AAA GCA AGA GAA 
AGO ATC AAG ATG CTG TAC TTC CAA ATT A-3'. Site directed 
mutagenesis was performed using the above primers according to the 
standard protocol, as suggested by the manufacturer (Stratagene, TX) and 
using the full length Promoter C cloned in the PGL3-basic vector as a 
template. All sequences were verified by sequencing (Genewiz, 
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Southplainfield, NJ) with either the Promoter CR primer and/or the gene 
specific Promoter CR primer, ProCRs-5' (Supplementary Table 7). 
Sequence analysis and verification of Evi-l mutation was carried out using 
the Jellyfish software. Plasmid DNA was prepared for transfections using 
the Endofree Plasmid Maxi Kit (Qiagen, Valencia, CA). Transfection of 
Promoter C and Promoter C/Evi-l-M and luciferase activity were performed 
as described in the "Materials and Methods" section of Chapter 2. 
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Results 
Identification of the trans-acting factor regulated by Bcr-abl 
Based upon initial results with the luciferase reporter system 
obtained by deleting portions of Promoter C cloned into the PGL3 -basic 
vector as described in Chapter 2 (Figure 23C), the region between -110 and 
-127 from TSS C was predicted to contain the necessary cis-elements needed 
for Bcr-abl mediated upregulation of SMS1. 
Thus to confirm the existence of a DNA binding factor present in Bcr-
abl positive cells and absent in Bcr-abl negative cells, we performed binding 
assays with nuclear extracts using an oligonucleotide corresponding to the 
putative core Promoter C (-110/-127) and spanning few extra nucleotides on 
each side (-133/-97). The radiolabeled oligonucleotide probe was incubated 
with Bcr-abl positive K562 and HL-60IBcr-abl and Bcr-abl negative HL-
60/ct nuclear cell extracts (Figure 24). This analysis revealed 3 separate 
bands unique to Bcr-abl positive cells, providing an indication of the 
existence of different binding factors. 
Computational analysis of the core Promoter C using MatInspector 
(Genomatix) and TRANSFAC were used to identify matches in DNA 
consensus sequences within the -110 and -127 region. Based on this 
analysis, 5 candidate transcription factors were identified (Supplementary 
Table 9). Importantly, interferon regulatory factor 4 (IRF4) is not expressed 
in K562 cells so it can be excluded from further analysis (344,345). 
To investigate the potential involvement of YYl in the regulation of 
SMSl transcription, YYl was transiently downregulated by shRNA and its 
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Figure 24. Binding of potential transacting factors to Promoter C 
HL-601 K562 HL-601 
Ct Bcr-abl 
Figure 24. Binding of potential transacting factors to Promoter C. Electromobility 
shift assay of oligonucleotide within Promoter C spanning -133 to -97 as numbered from 
the identified TSS C. Equal amounts of nuclear proteins from 6xl06 of HL-60/ct, K562 
and HL-60IBcr-abl cells were incubated and prelabeled with the Promoter C 
oligonucleotide, and binding was studied using a 5% nondenaturing polyacrylamide gel 
as described in the "Materials and Methods" section. Arrows indicate bands unique to 
Bcr-abl positive, K562 and HL-60 cells as compared to Bcr-abl negative, HL-60/ct cells. 
effect on SMSl hnRNA levels were determined. Cells were harvested 48 and 
72 hours post transfection. As shown in Figure 25, significant down-
regulation of YYl was achieved starting at 24 hours post transfection (Figure 
25A) but no significant differences in SMSl transcription was observed at 
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any time point (Supplementary Figure 25B). Similar results were obtained 
when SMSI transcription was measured after 96 hours of YYl down-
regulation (data not shown), suggesting that YYl is not involved in the 
regulation of SMSl transcription. 
Figure 25. YYl down-regulation does not impair SMSI transcription 
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Figure 25. YYl down-regulation does not impair SMSI transcription. ShRNA 
mediated downregulation of YYl in K562 cells resulted in an ,.... 7-8-fold decrease of YYl 
expression at 48 and 72 hours post-transfections (A) yet it did not result in decreased 
SMSl transcription (B). QRT-PCR was performed using YYl primers and SMSI 
primers targeting intron 7/exon 8 as indicated in the "Materials and Methods" section and 
normalized against B-actin. Abbreviations: AS-Allstar negative scrambled siRNA 
(Qiagen, CA). 
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To determine if Evi-l is responsible for activation of Promoter C in 
Bcr-abl positive cells, we produced a Promoter C with mutated Evi-l 
consensus sequence and tested it for luciferase reporter activity in K562 cells 
as compared to wild type Promoter C (Supplementary Figure 10). These 
results demonstrated no significant difference between transcriptional 
activity comparing PGL3-Promoter C and PGL3-Promoter ClEvi-1 thus 
suggesting that Evi -1 is not involved in regulating SMS 1 transcription. 
Moreover negative results were also obtained when antibodies against Evi-1 
were used to cause a supershift of one or more bands evidenced by EMSA 
but no supershift could be observed (data not shown). 
Figure 26. Transfection of Promoter C harboring the mutated Evi-
l-consensus sequence does not result in decreased SMSI 
transcription 
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Figure 26. Transfection of Promoter C harboring the mutated Evi-l-consensus 
sequence does not result in decreased SMSI transcription. Luciferase activity from 
K562 cell lysates measured after transfection with either 2.5ug of Promoter C or 
Promoter C with a mutated Evi-l binding site and 2.5ug of pCMV-~-galactosidase 
reporter vector. Cells were collected 24 hours after electroporation. Data represents 
luciferase activity normalized to pCMV -f3-galactosidase activity and pGL3-vector only 
control. RLU: Relative Light Units. B-gal: ~-galactosidase. 
Finally, the involvement of STAT5 in the regulation of SMSl 
transcription was considered. STAT5 was transiently downregulated in K562 
cells with siRNA and cells were harvested 168 hours post transfection 
(Figure 27). QRT-PCR analysis for SMSI transcription was performed as 
described in the "Materials and Methods" section. Indeed, an approximate 
4-5 fold reduction of SMSl transcription upon STAT5 down-regulation was 
observed, thus suggesting that this transcription factor might be in part 
involved in Bcr-abl-mediated regulation of SMSl transcription. 
Importantly an indirect confirmation of the possible involvement of 
STAT5 and exclusion of the other transcription factors for the regulation of 
SMSl comes from results obtained with the final deletion constructs of 
Promoter C: -119 and -113 (Figure 23). In fact deleting nucleotides of 
Promoter C up to -113 does not significantly affect Promoter C 
transcriptional activity. Given the fact that STAT5 consensus sequence sits 
at nucleotides -108/-90 f Promoter C, makes STAT5 the most likely 
candidate. 
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Figure 27. STAT5 inhibition may inhibit SMSI transcription. STAT5 inhibition in 
K562 cells resulted in an approximate 4-fold decrease of SMSI transcription. SMSl 
transcription was determined by QRT-PCR 168 hours post siRNA transfection. QT-PCR 
was perfonned as indicated in the "Materials and Methods" section and normalized 
against B-actin. Abbreviations: AS-Allstar negative scrambled siRNA (Qiagen, CA). 
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Figure 28A +B. Roles of different SLs and SL metabolizing enzymes 
in CML cells 
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Figure 25. Roles of different SLs and SL metabolizing enzymes in CML cells. A. 
Bcr-abl increases the expression of SKI and SMSI causing an increase of the pro-
proliferative lipids SIP and DAG and the decrease of ceramide levels. The particular SL 
profile contributes to the proliferative advantage and pro-survival characteristics of CML 
cells. B. Pharmacological inhibition of Bcr-abl by Imatinib activates CerS 1 and inhibits 
SKI and SMSI with consequent accumulation of C l8_ceramide levels and decrease of 
DAG and SIP levels. This particular profile contributes to the cytotoxic effect of this 
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Supplementary Tables 
Supplementary Table 6 
Supplementary Table 6. Primer sets sequences used for QRT-PCR analysis and their 
respecti ve annealing temperatures. 
Primer set Primer Sequence Anneal 
Intron 5/exon 6 Intron5F 5' -TGACTGGACTITTCT ATGTCTTGTG -3' 58 
Intron 5/exon 6 Exon6R 5' -GeT ACCAGCTTCTCCCATTG·3' 58 
Intron7/exon 8 Intron7F 5'-ATTGAGTCATTGAAAAATIACAG-3' 58 
Intron7/exon 8 Exon8R 5' -GCCAACT ATGCAGAAAAATC-3' 58 
Exon7F/R Exon7F 5' ·GCCAGGACTTGATCAACCT AACC-3' 58 
Exon 7F/R Exon 7R 5'CAAGAACGGCCATGCCAA TGG-3' 58 
Exon 5/exon 6 Exon 5F 5'·AAGACGAGAACCTGCCTCAGC -3' 58 
Exon 5/exon 6 Exon 5/6R 5' ~GCTGTTGCAGGTGATGGAACT -3' 58 
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Supplementary Table 6-continued 
Exon 10/exon 11 exon 10/11 F 5' -GCCAATCAGCAAGTGCT AAAG-3' 58 
Exon 10/exon 11 exon 11 R 5' -AGG CCAATGGT AAGATCGAG-3 58 
Promoter A ProAF 5' -GTGCCCT AGTCCAGCT AACG-3' 62 
Promoter A ProAR 5' -AGGATTCTTCCTTCTTTCAAA TG-3' 62 
Promoter B Exon5F 5' -GCTGTTG CAG GTGATGGAACT -3' 58 
Promoter B Exon 5/6R 5'-GCTGTTGCAGGTGATGGAACT-3' 58 
Promoter C Exon7F 5'-GCCAGGACTTGATCAACCTAA CC-3' 58 
Promoter C Exon 7R 5'CAAGAACGGCCA TGCCAA TGG-3' 58 
Promoter 0 ProOF 5' -CGAGAGACCAAGGAAGAATCC-3' 64 
Promoter 0 PraDR 5'-CTCTCTCTTGGCAGGTCAGC-3' 64 
Promoter C Luc. PraCLF 5'-TCTGTGAGTTGCTGT ATGTTA-3' 52 
Promoter C Luc ProCLR 5'-AAGTCCTGGCCTGTGAAA TG-3' 52 
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Supplementary Table 7 
Supplementary Table 7. Deletion constructs cloned into the PGL3-basic vector. All 
constructs were amplified using the reverse primer ProeR indicated in the table below 
using standard peR conditions as described in the "Materials and Methods" section. 
Constructs are named according to their position relative to TSS C. 
Promoter C Construct Primer sequence 
Promoter C full length 5' -TCTGTGAGTTGCTGT ATGTT ATG -3' 
-158 5' -TGCGTTTTGAGAGGGGT AAT -3' 
-127 5' -AGCATCTTGAT ATTTTCTCTTGCTTTC-3' 
-119 5' -GAT ATTTTCTCTTGCTTTCACAGAA-3' 
-113 5' -TTCTCTTGCTTTCACAGAAGG-3' 
-110 5' -TCTTG CTTTCACAGAAGGAAGAATC-3' 
-87 5'TCCTGCTCAAAAA TGAGGTG' 
ProCRs 5' -AAGTCCTGGCCTGTGAAATG-3' 
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Supplementary Table 8 
Supplementary table 8. Identification of the 5'RLM RACE products by alignment of 
RACE products with human SMSl (SGMSl) using BLAST software. Closest proximal 
downstream exons are identified with the # of bps from the nearest proximal downstream 
exon. 
SMS1 5' RLM-RACE Putative Proximal downstream # of bps from 
products Promoter exon proximal 
downstream exon 
Int 1/exon 2/exon 7 Promoter A exon 1 -1429 
Int 2/ex 3/ex 4/ex 5/ ex 6 Promoter B exon 6 -35477 
Int 2/exon 7 Promoter B exon7 -211065 
Exon 7 Promoter C exon 7 -97 
Int 6/exon 7 Promoter 0 exon 7 -73741 
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Supplementary Table 9 
Supplementary table 9. Predicted transcription factors and the site of their binding to 
Promoter C as obtained from Matlnspector and TRANSFAC. 







Chapter 3. Concluding discussion 
DISCUSSION 
Summary 
This dissertation was designed to explore Bcr-abl's role as a potential 
regulator of SMS. In a foundational study, we screened cell lines from a 
variety of leukemia and lymphoma and tested the activity of SMS. This 
study revealed that K562 cells, derived from the pleural effusion of a patient 
with CML in blast crisis, had increased SMS activity compared to all other 
cell lines tested (Figure 6). In particular, expression of the SMSI gene was 
enhanced and inhibition of SMS1 impaired cell proliferation of Bcr-abl 
positive cells. Thus, our overall hypothesis was that enhanced transcription 
of SMSl contributes to the undifferentiated, pro-proliferative phenotype of 
Bcr-abl positive cells. 
Initial characterization of SMS described SMS as an important 
housekeeping enzyme for the synthesis of SM, an abundant phospholipid 
with an important structural role for the integrity of the plasma membrane. 
Its enzymatic activity was described as a transferase, in that it transfers the 
phosphorylcholine moiety from PC onto ceramide, therefore creating SM 
and DAG (307-313). But in addition to SMS's role in the synthesis ofSM, 
SMS modulates the bioactive lipids, ceramide and DAG (Figure 1). These 
lipids have opposing functions on cellular processes: ceramide is known to 
regulate processes such as senescence and cell death while DAG regulates 
processes such as proliferation and transformation (8,307-313). The 
hypothesized role of Bcr-abl in mediating SMS upregulation was therefore 
based upon SMS' ability to modulate ceramide and DAG, as well as the 
observation that Bcr-abl positive cells had increased SMS activity. 
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Further evidence had been provided supporting the possibility of SMS 
as a regulated entity by the following important studies. In general, increased 
SMS activity correlates with increased proliferation (as in the case of 
regenerating rat liver (192) and in quiescent primary astrocytes stimulated 
with basic fibroblast growth factor (193)) and some transformed phenotypes, 
such as hepatocellular carcinoma. On the other hand, decreased SMS 
activity has been observed prior to the onset of apoptosis (194). Importantly, 
the loss of SMS activity was found to be a caspase-dependent event thus 
suggesting that inhibition of SMS could be a regulated process required for 
the full development of the apoptotic program. 
Bcr-abl's role as an upstream regulator of SMS was the focus of Aim 
1. These results are the subject of Chapter 1 and provided the data for the 
manuscript, "Sphingomyelin synthase 1 activity is regulated by the BCR-
ABL oncogene"'. 
Aim 1 focused on the evidence of a link between Bcr-abl expression 
and elevated SMS activity. These studies demonstrated that SMSl, as 
opposed to SMS2 was the isoform responsible for increased SMS activity 
and responsible for maintain cellular proliferation of Bcr-abl positive cells 
(Figure 12). In addition, evidence was provided demonstrating that 
inhibition of Bcr-abl, of SMS activity or of SMSl expression resulted in an 
alteration of the ratio of bioactive lipids, ceramide and DAG in favor of 
ceramide (Figures 9 and 11). Importantly, SMS inhibition significantly 
affected cellular proliferation of Bcr-abl positive cells (Figure 12) 
consistently with the shift of the ceramide to DAG ratio in favor of 
ceramide. Increased SMSl expression and SMS activity were also observed 
in progenitor cells isolated from patients with CML in blast crisis and 
pharmacological inhibition of SMS caused a decrease of their proliferation. 
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Aim 2 focused on establishing the mechanism by which Bcr-abl 
regulates SMSl, and in particular how it enhances SMSl expression. These 
studies provided evidence that Bcr-abl transcriptionally upregulates SMSl 
and it does so by activation of specific transcription start sites. We 
demonstrated that Bcr-abl upregulated SMSl, to the most extent, from TSS 
C and its upstream Promoter C. Finally, we showed that the cis-elements 
necessary for Bcr-abl-mediated SMSl upregulation, resides between 
nucleaotides -113 and -110 upstream to TSS C. 
Implications and Significance 
These studies provide the very first molecular connection between an 
oncogene, Bcr-abl and SMS. This connection is novel and significant at 
multiple levels. First, treatment or containment of CML blast phase still 
represents a significant clinical challenge. By providing a molecular link 
between Bcr-abl and SMS 1, these studies have thus provided the first steps 
on understanding the role of SMS 1 tn the maintenance of the 
undifferentiated phenotype of CML blasts cells, which is ultimately 
responsible for their aggressiveness and resistance to chemotherapy. These 
types of studies are of utmost importance since, in spite of the success 
obtained in controlling the chronic phase of CML, BCR-ABLI inhibitors 
have limitations since CML patients develop mutations over time resulting 
in poor clinical outcome. In addition, BCR-ABLI inhibitors are not 
successful in the blast stage of CML. Interestingly, even if K562 cells are 
blast phase CML, and therefore characterized by a block of differentiation 
potentially due to the accumulation of mutations in addition to the formation 
of the Bcr-abl chimaera, SMS 1 activity is still under the control of the Bcr-
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abl tyrosine kinase activity. Therefore it is unlikely that SMS 1 may represent 
a "druggable" target to contain newly diagnosed blast phase CML. On the 
other hand, in spite of the success obtained in controlling the chronic phase 
of CML, the increase in resistance to Bcr-abl inhibitors is starting to 
represent a significant medical challenge. Thus, establishing SMS 1 as an 
important down-stream regulator of Bcr-abl may provide the basis for future 
work set to test SMS 1 as a potential novel pharmacological target for CML, 
in particular for those cases that arise from resistance to Bcr-abl inhibitors. 
The characterization of the molecular mechanism that links Bcr-abl 
and SMS 1 is also critical since it will reveal the transcription factor 
responsible for Bcr-abl-mediated regulation of SMSI. It could then be 
hypothesized that in conditions in which the expression or activity of this 
newly identified transcription factor are altered (i.e. specific pathologies), 
then also SMSl expression might be affected with potential significant 
biological consequences. 
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FUTURE DIRECTIONS AND CONCLUDING REMARKS 
There are a number of interesting and unanswered questions that branch 
from this project and that represent the next challenges for the full understanding 
of the Bcr-abl/SMS connection and even for the biology of SMS in general. 
How does SMSI regulate proliferation and/or differentiation? 
This dissertation has focused on establishing Bcr-abl as an upstream 
activator of SMSI via SMSl transcription of Promoter/TSS C. Future studies need 
to be conducted to understand the downstream mechanisms through which SMS 1 
regulates proliferation upon Bcr-abl expression. 
Bcr-abl and sphingolipids 
In general, the role of SLs in Bcr-Abl mediated signaling is unclear. In 
particular, whereas bcr-abl expression was shown to impart total or partial 
resistance to treatment with exogenous short chain ceramide analogues (C2 or C6-
ceramide), bcr-abl was also found to accelerate ceramide-mediated apoptosis by 
these same analogues (292-294). Recently, accumulation of endogenous ceramide 
and decrease of the anti-apoptotic sphingolipid, SIP was shown to be in part 
responsible for the cytotoxic effect exerted by imatinib treatment in CML derived 
cell lines. Moreover, it was also shown that a shift of the balance between 
endogenous ceramide and SIP in favor of SIP may be of critical relevance for 
imparting imatinib resistance to CML cells (298,299). Thus it is possible that 
increased SMSl expression in Bcr-abl positive cells leads to less ceramide 
accumulation which brings a proliferative advantage (Figure 28A). 
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Interestingly, a link between ceramide and bcr-abl may involve the protein 
phosphatase 2A (PP2A). In particular, inhibition of the tumor suppressor PP2A has 
been proposed as a mechanism through which Bcr-abl promotes its tumorigenic 
effects. Indeed expression of Bcr-abl was shown to lower PP2A activity by 
increasing the level of its inhibitor IPP2A (346,347). In fact, Perrotti et al. 
demonstrated that the cytotoxic effect of the immunomodulator FTY720 to CML 
cells occurs through activation of PP2A (303). Interestingly, it was recently shown 
that FTY720 treatment induces accumulation of ceramide (304) and ceramide is 
known to activate PP2A by binding to SET and dissociating it from PP2A (115). 
Therefore a novel link between FTY720/ceramide accumulation/activation of 
PP2A and inhibition of bcr-abl may exist. It is tempting to speculate that ceramide 
accumulated after down-regulation of SMSl may contribute to blocking cell 
proliferation by activation of PP2A. 
Bcr-abl and DAG 
As already discussed, it is very surprising that the relationship between Bcr-
abl and DAG has not been documented in the literature. DAG has been indirectly 
linked to cell proliferation in bcr-abl positive cells through activation of PLCyl, 
classical and novel protein kinases C (PKCs), and mTor. Indirect evidence of the 
involvement of DAG as a downstream signaling molecule of Bcr-abl come from 
reports showing that activation of phospholipase C (PLC) yl and of the PI3KJAkt 
pathway are required for Bcr-abl signaling through mTOR/p70S6-kinase 
(305,306). The regulation of mTORlp70S6-kinase by PLCyl seems to occur via 
modulation of both calcium signaling (CaMKII) (presumably through formation of 
IP3) and classical and novel protein kinase C (likely through production of DAG). 
In our system, we observed a very significant drop of DAG levels when either Bcr-
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abl or SMS/SMS 1 were inhibited. Being SMS 1 regulated by Bcr-abl, it is possible 
that part of the observed drop of DAG levels after inhibition of Bcr-abl is due to 
the decrease of SMS/SMS 1 activity, in addition to inhibition of PLCyl and it is 
possible that DAG regulated by SMSI maybe involved in the regulation of PKCs and 
mTor. 
What is the transcription (actor responsible for BeT-abI mediated SMSI 
upregulation? 
Deletion analysis has demonstrated that the region of Promoter C., -113 to -
110 is necessary for Bcr-abl mediated upregulation of SMS1. Although this region 
contains only 3 base pairs, an oligonucleotide labeled probe may need at least 5-10 
bases on each side of the functional control element. For most proteins contained 
within crude extracts, probes are made with 20-30 base pairs in order to yield 
consistent and high quality results. The length of these oligonucleotides may be 
necessary, since the adjacent sequences, although not necessarily required for 
recognition of the protein, may be needed for a stable protein-DNA interaction 
(340). For example, EMSA experiments to detect NF-KB complexes are usually 
performed with 19-bp oligonucleotide probes (348). Therefore, it is possible that 
the stretch of -110 to -113 nucleotides on Promoter C is the one necessary for 
stable protein-DNA interaction and that the real consensus sequence for the 
binding of the transcription factor is slightly closer to the TSS C. This scenario 
supports the involvement of STAT5 as the transcription factor binding to Promoter 
C, since the putative consensus sequence for ST AT5 on Promoter C is between 
nucleotides -108/-90 and mostly excludes the other putative factors. 
Studies have shown a pronounced constitutive activation of ST AT5 in both 
Bcr-abl positive cell lines as well as CML patient samples (349). Importantly, 
175 
down-regulation of STAT5 with siRNA in prImary CML samples inhibited 
myeloid colony formation (319) and fetal liver hematopoietic progenitors from 
ST A T5 knockout mice did not induce leukemia in recipient mice after transduction 
with BCR-ABL (350). Activation of STAT5 in bcr-abl positive cells may be a 
result of phosphorylation by bcr-abl, the janus kinase 2 or the Src kinases 
(349,351-353). Studies have shown that STAT5 activation causes cell growth and 
transformation by promoting cell proliferation, interfering with differentiation 
programs and inhibiting apoptosis [For a review (354)]. These studies, in 
combination with the results shown in Supplementary Figure 11, provide 
promIsIng evidence of STATS's involvement in Bcr-abl mediated SMSI 
regulation. 
In summary, the discovery of the bcr-abl/smsl connection provides the first 
molecularly-characterized model for a better understanding of potential modes of 
regulation and down-stream functions of the elusive SMSI. The potential 
regulation of SMSl transcription by ST AT5 and the potential involvement of PP2A 
as target for SMS 1 activity in bcr-abl cells would establish novel connections in 
the bcr-abl signaling network. Being SMSl a potential target for STAT5, 
conditions in which STAT5 is up-regulated may also cause an up-regulation of 
SMS1. Furthermore, the same down-stream functions of SMS 1 in Bcr-abl cells 
could be also aberrant in other pathological conditions associated with altered smsl 
expression (or STAT5) and/or activity. Finally, in spite of the success obtained in 
controlling the chronic phase of CML, bcr-abl inhibitors are showing a few 
setbacks. Thus, establishing SMS 1 as an important down-stream regulator of bcr-
abl signaling may provide the basis for future work set to test SMS 1 as a potential 
novel pharmacological target for CML. 
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